0001628280-20-015938.txt : 20201106 0001628280-20-015938.hdr.sgml : 20201106 20201106160914 ACCESSION NUMBER: 0001628280-20-015938 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201106 DATE AS OF CHANGE: 20201106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Accelerate Diagnostics, Inc CENTRAL INDEX KEY: 0000727207 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 841072256 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31822 FILM NUMBER: 201294488 BUSINESS ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 BUSINESS PHONE: 303-863-8088 MAIL ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 FORMER COMPANY: FORMER CONFORMED NAME: ACCELR8 TECHNOLOGY CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: HYDRO SEEK INC DATE OF NAME CHANGE: 19880802 10-Q 1 axdx-20200930.htm 10-Q axdx-20200930
0000727207falseDecember 31Q32020P1YP2Yus-gaap:AccountingStandardsUpdate201613Member0.03234280.032342800007272072020-01-012020-09-30xbrli:shares00007272072020-11-03iso4217:USD00007272072020-09-3000007272072019-12-31iso4217:USDxbrli:shares00007272072020-07-012020-09-3000007272072019-07-012019-09-3000007272072019-01-012019-09-3000007272072018-12-3100007272072019-09-300000727207us-gaap:CommonStockMember2020-06-300000727207us-gaap:CommonStockMember2019-06-300000727207us-gaap:CommonStockMember2019-12-310000727207us-gaap:CommonStockMember2018-12-310000727207us-gaap:CommonStockMember2020-07-012020-09-300000727207us-gaap:CommonStockMember2019-07-012019-09-300000727207us-gaap:CommonStockMember2020-01-012020-09-300000727207us-gaap:CommonStockMember2019-01-012019-09-300000727207us-gaap:CommonStockMember2020-09-300000727207us-gaap:CommonStockMember2019-09-300000727207us-gaap:AdditionalPaidInCapitalMember2020-06-300000727207us-gaap:AdditionalPaidInCapitalMember2019-06-300000727207us-gaap:AdditionalPaidInCapitalMember2019-12-310000727207us-gaap:AdditionalPaidInCapitalMember2018-12-310000727207us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000727207us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300000727207us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000727207us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-300000727207us-gaap:AdditionalPaidInCapitalMember2020-09-300000727207us-gaap:AdditionalPaidInCapitalMember2019-09-300000727207us-gaap:RetainedEarningsMember2020-06-300000727207us-gaap:RetainedEarningsMember2019-06-300000727207us-gaap:RetainedEarningsMember2019-12-310000727207us-gaap:RetainedEarningsMember2018-12-310000727207srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-12-310000727207srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-12-310000727207us-gaap:RetainedEarningsMember2020-07-012020-09-300000727207us-gaap:RetainedEarningsMember2019-07-012019-09-300000727207us-gaap:RetainedEarningsMember2020-01-012020-09-300000727207us-gaap:RetainedEarningsMember2019-01-012019-09-300000727207us-gaap:RetainedEarningsMember2020-09-300000727207us-gaap:RetainedEarningsMember2019-09-300000727207us-gaap:TreasuryStockMember2020-06-300000727207us-gaap:TreasuryStockMember2019-06-300000727207us-gaap:TreasuryStockMember2019-12-310000727207us-gaap:TreasuryStockMember2018-12-310000727207us-gaap:TreasuryStockMember2020-09-300000727207us-gaap:TreasuryStockMember2019-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300000727207srt:MinimumMember2020-01-012020-09-300000727207srt:MaximumMember2020-01-012020-09-300000727207axdx:InstrumentsMember2020-01-012020-09-3000007272072020-06-3000007272072019-06-300000727207axdx:PaycheckProtectionProgramCARESActMemberus-gaap:UnsecuredDebtMember2020-04-14xbrli:pure0000727207axdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:UnsecuredDebtMember2020-09-300000727207srt:MinimumMember2020-09-300000727207srt:MaximumMember2020-09-300000727207srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-01-010000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionAMemberus-gaap:CashAndCashEquivalentsMember2020-01-012020-09-300000727207axdx:FinancialInstitutionBMemberus-gaap:CreditConcentrationRiskMemberus-gaap:CashAndCashEquivalentsMember2020-01-012020-09-300000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionCMemberus-gaap:CashAndCashEquivalentsMember2020-01-012020-09-300000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionDMemberus-gaap:CashAndCashEquivalentsMember2020-01-012020-09-300000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionAMemberus-gaap:CashAndCashEquivalentsMember2019-01-012019-12-310000727207axdx:FinancialInstitutionBMemberus-gaap:CreditConcentrationRiskMemberus-gaap:CashAndCashEquivalentsMember2019-01-012019-12-310000727207us-gaap:CustomerConcentrationRiskMemberaxdx:OneCustomerMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMember2020-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Member2020-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMember2020-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2020-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2020-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2020-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2020-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2020-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2020-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-09-300000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2019-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2019-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2019-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMember2019-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2019-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2019-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2019-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2019-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2019-12-310000727207us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2019-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2019-12-310000727207axdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:UnsecuredDebtMember2018-04-042018-04-040000727207axdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:UnsecuredDebtMember2019-12-310000727207us-gaap:UnsecuredDebtMember2020-09-300000727207us-gaap:CertificatesOfDepositMember2020-09-300000727207us-gaap:USTreasuryAndGovernmentMember2020-09-300000727207us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-300000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2020-09-300000727207us-gaap:CorporateDebtSecuritiesMember2020-09-300000727207us-gaap:CertificatesOfDepositMember2019-12-310000727207us-gaap:USTreasuryAndGovernmentMember2019-12-310000727207us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2019-12-310000727207us-gaap:CorporateDebtSecuritiesMember2019-12-310000727207us-gaap:ComputerEquipmentMember2020-09-300000727207us-gaap:ComputerEquipmentMember2019-12-310000727207us-gaap:TechnologyEquipmentMember2020-09-300000727207us-gaap:TechnologyEquipmentMember2019-12-310000727207us-gaap:LeaseholdsAndLeaseholdImprovementsMember2020-09-300000727207us-gaap:LeaseholdsAndLeaseholdImprovementsMember2019-12-310000727207axdx:InstrumentsMember2020-09-300000727207axdx:InstrumentsMember2019-12-310000727207us-gaap:ConstructionInProgressMember2020-09-300000727207us-gaap:ConstructionInProgressMember2019-12-310000727207us-gaap:AssetsLeasedToOthersMember2020-09-300000727207us-gaap:AssetsLeasedToOthersMember2019-12-310000727207axdx:NationalInstituteofHealthGrantMember2015-02-012015-02-2800007272072015-02-012020-09-300000727207axdx:NationalInstituteofHealthGrantMember2020-01-012020-09-300000727207axdx:NationalInstituteofHealthGrantMember2019-01-012019-09-300000727207axdx:ProductsandServicesnotYetDeliveredMember2020-09-300000727207axdx:ProductsandServicesnotYetDeliveredMember2019-12-310000727207axdx:PaycheckProtectionProgramCARESActMemberus-gaap:UnsecuredDebtMember2020-09-300000727207axdx:PaycheckProtectionProgramCARESActMemberus-gaap:UnsecuredDebtMember2019-12-310000727207axdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMember2020-09-300000727207axdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMember2019-12-31axdx:loan0000727207axdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMember2020-07-012020-09-300000727207axdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMembersrt:MinimumMember2020-09-300000727207axdx:OtherLoansMembersrt:MaximumMemberus-gaap:NotesPayableOtherPayablesMember2020-09-30axdx:payment0000727207srt:ScenarioForecastMemberaxdx:PaycheckProtectionProgramCARESActMemberus-gaap:UnsecuredDebtMember2020-11-142020-11-140000727207srt:ScenarioForecastMemberaxdx:PaycheckProtectionProgramCARESActMemberus-gaap:UnsecuredDebtMember2021-08-142021-08-140000727207axdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:UnsecuredDebtMember2018-03-2700007272072018-03-272018-03-2700007272072018-04-042018-04-040000727207axdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:UnsecuredDebtMember2018-04-040000727207axdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:LongTermDebtMemberus-gaap:UnsecuredDebtMember2018-04-040000727207axdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:AdditionalPaidInCapitalMemberus-gaap:UnsecuredDebtMember2018-04-04axdx:day00007272072018-04-040000727207us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2019-07-012019-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000727207us-gaap:EmployeeStockOptionMember2020-07-012020-09-300000727207us-gaap:EmployeeStockOptionMember2019-07-012019-09-300000727207us-gaap:EmployeeStockOptionMember2020-01-012020-09-300000727207us-gaap:EmployeeStockOptionMember2019-01-012019-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:UnsecuredDebtMember2020-01-012020-09-300000727207srt:MaximumMemberaxdx:TwoPointFiveZeroConvertibleNotesdue2023Memberus-gaap:UnsecuredDebtMember2020-01-012020-09-300000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2019-12-310000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2020-01-012020-09-300000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2020-09-300000727207us-gaap:CostOfSalesMember2020-07-012020-09-300000727207us-gaap:CostOfSalesMember2019-07-012019-09-300000727207us-gaap:CostOfSalesMember2020-01-012020-09-300000727207us-gaap:CostOfSalesMember2019-01-012019-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012019-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2020-09-300000727207srt:MinimumMemberus-gaap:PerformanceSharesMember2020-01-012020-09-300000727207srt:MaximumMemberus-gaap:PerformanceSharesMember2020-01-012020-09-300000727207us-gaap:PerformanceSharesMember2020-01-012020-09-300000727207axdx:Grantedin2018Membersrt:MinimumMemberus-gaap:PerformanceSharesMember2020-01-012020-09-300000727207srt:MaximumMemberaxdx:Grantedin2018Memberus-gaap:PerformanceSharesMember2020-01-012020-09-300000727207us-gaap:PerformanceSharesMember2018-08-012018-08-310000727207us-gaap:PerformanceSharesMember2020-07-012020-09-300000727207us-gaap:PerformanceSharesMember2019-01-012019-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMembersrt:MinimumMember2020-01-012020-09-300000727207srt:MaximumMemberaxdx:PerformanceBasedRestrictedStockUnitsMember2020-01-012020-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMember2020-01-012020-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMember2020-07-012020-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMember2020-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMember2019-01-012019-09-30axdx:segment0000727207us-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:AccountsReceivableMember2020-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:AccountsReceivableMember2019-12-310000727207us-gaap:GeographicDistributionDomesticMember2020-07-012020-09-300000727207us-gaap:GeographicDistributionDomesticMember2019-07-012019-09-300000727207us-gaap:GeographicDistributionDomesticMember2020-01-012020-09-300000727207us-gaap:GeographicDistributionDomesticMember2019-01-012019-09-300000727207us-gaap:GeographicDistributionForeignMember2020-07-012020-09-300000727207us-gaap:GeographicDistributionForeignMember2019-07-012019-09-300000727207us-gaap:GeographicDistributionForeignMember2020-01-012020-09-300000727207us-gaap:GeographicDistributionForeignMember2019-01-012019-09-300000727207axdx:AcceleratePhenoMember2020-07-012020-09-300000727207axdx:AcceleratePhenoMember2019-07-012019-09-300000727207axdx:AcceleratePhenoMember2020-01-012020-09-300000727207axdx:AcceleratePhenoMember2019-01-012019-09-300000727207axdx:OtherRevenueMember2020-07-012020-09-300000727207axdx:OtherRevenueMember2019-07-012019-09-300000727207axdx:OtherRevenueMember2020-01-012020-09-300000727207axdx:OtherRevenueMember2019-01-012019-09-300000727207us-gaap:ProductMember2020-07-012020-09-300000727207us-gaap:ProductMember2019-07-012019-09-300000727207us-gaap:ProductMember2020-01-012020-09-300000727207us-gaap:ProductMember2019-01-012019-09-300000727207us-gaap:ServiceMember2020-07-012020-09-300000727207us-gaap:ServiceMember2019-07-012019-09-300000727207us-gaap:ServiceMember2020-01-012020-09-300000727207us-gaap:ServiceMember2019-01-012019-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicDistributionDomesticMember2020-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicDistributionDomesticMember2019-12-310000727207us-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMember2020-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMember2019-12-310000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMember2020-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMember2019-12-310000727207srt:DirectorMemberaxdx:ConvertibleNoteHolderMembersrt:ChiefOperatingOfficerMember2020-09-300000727207srt:DirectorMemberaxdx:ConvertibleNoteHolderMembersrt:ChiefOperatingOfficerMember2019-12-310000727207srt:ChiefOperatingOfficerMember2019-08-202019-08-2000007272072019-08-1900007272072019-08-202019-08-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____

Commission file number: 001-31822
ACCELERATE DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware84-1072256
(State or other jurisdiction(I.R.S. Employer Identification No.)
of incorporation or organization)
3950 South Country Club Road, Suite 470
Tucson,Arizona85714
(Address of principal executive offices)(Zip Code)

(520) 365-3100
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 parAXDXThe Nasdaq Stock Market LLC
value per share(The Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 3, 2020, there were 57,029,694 shares of the registrant’s common stock outstanding.



TABLE OF CONTENTS


2

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements
ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEET
(in thousands, except share data)
September 30,December 31,
20202019
Unaudited
ASSETS
Current assets:
Cash and cash equivalents$27,029 $61,014 
Investments50,463 47,437 
Trade accounts receivable2,610 3,222 
Inventory9,459 8,059 
Prepaid expenses961 955 
Other current assets1,517 1,165 
Total current assets92,039 121,852 
Property and equipment, net7,104 7,905 
Right of use assets3,402 3,917 
Other non-current assets1,674 750 
Total assets$104,219 $134,424 
LIABILITIES AND STOCKHOLDERS EQUITY
Current liabilities:
Accounts payable$2,372 $2,351 
Accrued liabilities3,176 3,828 
Accrued interest191 1,262 
Deferred revenue338 271 
Current portion of long-term debt511  
Current operating lease liability482 450 
Total current liabilities7,070 8,162 
Non-current operating lease liability3,231 3,579 
Other non-current liabilities259 19 
Long-term debt5,028  
Convertible notes138,299 130,043 
Total liabilities$153,887 $141,803 
Commitments and contingencies
Stockholders’ deficit:
Preferred shares, $0.001 par value;
5,000,000 preferred shares authorized and none outstanding as of September 30, 2020 and December 31, 2019
  
Common stock, $0.001 par value;
85,000,000 common shares authorized with 57,027,429 shares issued and outstanding on September 30, 2020 and 85,000,000 common shares authorized with 54,708,792 shares issued and outstanding on December 31, 2019
57 55 
Contributed capital469,302 452,344 
Treasury stock(45,067)(45,067)
Accumulated deficit(474,054)(414,653)
Accumulated other comprehensive income (loss)94 (58)
Total stockholders’ deficit(49,668)(7,379)
Total liabilities and stockholders’ deficit$104,219 $134,424 

See accompanying notes to condensed consolidated financial statements.
3


ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Unaudited
(in thousands, except per share data)
Three Months EndedNine Months Ended
September 30,September 30,September 30,September 30,
2020201920202019
Net sales$3,588 $2,271 $8,056 $5,827 
Cost of sales2,287 1,117 4,745 2,940 
Gross profit1,301 1,154 3,311 2,887 
Costs and expenses:
Research and development5,001 6,064 16,191 19,145 
Sales, general and administrative11,465 12,743 35,738 38,302 
Total costs and expenses16,466 18,807 51,929 57,447 
Loss from operations(15,165)(17,653)(48,618)(54,560)
Other income (expense):
Interest expense(3,955)(3,598)(11,540)(10,585)
Foreign currency exchange gain (loss)229 (89)191 (142)
Interest income149 676 753 2,329 
Other expense, net(15)(9)(82)(12)
Total other expense, net(3,592)(3,020)(10,678)(8,410)
Net loss before income taxes(18,757)(20,673)(59,296)(62,970)
Provision for income taxes 239   
Net loss$(18,757)$(20,434)$(59,296)$(62,970)
Basic and diluted net loss per share$(0.33)$(0.37)$(1.07)$(1.16)
Weighted average shares outstanding56,560 54,553 55,617 54,456 
Other comprehensive loss:
Net loss$(18,757)$(20,434)$(59,296)$(62,970)
Net unrealized gain (loss) on debt securities available-for-sale(117)10 62 229 
Foreign currency translation adjustment71 (113)90 (139)
Comprehensive loss$(18,803)$(20,537)$(59,144)$(62,880)

See accompanying notes to condensed consolidated financial statements.
4


ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
Unaudited
(in thousands)
Nine Months Ended
September 30,September 30,
20202019
Cash flows from operating activities:
Net loss$(59,296)$(62,970)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization2,270 1,862 
Amortization of investment discount43 (400)
Equity-based compensation12,291 9,409 
Amortization of debt discount and issuance costs8,256 7,370 
Realized loss on sale of investments3  
Loss on disposal of property and equipment546 577 
Contributions to deferred compensation plan(248) 
(Increase) decrease in assets:
Accounts receivable532 (782)
Inventory and instruments in property and equipment(1,734)(3,286)
Prepaid expense and other(1,267)(319)
Increase (decrease) in liabilities:
Accounts payable76 788 
Accrued liabilities, and other(759)(2,115)
Accrued interest(1,071)(1,071)
Deferred revenue and income67 33 
Deferred compensation240 (25)
Net cash used in operating activities(40,051)(50,929)
Cash flows from investing activities:
Purchases of equipment(1,364)(148)
Purchase of marketable securities(44,589)(20,710)
Proceeds from sales of marketable securities 13,400 
Maturities of marketable securities41,707 78,922 
Net cash (used in) provided by investing activities(4,246)71,464 
Cash flows from financing activities:
Proceeds from issuance of common stock296 1,363 
Proceeds from exercise of options4,458 4,879 
Proceeds from debt5,552  
Payment of debt(13) 
Net cash provided by financing activities10,293 6,242 
Effect of exchange rate on cash19 (99)
(Decrease) increase in cash and cash equivalents(33,985)26,678 
Cash and cash equivalents, beginning of period61,014 66,260 
Cash and cash equivalents, end of period$27,029 $92,938 

See accompanying notes to condensed consolidated financial statements.
5



ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS (CONTINUED)
Unaudited
(in thousands)
Nine Months Ended
September 30,September 30,
20202019
Non-cash investing activities:
Net transfer of instruments from inventory to property and equipment$1,284 $3,225 
Supplemental cash flow information:
Interest paid$4,288 $4,288 
Income taxes paid, net of refunds$46 $54 

See accompanying notes to condensed consolidated financial statements.
6


ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
Unaudited
(in thousands)
Three Months EndedNine Months Ended
September 30,September 30,
2020201920202019
Common stock shares outstanding
Beginning56,249 54,512 54,709 54,232 
Proceeds from issuance of common stock 56  56 
Exercise of options770 66 2,287 334 
Issuance of common stock under employee purchase plan8 7 31 19 
Ending57,027 54,641 57,027 54,641 
Common stock
Beginning$56 $55 $55 $54 
Exercise of Options1  2 1 
Ending$57 $55 $57 $55 
Contributed capital
Beginning$463,178 $443,857 $452,344 $432,885 
Proceeds from issuance of common stock 1,000  1,000 
Exercise of options1,427 510 4,458 4,879 
Issuance of common stock under employee purchase plan79 112 294 362 
Equity-based compensation4,618 3,130 12,206 9,483 
Ending$469,302 $448,609 $469,302 $448,609 

See accompanying notes to condensed consolidated financial statements.
7



ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (CONTINUED)
Unaudited
(in thousands)
Three Months EndedNine Months Ended
September 30,September 30,
2020201920202019
Accumulated deficit
Beginning$(455,297)$(372,884)$(414,653)$(330,348)
Cumulative effect of accounting changes— — (105) 
Net loss(18,757)(20,434)(59,296)(62,970)
Ending$(474,054)$(393,318)$(474,054)$(393,318)
Treasury stock
Beginning$(45,067)$(45,067)$(45,067)$(45,067)
Ending$(45,067)$(45,067)$(45,067)$(45,067)
Accumulated other comprehensive (loss) income
Beginning$140 $44 $(58)$(149)
Net unrealized gain on debt securities available-for-sale(117)10 62 229 
Foreign currency translation adjustment71 (113)90 (139)
Ending$94 $(59)$94 $(59)
Total stockholders' equity (deficit)$(49,668)$10,220 $(49,668)$10,220 

See accompanying notes to condensed consolidated financial statements.

8


ACCELERATE DIAGNOSTICS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unaudited

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES

Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on February 28, 2020.

The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2020, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, tax valuation accounts and equity–based compensation. Actual results could differ materially from those estimates.

Estimated Fair Value of Financial Instruments

The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

9


Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.

The estimated fair value of the Company’s convertible note represents a Level 2 measurement. See Note 11, Convertible Notes for further detail on the Company’s convertible notes.

The estimated fair value of the Company’s long-term debt represents a Level 3 measurement. The promissory notes issued under the Paycheck Protection Program (PPP) and other long-term debt is privately held with no public market. The carrying amount of these notes approximates fair value. See Note 10, Long-Term Debt for further detail on the Company’s long-term debt.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe, however, that the market risk arising from holding these financial instruments is minimal.

Investments

The Company invests in various debt securities available-for-sale and equity securities which are primarily held in the custody of major financial institutions. Debt securities available-for-sale consist of certificates of deposit, U.S. government and agency securities, commercial paper, asset-backed securities, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

On a quarterly basis, we perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security available-for-sale is considered impaired if its fair value is less than its amortized cost basis at the reporting date.

If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security available-for-sale.

10


Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.

Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.

We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the condensed consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. The allowance for credit losses as of September 30, 2020 was $0.3 million.

Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.

The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and this evaluation is performed at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of September 30, 2020 and December 31, 2019.

Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.

11


Warranty Reserve

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.

Warranty reserve activity for the three and nine months ended September 30, 2020 and 2019 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Beginning balance$305 $196 $403 $215 
Provisions72 77 72 147 
Warranty cost incurred
(40)(51)(138)(140)
Ending balance$337 $222 $337 $222 

Paycheck Protection Program (PPP) Loan

The PPP was established by the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, through a significant expansion of the Small Business Administration (“SBA”) 7(a) loan program. On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million.

The Company elected to account for the PPP Note in accordance with ASC 470, Debt, with interest accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. The Company recognized the entire PPP Note amount as a liability on the balance sheet, with interest accrued and expensed over the term of the loan. The Company did not impute additional interest at a market rate because transactions where interest rates are prescribed by governmental agencies are excluded from the scope of ASC 835-30.

The PPP Note will remain a liability until either of the following criteria are met:

the Company has been legally released from being the primary obligor under the liability (i.e. the PPP Note is forgiven); or

the Company pays the lender and is relieved of its obligation for the liability

See Note 10, Long-Term Debt for further detail regarding the PPP Note.

Convertible Notes

The Company accounts for convertible debt instruments that may be settled in cash or equity upon conversion, which includes the 2.50% Senior Convertible Notes due 2023 (the “Notes”), by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determined the carrying amount of the liability component of the Notes by using estimates and assumptions that market participants would use in pricing a debt instrument. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.

The equity component is treated as a discount on the liability component of the Notes, which is amortized over the term of the Notes using the effective interest rate method. Debt issuance costs related to the Notes are allocated to the liability and equity components of the Notes based on their relative values. Debt issuance costs allocated to the liability component are amortized over the life of the Notes as additional non-cash interest expense. Transaction costs allocated to equity are netted with the equity component of the convertible debt instrument in stockholders’ deficit.
12



Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

Identification of the contract with a customer

Identification of the performance obligations in the contract

Determination of the transaction price

Allocation of the transaction price to the performance obligations

Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized and the term between invoicing and when payment is due is not typically significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine relative standalone selling prices based on the price charged to customers for each individual performance obligation.

Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2020.

Cost of Sales

Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related expenses.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.

13


Restructure Activity

During the three months ended September 30, 2020, following the completion of a strategic review of its Europe, the Middle East and Africa (“EMEA”) business, the Company's board of directors approved a plan to reduce its workforce, focus the geographies it plans to operate in, and terminate agreements with some distributors in geographies it plans on exiting (collectively, the “EMEA Restructuring Plan”). As of September 30, 2020, the Company substantially completed the workforce reduction portion of the EMEA Restructuring Plan, while the remaining restructuring activities are likely to occur through the end of the year. Restructuring charges are primarily comprised of employee severance and other post-employment benefits. The Company evaluates the nature of these costs to determine if they relate to on-going benefit arrangements which are accounted for under ASC 712 or one-time benefit arrangements which are accounted for under ASC 420. The Company incurred expense of $0.4 million in connection with the EMEA Restructuring Plan.

Leases

The Company accounts for commercial leases in accordance with ASC 842, Leases. We determine if an arrangement is or contains a lease and the type of lease at inception. The Company classifies commercial leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.

Lessee

Operating leases are included in right-of-use (“ROU”) assets and operating lease liabilities within our consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. As of September 30, 2020 and December 31, 2019, the Company was not party to finance lease arrangements.

Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions.

Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.
14



Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.

Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”), provides certain key employees, with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.

Equity-Based Compensation

The Company may award stock options, restricted stock units (“RSUs”), performance-based awards, and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

Expected term: The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. For consultant awards, the estimated expected term is the same as the life of the award.

Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.

The Company records the fair value of RSUs or stock grants based on published closing market price on the day before the grant date. The Company accounts for forfeitures as they occur rather than on an estimated basis.

15


Deferred Tax Assets

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.

Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss).

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.

Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options and unvested RSUs. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes at the balance sheet date were converted. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.

Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds investments classified as debt securities available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.

NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Standards that were recently adopted

In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Fair Value Measurement (Topic 820); Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies, among other things, the disclosures required for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs. The guidance removes, among other things, the disclosure requirement to disclose transfers between Levels 1 and 2. Level 3 fair value measurement disclosures should be applied prospectively while all other amendments should be applied retrospectively. The Company adopted ASU 2018-13 on January 1, 2020, which had no impact to our condensed consolidated financial statements as the Company did not carry Level 3 fair value items upon implementing this ASU on January 1, 2020.

16


In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments. In November 2018, ASU 2018-19 was issued which amended the standard to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU 2019-04, 2019-05, 2019-10, ASU 2019-11, 2020-02 and 2020-03 to provide additional guidance on the credit losses standard. ASU 2016-13 amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Previously, an “incurred loss” methodology was used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. This amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities are now recorded in current period net income. The Company adopted ASU 2016-13 on January 1, 2020. We adopted this standard using a modified-retrospective approach, and recorded a $0.1 million cumulative-effect adjustment to the opening balance of accumulated deficit in connection with the adoption. This adjustment was recorded to establish an allowance for trade account receivables and investment in leases. No cumulative-effect adjustment was recorded for unrealized losses on debt securities available-for-sale as the issuers of such securities held by us were of high credit quality. As a result, the condensed consolidated financial statements for the current periods are presented under the new standard, while the comparative prior year period is not adjusted and continues to be reported in accordance with our historical accounting policy.

Standards not yet adopted

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2020-06 reduces the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, this ASU amends the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. This ASU will reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP standards. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU is effective for us on January 1, 2022, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the FASB Emerging Issues Task Force). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321, the accounting for the equity method investments in Topic 323 and the accounting for certain forward contracts and purchased options in Topic 815. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740); Simplifying the Accounting for Income Taxes. ASU 2019-12 reduces complexity in the accounting standard. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

NOTE 3. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.

The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2020, four of the Company's financial institutions held 18%, 38%, 21% and 11% of the Company’s cash and cash equivalents, respectively. As of December 31, 2019, two of the Company's financial institutions held 73% and 18% of the Company’s cash and cash equivalents, respectively.

17


The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. None of the Company's customers accounted for 10% or more of the net accounts receivable balance as of September 30, 2020. The Company had one customer that accounted for 11% of the Company’s net accounts receivable balance as of December 31, 2019.

The Company did not have any customers who represented 10% or more of the Company’s total revenue during the three and nine months ended September 30, 2020 and 2019.


NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
Cash and cash equivalents:
Money market funds$5,013 $ $ $5,013 
Commercial paper 1,875  1,875 
Total cash and cash equivalents5,013 1,875  6,888 
Equity investments:
Mutual funds248   248 
Total equity investments248   248 
Debt securities available-for-sale:
Certificates of deposit 6,857  6,857 
U.S. Treasury securities13,484   13,484 
Commercial paper 9,345  9,345 
Corporate notes and bonds 20,529  20,529 
Debt securities available-for-sale13,484 36,731  50,215 
Total assets measured at fair value$18,745 $38,606 $ $57,351 

18


December 31, 2019
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
Cash and cash equivalents:
Money market funds$43,745 $ $ $43,745 
Commercial paper 1,993  1,993 
Corporate notes and bonds 1,006  1,006 
Total cash and cash equivalents43,745 2,999  46,744 
Debt securities available-for-sale:
Certificates of deposit 5,663  5,663 
U.S. Treasury securities12,579   12,579 
U.S. Agency securities 3,998  3,998 
Commercial paper 2,491  2,491 
Corporate notes and bonds 22,706  22,706 
Debt securities available-for-sale12,579 34,858  47,437 
Total assets measured at fair value$56,324 $37,857 $ $94,181 

Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.

Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.

Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

In 2018, the Company issued the Notes, for total proceeds of $171.5 million, as described in Note 11, Convertible Notes. At September 30, 2020 and December 31, 2019, the fair value of the Notes were $110.7 million and $133.8 million, respectively. The fair value of the Notes is highly correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. The fair value of the Notes are classified as Level 2 within the fair value hierarchy. See Note 11, Convertible Notes for further detail on the Company’s convertible notes.

The Company's PPP Note along with its other long-term notes, cumulatively $5.5 million, approximate their fair value. The estimated fair value of the Company’s long-term debt represents a Level 3 measurement. See Note 10, Long-Term Debt for further detail on the Company's long-term debt.

19


NOTE 5. INVESTMENTS

The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit$6,838 $19 $ $6,857 
U.S. Treasury securities13,435 49  13,484 
U.S. Agency securities    
Commercial paper9,345 1 (1)9,345 
Corporate notes and bonds20,513 19 (3)20,529 
Total$50,131 $88 $(4)$50,215 

December 31, 2019
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit$5,646 $17 $ $5,663 
U.S. Treasury securities12,564 16 (1)12,579 
U.S. Agency securities4,002  (4)3,998 
Commercial paper2,492  (1)2,491 
Corporate notes and bonds22,711 6 (11)22,706 
Total$47,415 $39 $(17)$47,437 

The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020December 31, 2019
Amortized
Cost
Fair ValueAmortized
Cost
Fair Value
Due in less than 1 year$49,874 $49,958 $43,627 $43,650 
Due in 1-3 years257 257 3,788 3,787 
$50,131 $50,215 $47,415 $47,437 

Proceeds from sales of debt securities available-for-sale (including principal paydowns) for each of the three months ended September 30, 2020 and 2019 was $0, and for the nine months ended September 30, 2020 and 2019 were $0 and $13.4 million, respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2020 and 2019. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019.

As of September 30, 2020, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%. As of September 30, 2020 there were no debt securities available-for-sale in a material unrealized loss position.

20


As of September 30, 2020 the Company carried debt securities available-for-sale that were certificates of deposits, which were not covered by a rating agency or the credit rating was below the Company's minimum credit rating. As of September 30, 2020 all of the Company's certificate deposits were below the FDIC's insurance limit of $250,000 per depositor which mitigated the Company's investment risk. All other debt securities available-for-sale had a credit rating of A- or better as of September 30, 2020.

Equity securities are comprised of investments in mutual funds. The fair value of equity securities at September 30, 2020 was $0.2 million. There were no material unrealized gains or losses on equity securities recorded in income for the three and nine months ended September 30, 2020. These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for the three and nine months ended September 30, 2020.

NOTE 6. INVENTORY

Inventories consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):

September 30,December 31,
20202019
Raw materials$5,128 $4,854 
Work in process2,257 1,561 
Finished goods2,074 1,644 
$9,459 $8,059 


NOTE 7. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):

September 30,December 31,
20202019
Computer equipment$2,599 $2,477 
Technical equipment3,943 3,681 
Facilities3,690 3,883 
Instruments6,599 7,491 
Capital projects in progress1,047 238 
Total property and equipment$17,878 $17,770 
Accumulated depreciation(10,774)(9,865)
Property and equipment, net$7,104 $7,905 

Depreciation expense for each of the three months ended September 30, 2020 and 2019 was $0.6 million, and for the nine months ended September 30, 2020 and 2019 was $1.8 million and $1.7 million, respectively.

Gross assets under operating leases where the Company is the lessor at September 30, 2020 and December 31, 2019 were $4.3 million and $4.6 million, respectively. The underlying accumulated depreciation under operating leases where the Company is the lessor at September 30, 2020 and December 31, 2019 was $1.1 million and $0.8 million, respectively.

NOTE 8. LICENSE AGREEMENTS AND GRANTS

National Institute of Health Grant

In February 2015, the National Institute of Health awarded Denver Health and the Company a five-year, $5.0 million grant to develop a fast and reliable identification and categorical susceptibility test for carbepenem-
21


resistant Enterobacteriaceae directly from whole blood. The grant is paid to the Company incrementally through sub-awards. The cumulative amount awarded to date under these sub-awards is $1.5 million. The amount invoiced for the nine months ended September 30, 2020 and 2019 was $0.1 million and $0.2 million, respectively. Subsequent to the original term of the grant the National Institute of Health has provided incremental annual extensions that have allowed the Company to provide additional services.

NOTE 9. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS

Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2020 and December 31, 2019 follows (in thousands):

September 30,December 31,
20202019
Products and services not yet delivered$338 $271 

We recognized $0.1 million and $0.2 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2020, respectively, and $0.2 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2019. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.

Transaction Price Allocated to Remaining Performance Obligations

As of September 30, 2020, $8.6 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.

The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

NOTE 10. LONG-TERM DEBT

As of September 30, 2020 and December 31, 2019, long-term debt consisted of the following (in thousands):

September 30,December 31,
20202019
PPP Loan - 1% interest
$4,803 $ 
Other Loans - various interest736  
Total debt5,539  
Current portion of long-term debt511  
Long-term debt$5,028 $ 

22


The following presents maturities of future principal obligations of long-term debt as of September 30, 2020 (in thousands):

Remainder of 2020$76 
2021825 
20221,604 
20231,291 
20241,304 
Thereafter439 
Total$5,539 

Other notes payable

During the three months ended September 30, 2020, the Company entered into three loan agreements with two capital asset financing companies. Loan proceeds were $0.7 million, with interest rates ranging from 9.8% to 12.4% and maturities ranging from January 1, 2022 to September 2022. As of September 30, 2020, the current portion of long-term debt was $0.3 million and long-term debt was $0.4 million.

PPP Loan

On April 14, 2020, the Company entered into the PPP Note evidencing an unsecured loan in the amount of $4.8 million made to the Company under the PPP. The PPP was established under the CARES Act and is administered by the SBA.

On September 3, 2020 the Company's loan provider amended the PPP Note per the Paycheck Protection Program Flexibility Act (“PPP Flexibility Act”), which was enacted after the PPP Note was approved and funded. The PPP Flexibility Act amended the CARES Act to require that all PPP Notes made prior to June 5, 2020 be extended to a 5-year term. In accordance with this amendment the PPP Notes' original maturity date of April 14, 2022 was amended to April 14, 2025. The original terms of the loan required 18 monthly payments of principal and interest in the amount of $0.3 million starting November 14, 2020. These amended terms now require 45 monthly payments of principal and interest in the amount of $0.1 million starting August 14, 2021. The PPP Note's interest rate was unchanged and bears interest at a rate of 1% per annum.

The PPP Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from the PPP Note may only be used for payroll costs (including benefits), interest on mortgage obligations, rent, utilities and interest on certain other debt obligations.

The PPP Note contains customary events of default relating to, among other things, payment defaults, making materially false and misleading representations to the lender or breaching the terms of the PPP Note documents. The occurrence of an event of default will result in an increase in the interest rate to 18% per annum and provides the lender with customary remedies, including the right to require immediate payment of all amounts owed under the PPP Note.

Pursuant to the terms of the CARES Act and the PPP, the Company may apply to the lender for forgiveness for the amount due on the PPP Note. The amount eligible for forgiveness is based on the amount of PPP Note proceeds used by the Company (during the 24 week period after the lender makes the first disbursement of PPP Note proceeds) for the payment of certain covered costs, including payroll costs (including benefits), rent and utilities, subject to certain limitations and reductions in accordance with the CARES Act and the PPP. No assurance can be given that the Company will obtain forgiveness of the PPP Note in whole or in part. As of September 30, 2020 the Company had submitted their application for forgiveness to the loan provider, which is currently under review.

23


NOTE 11. CONVERTIBLE NOTES

On March 27, 2018, the Company issued $150.0 million aggregate principal amount of 2.50% Senior Convertible Notes due 2023. In connection with the offering of the Notes, the Company granted the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes on the same terms and conditions. On April 4, 2018, the option was partially exercised, which resulted in $21.5 million of additional proceeds, for total proceeds of $171.5 million. The Notes are the Company's senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year.

The $171.5 million of proceeds received from the issuance of the Notes were allocated between long-term debt (the “liability component”) of $116.6 million and contributed capital (the “equity component”) of $54.9 million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Notes. The liability component will be accreted up to the face value of the Notes of $171.5 million, which will result in additional non-cash interest expense being recognized through the Maturity Date. The equity component will not be remeasured as long as it continues to meet the conditions for equity classification.

The Company incurred approximately $5.0 million of issuance costs related to the issuance of the Notes, of which $3.4 million and $1.6 million were recorded to long-term debt and contributed capital, respectively. The $3.4 million of issuance costs recorded as long-term debt on the condensed consolidated balance sheet are being amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par and debt issuance cost amortization, is 11.52%.

The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:

if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;

during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or

the occurrence of certain corporate events, such as a change of control, merger or liquidation.

At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date.

24


The Notes at September 30, 2020 and December 31, 2019 consisted of the following (in thousands):

September 30,December 31,
20202019
Outstanding principal$171,500 $171,500 
Unamortized debt discount(31,267)(39,042)
Unamortized debt issuance(1,934)(2,415)
Net carrying amount of the liability component$138,299 $130,043 

Interest expense for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Contractual coupon interest
$1,072 $1,072 $3,216 $3,216 
Amortization of the debt discount
2,666 2,379 7,775 6,940 
Amortization of debt issuance costs
165 147 481 429 
Total interest expense on convertible notes$3,903 $3,598 $11,472 $10,585 

As of September 30, 2020 and December 31, 2019, no Notes were convertible pursuant to their terms.

In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.

25


NOTE 12. EARNINGS PER SHARE

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Shares issuable upon the release of restricted stock units722 20 722 20 
Shares issuable upon exercise of stock options8,952 10,159 8,952 10,159 
9,674 10,179 9,674 10,179 

Potentially dilutive common shares would also include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 11, Convertible Notes, the Company issued $171.5 million of Notes due 2023. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes. As of September 30, 2020, no Notes were convertible pursuant to their terms. The number of shares issuable upon conversion of the Notes is 5.5 million shares.

In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.

NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION

The following table summarizes option activity under all plans for the nine months ended September 30, 2020:

Number of SharesWeighted Average Exercise Price per Share
Options Outstanding January 1, 202010,132,562 $12.28 
Granted1,693,083 8.55 
Forfeited(486,864)13.86 
Exercised(2,219,281)2.01 
Expired(167,187)19.83 
Options Outstanding September 30, 20208,952,313 $13.89 

26


The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for the three months ended September 30, 2020 and 2019:

Three Months Ended September 30,
20202019
Expected term (in years)6.146.46
Volatility62 %59 %
Expected dividends  
Risk free interest rates0.42 %1.47 %
Weighted average fair value$8.10 $9.66 

The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2020:

Options
Outstanding
Options
Exercisable
Number of options8,952,313 4,767,274 
Weighted average remaining contractual term (in years)6.264.51
Weighted average exercise price$13.89 $13.28 
Weighted average fair value$8.73 $8.60 
Aggregate intrinsic value (in thousands)$15,514 $12,387 

The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2020:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 202014,332 $16.66 
Granted807,751 11.47 
Forfeited(31,307)9.72 
Vested/released(68,641)9.85 
Outstanding September 30, 2020722,135 $11.80 

The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cost of sales$119 $65 $249 $172 
Research and development1,349 897 2,807 3,226 
Sales, general and administrative3,208 2,169 9,235 6,011 
$4,676 $3,131 $12,291 $9,409 

27


The table below summarizes share-based compensation cost capitalized to inventory or inventory transferred to property and equipment (also referred to as instruments) for the three and nine months ended September 30, 2020 and 2019 (in thousands):


Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cost capitalized to inventory
$61 $92 $199 $332 

As of September 30, 2020, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $17.4 million and $3.9 million, respectively. This is expected to be recognized over the years 2020 through 2025.

Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based options issued under the plan. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

In August 2018, the Company granted 225,000 performance-based stock options. Of these performance-based stock options performance obligations had been met for 75,000 options which became exercisable in the prior year. The remaining 150,000 options were forfeited for the performance targets not being achieved. Of the total options forfeited, 50,000 of those options were forfeited during the nine months ended September 30, 2020. No stock compensation expense for the forfeited performance-based stock options was recognized. The stock compensation expense for the vested options was recorded in prior periods.

During the nine months ended September 30, 2020, the Company granted another 105,000 performance-based stock options. During the three and nine months ended September 30, 2020, 22,500 performance-based stock options vested due to the performance obligations being achieved. None of these options have been forfeited as of September 30, 2020.

The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):


Nine Months Ended September 30,
20202019
Performance-based stock option expense
$109 $107 

Included in the above-noted RSU and restricted stock award outstanding amount are performance-based RSU's which vest only upon the achievement of certain targets. Performance-based RSU's contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During the nine months ended September 30, 2020, the Company granted 361,338 performance-based RSU's. During the three and nine months ended September 30, 2020, 40,500 performance-based RSU's were released due to the performance obligations being achieved. At September 30, 2020 306,785 performance-based RSU's were outstanding. None of these performance-based RSU have been forfeited due to performance obligations not being achieved.

28


The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):

Nine Months Ended September 30,
20202019
Performance-based RSU expense
$401 $ 

NOTE 14. INCOME TAXES

For the nine months ended September 30, 2020, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2020 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $59.3 million, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions. At September 30, 2020, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.

On March 27, 2020, the U.S. enacted the CARES Act. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Management does not expect the CARES Act to have a material impact on the Company’s income tax position for financial reporting purposes. The Company will continue its assessment of the CARES Act on its financial statements, as changes in tax legislation and further guidance for the CARES Act become available in the subsequent quarters.

The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2020, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.

NOTE 15. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cash paid for amounts included in lease liabilities
Operating cash flows from operating leases$185 $168 $556 $333 
ROU assets obtained in exchange for lease obligations
Operating leases$ $3,639 $17 $3,639 
Lease Cost
Operating leases$277 $213 $790 $378 
Short-term leases$17 $103 $45 $697 

The weighted average remaining lease term on our operating leases is 4.7 years. The weighted average discount rate on those leases is 7%.

29


The following presents maturities of operating lease liabilities in which we are the lessee as of September 30, 2020 (in thousands):

Remainder of 2020$174 
2021753 
2022877 
2023968 
20241,055 
Thereafter619 
Total lease payments4,446 
Less imputed interest(733)
$3,713 

The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2020, the total net investment in these leases was $2.6 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2020 (in thousands):

Remainder of 2020$223 
2021851 
2022794 
2023431 
2024123 
Thereafter150 
Total undiscounted cash flows2,572 
Less imputed interest 
Present value of lease payments$2,572 

NOTE 16. INDUSTRY, GEOGRAPHIC AND REVENUE DISAGGREGATION

The Company operates as one operating segment. Sales to customers outside the U.S. represented 6% and 23% for the three months ended September 30, 2020 and 2019, respectively, and 7% and 26% for the nine months ended September 30, 2020 and 2019, respectively.

As of September 30, 2020 and December 31, 2019, balances due from foreign customers, in U.S. dollars, were $1.2 million and $2.1 million, respectively.

The following presents total net sales by geographic territory for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Domestic$3,386 $1,757 $7,477 $4,308 
Foreign202 514 579 1,519 
$3,588 $2,271 $8,056 $5,827 

30


The following presents total net sales by line of business for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Accelerate Pheno revenue
$3,582 $2,221 $7,980 $5,702 
Other revenue6 50 76 125 
$3,588 $2,271 $8,056 $5,827 

The following presents total net sales by products and services for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Products$3,402 $2,143 $7,481 $5,531 
Services186 128 575 296 
$3,588 $2,271 $8,056 $5,827 

Lease revenue included in net sales was $1.7 million and $0.2 million for the three months ended September 30, 2020 and 2019, respectively, and $2.4 million and $0.6 million for the nine months ended September 30, 2020 and 2019, respectively, which does not represent revenues recognized from contracts with customers.

The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20202019
Domestic$6,563 $7,244 
Foreign541 661 
$7,104 $7,905 

NOTE 17. RELATED PARTY TRANSACTIONS

As discussed in Note 11, Convertible Notes, the Company issued Notes in March 2018. As of September 30, 2020 and December 31, 2019 an entity controlled by one member of the Company's board of directors held an aggregate of $42.0 million of the Notes.

On August 20, 2019, the Company and an entity affiliated with the then Chief Operating Officer and current Chief Executive Officer of the Company entered into a securities purchase agreement (the “Purchase Agreement”) for the issuance and sale by the Company of an aggregate of 55,586 shares of the Company’s common stock (the “Shares”) in an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The Shares were sold at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the shares) of $17.99 per share, which was equal to the consolidated closing bid price reported by Nasdaq immediately preceding the time the Company entered into the Purchase Agreement. The $1.0 million of proceeds were recorded to contributed capital.

31



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introductory Note

Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to the “Company,” “Accelerate,” “we,” “us” or “our” are references to the combined business of Accelerate Diagnostics, Inc. The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) summarizes the significant factors affecting our results of operations, liquidity, capital resources and contractual obligations. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and related notes included elsewhere herein.

All amounts in the MD&A have been rounded to the nearest thousand unless otherwise indicated.

Forward-Looking Statements

This Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company intends that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements, which can be identified by the use of words such as “may,” “will,” “expect,” “anticipate,” “estimate,” or “continue,” or variations thereon or comparable terminology, include but are not limited to, statements about the plans and objectives of management for future operations, including plans and objectives relating to the products and future performance of the Company; projections of our future financial performance and demand for our products; the anticipated impacts from the COVID-19 pandemic on the Company, including to our business, results of operations, cash flows and financial position, as well as our future responses to the COVID-19 pandemic; our plans or expectations with relating to our agreement with BioCheck, Inc. (“BioCheck”); and our agreement with Ascend Diagnostics Ltd. (“Ascend”). In addition, all statements other than statements of historical facts that address activities, events, or developments the Company expects, believes, or anticipates will or may occur in the future, and other such matters, are forward-looking statements.

Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. There can be no assurances that results described in forward-looking statements will be achieved, and actual results could differ materially from those suggested by the forward-looking statements. The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties, including the duration and severity of the COVID-19 pandemic and its ultimate effect on our business, results of operations, cash flows and financial position, as well as our ability (or inability) to execute on our plans to respond to the COVID-19 pandemic. Other important factors that could cause our actual results to differ materially from those in our forward-looking statements include those discussed herein, and in other reports filed with the SEC including but not limited to the risks in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, the section entitled “Risk Factor” in this Form 10-Q and in the Company's subsequent filings with the SEC. These forward-looking statements are also based on assumptions that the Company will retain key management personnel, the Company will be successful in the commercialization of the Accelerate Pheno® system, the Company will obtain sufficient capital to commercialize the Accelerate Pheno system and continue development of complementary products, the Company will be able to protect its intellectual property, the Company’s ability to respond to technological change, the Company will accurately anticipate market demand for the Company’s products and there will be no material adverse change in the Company’s operations or business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. Any forward-looking statements made by us in this Form 10-Q speak only as of the date on which they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

32


Overview

Accelerate Diagnostics, Inc. (“Accelerate”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Microbiology laboratories are in need of new tools to address what the U.S. Centers for Disease Control and Prevention (the “CDC”) calls one of the most serious healthcare threats of our time, antibiotic resistance. A significant contributing factor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results. The delay of identification and antibiotic susceptibility results is often due to the reliance by microbiology laboratories on traditional culture-based tests that often take two to three days to complete. Our technology platform is built to address these challenges by delivering significantly faster testing of infectious pathogens.

Our first system to address these challenges is the Accelerate Pheno system. The Accelerate Pheno system utilizes genotypic technology to identify (“ID”) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (“AST”), which determines whether live bacterial and fungal cells are resistant or susceptible to a particular antimicrobial. The Accelerate PhenoTest® BC Kit, which is the first test kit for the system, provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. This information is used to rapidly modify antibiotic therapy to lessen side-effects, improve clinical outcomes, and help preserve the useful life of antibiotics.

On June 30, 2015, we declared our conformity to the European In Vitro Diagnostic Directive 98/79/EC and applied a CE Mark to the Accelerate Pheno system and the Accelerate PhenoTest BC Kit for in vitro diagnostic use. On February 23, 2017, the U.S. Food and Drug Administration (“FDA”) granted our de novo request to market our Accelerate Pheno system and Accelerate PhenoTest BC Kit.

In 2017, we began selling the Accelerate Pheno system in hospitals in the U.S., Europe, and the Middle East. Consistent with the Company's “razor” / “razor-blade” business model, revenues to date have principally been generated from the sale of the instruments and the sale of single use consumable test kits.

Improving our commercial and implementation capabilities remains an emphasis going forward, along with geographic expansion and product innovation.

On April 13, 2020 we signed a non-exclusive agreement with BioCheck to sell MS-FAST, a fully-automated chemiluminescence immunoassay analyzer, along with BioCheck’s SARS-CoV-2 tests for the detection of IgG and IgM antibodies (together the “BioCheck COVID-19 Serology System”). We will pay BioCheck a pre-defined price for the sale of each BioCheck COVID-19 Serology System device and assay. The BioCheck COVID-19 Serology System has a CE Mark and has obtained FDA Emergency Use Authorization. The Company has commercially released this product in the U.S. and in Europe, but has not sold any BioCheck COVID-19 Serology Systems during the nine months ended September 30, 2020.

On July 29, 2020 we signed an an exclusive product supply and collaboration agreement with Ascend to commercialize a benchtop MALDI identification platform to complement the Company's expanded product offering plans.

These are the first third-party product commercialization agreements entered into by the Company. As such, there are uncertainties regarding market demand, market acceptance, supply constraints, FDA authorization, ramp up expenditures, and other factors impacting market penetration.

COVID-19 Update

In late 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China, which has since spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic. Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19, such as travel bans and restrictions, quarantines, shelter-in-place, stay-at-home or total lock-down (or similar) orders and business limitations and shutdowns. For example, the State of Arizona has implemented several orders promoting physical distancing, limiting certain activities, and restricting the operations of certain businesses, including restaurants, bars, gyms, theaters and water parks. The COVID-19 pandemic and these measures have caused, and are continuing to cause, business slowdowns or shutdowns in affected areas, both regionally and worldwide, which have significantly impacted our
33


business and results of operations, starting in the first quarter of 2020. For example, this included diminished access to our customers, including hospitals, which has severely limited our ability to sell or implement the Accelerate Pheno systems. In addition, in April and May 2020 our Accelerate Pheno kit orders declined as many hospitals curtailed elective surgeries to respond to COVID-19. Since May 2020, our Accelerate Pheno kit orders have returned to more normal levels, but could decline again if COVID-19 surges cause hospitals to reduce or prohibit elective surgeries. Furthermore, our expected rate of growth of our consumable test kit sales has been reduced because of the negative impact of the COVID-19 pandemic on Accelerate Pheno system new sales and implementations.

The reduced sales and implementations caused by the COVID-19 pandemic lowered our expected revenue growth for 2020. Due to this reduced revenue growth's impact on cash we furloughed certain employees and implemented salary reductions for executives and other highly compensated employees. We expect some of the furloughs to be permanent, and others to continue until the end of the year.

As a medical device company, we have not experienced any disruptions to our ability to manufacture our products at our Tucson, Arizona headquarters under the various State of Arizona executive orders relating to the COVID-19 pandemic because we were classified as an essential service. We currently expect that, should future orders be issued, we would be able to sustain our essential operations. Our third-party manufacturing supply chain for Accelerate Pheno systems and consumable test kits remains stable. However, the economic effects of the COVID-19 pandemic remain unpredictable, and we are closely monitoring the ability of all our suppliers to provide us with materials necessary for the manufacture of Accelerate Pheno systems and consumable test kits.

Additionally, the Company received loan proceeds of approximately $4.8 million under the Paycheck Protection Program established under the CARES Act. For additional information about the loan, refer to Part I, Item 1, Note 10, (Long-Term Debt) in this Form 10-Q.

We continue to monitor the rapidly evolving situation caused by the COVID-19 pandemic, and we may take further actions required by governmental authorities or that we determine are prudent to support the well-being of our employees, customers, suppliers, business partners and others. The degree to which the COVID-19 pandemic ultimately impacts our business, results of operations, cash flows and financial position will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted. This includes, but is not limited to, the duration and spread of the pandemic, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.

Accordingly, our current results and financial condition discussed herein may not be indicative of future operating results and trends. Refer to the section entitled “Risk Factors” in this Form 10-Q for additional risks we face due to the COVID-19 pandemic.

Restructure Activity

Following the completion of a strategic review of its EMEA business, the Company's board of directors approved a plan to reduce its workforce, focus the geographies it plans to operate in, and terminate agreements with some distributors in geographies it plans on exiting (collectively, the “EMEA Restructuring Plan”). As of September 30, 2020, the Company substantially completed the workforce reduction portion of the EMEA Restructuring Plan, while the remaining restructuring activities are likely to occur through the end of the year.

Changes in Results of Operations: Three and nine months ended September 30, 2020 compared to three and nine months ended September 30, 2019

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20202019$ Change% Change20202019$ Change% Change
Net sales$3,588 $2,271 $1,317 58 %$8,056 $5,827 $2,229 38 %

For the three and nine months ended September 30, 2020, total revenues increased as compared to the three and nine months ended September 30, 2019 primarily due to increased sales of Accelerate PhenoTest BC Kits and instruments. Accelerate PhenoTest BC revenue has increased as customers complete their instrument
34


verifications and begin purchasing kits. In addition, the Company has incurred higher revenue in connection with sales-type leases of Accelerate PhenoTest Systems.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20202019$ Change% Change20202019$ Change% Change
Cost of sales$2,287 $1,117 $1,170 105 %$4,745 $2,940 $1,805 61 %
Gross profit$1,301 $1,154 $147 13 %$3,311 $2,887 $424 15 %

For the three and nine months ended September 30, 2020, cost of sales and gross profit increased as compared to the three and nine months ended September 30, 2019 as a result of higher sales.

Cost of sales included non-cash equity-based compensation of $0.1 million for each of the three months ended September 30, 2020 and 2019, and $0.2 million for each of the nine months ended September 30, 2020 and 2019.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20202019$ Change% Change20202019$ Change% Change
Research and development$5,001 $6,064 $(1,063)(18)%$16,191 $19,145 $(2,954)(15)%

Research and development expenses for the three and nine months ended September 30, 2020 decreased compared to the three and nine months ended September 30, 2019. The decrease was the result of a decrease in external studies spend and other cost containment measures.

Research and development expenses included non-cash equity-based compensation of $1.3 million and $0.9 million for the three months ended September 30, 2020 and 2019, respectively, and $2.8 million and $3.2 million for the nine months ended September 30, 2020 and 2019, respectively. Employee non-cash equity-based compensation increased compared to the three months ended September 30, 2019, which offset in part the decrease in other research and development expenses. This increase in expense was due to the vesting and release of performance based stock awards during the three months ended September 30, 2020. Employee non-cash equity-based compensation decreased compared to the nine months ended September 30, 2019. This decrease was due to a decrease in the weighted average fair value of stock option grants.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20202019$ Change% Change20202019$ Change% Change
Sales, general and administrative$11,465 $12,743 $(1,278)(10)%$35,738 $38,302 $(2,564)(7)%

Sales, general and administrative expenses for the three and nine months ended September 30, 2020 decreased as compared to the three and nine months ended September 30, 2019. This decrease is primarily the result of the COVID-19 pandemic, as hospitals have limited access to their facilities to primarily focus on COVID-19 initiatives. These circumstances resulted in decreased expenses associated with travel, trade shows, and instrument demonstration expenses. In addition management also implemented additional cost containment initiatives to reduce other expenses such as services and marketing expenses.

These cost reductions were offset in part by increases in non-cash equity-based compensation expenses for the three and nine months ended September 30, 2020 compared to the three and nine months ended September 30, 2019. Sales, general and administrative expenses included non-cash equity-based compensation of $3.2 million and $2.2 million for the three months ended September 30, 2020 and 2019, respectively, and $9.2 million and $6.0 million for the nine months ended September 30, 2020 and 2019, respectively. Non-cash equity-based compensation increased for the three and nine months ended September 30, 2020 as compared to the three
35


and nine months ended September 30, 2019 due to larger stock option and stock awards granted to employees in the current year periods.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20202019$ Change% Change20202019$ Change% Change
Loss from operations$(15,165)$(17,653)$2,488 (14)%$(48,618)$(54,560)$5,942 (11)%

For the three and nine months ended September 30, 2020, our loss from operations decreased as compared to the three and nine months ended September 30, 2019. The decreases were primarily the result of a decreases in research and development expenses, and sales, general and administrative expenses, combined with an increase in net sales as described above.

Loss from operations included non-cash equity-based compensation of $4.7 million and $3.1 million for the three months ended September 30, 2020 and 2019, respectively, and $12.3 million and $9.4 million for the nine months ended September 30, 2020 and 2019, respectively.

This loss and further losses are anticipated and was the result of our continued investments in sales and marketing, key research and development personnel, related costs associated with product development, and commercialization of the Company’s products.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20202019$ Change% Change20202019$ Change% Change
Total other expense, net$(3,592)$(3,020)$(572)19 %$(10,678)$(8,410)$(2,268)27 %

Other expense for the three and nine months ended September 30, 2020 increased as compared to the three and nine months ended September 30, 2019. The increases were primarily the result of decreased interest income and increased interest expense for the three and nine months ended September 30, 2020.

For the three months ended September 30, 2020 and 2019, the Company incurred interest expense associated with our Notes of $4.0 million and $3.6 million, respectively, and $11.5 million and $10.6 million for the nine months ended September 30, 2020 and 2019, respectively.

These amounts were partially offset by investment income of $0.1 million and $0.7 million for the three months ended September 30, 2020 and 2019, respectively, and $0.8 million and $2.3 million for the nine months ended September 30, 2020 and 2019, respectively.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20202019$ Change% Change20202019$ Change% Change
Provision for income taxes$— $239 $(239)NM$— $— $— NM

NM indicates percentage is not meaningful

For the three months ended September 30, 2020, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. For the three months ended September 30, 2019, the Company recorded an income tax benefit amount of $0.2 million to reverse the foreign income tax expense recorded in prior quarters as the Company no longer expects to pay current year income taxes in any of the foreign jurisdictions. For the nine months ended September 30, 2020 and 2019, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions.

36


Capital Resources and Liquidity

Our primary source of liquidity has been from sales of shares of common stock, the issuance of our convertible notes and cash from operations. As of September 30, 2020, the Company had $77.5 million in cash and cash equivalents and investments, a decrease of $31.0 million from $108.5 million at December 31, 2019. The primary reason for the decrease was due to cash used in operations during the period.

The Company is subject to lease agreements. The future minimum lease payments under these lease agreements are included in Part I, Item 1, Note 15, (Leases).

As of September 30, 2020, management believes that current cash balances will be sufficient to fund our capital and liquidity needs for the next twelve months.

Our primary use of capital has been for the commercialization and development of the Accelerate Pheno system. We believe our capital requirements will continue to be met with our existing cash balance and those provided by revenue, grants, exercises of stock options and/or additional issuance of equity or debt securities. However, if capital requirements vary materially from those currently planned, or if our business is negatively impacted by the COVID-19 pandemic more seriously or for longer than we currently expect, we may require additional capital sooner than expected. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us, if at all. Additional issuances of equity or convertible debt securities will result in dilution to our current common stockholders.

Summary of Cash Flows

The following summarizes selected items in the Company’s condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019:

Cash Flow Summary
Nine Months Ended September 30,
(in thousands)
20202019$ Change
Net cash used in operating activities$(40,051)$(50,929)$10,878 
Net cash (used in) provided by investing activities(4,246)71,464 (75,710)
Net cash provided by financing activities10,293 6,242 4,051 

Cash flows from operating activities

The net cash used in operating activities was $40.1 million and $50.9 million for the nine months ended September 30, 2020 and 2019, respectively. Net cash used in operating activities was primarily the result of net losses offset by equity-based compensation and amortization of debt discount and issuance costs. These losses are the result of continued investments in research and development, sales and marketing, along with other factors. A decrease in our net loss, along with increases in non-cash expenses resulted in a decrease in cash used in operating activities for the nine months ended September 30, 2020 compared to the prior year period.

Cash flows from investing activities

The net cash used in investing activities was $4.2 million for the nine months ended September 30, 2020. During the nine months ended September 30, 2020, the Company purchased marketable securities of $44.6 million, which were offset in part by maturities of marketable securities of $41.7 million. The net cash provided by investing activities was $71.5 million for the nine months ended September 30, 2019. During the nine months ended September 30, 2019, the Company had proceeds from sales and maturities of marketable securities of $92.3 million, which were offset in part by purchases of marketable securities of $20.7 million.

The Company had an increase in marketable securities purchases during the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019, due to the Company liquidating a portion of its money market funds carried as cash and cash equivalents as of December 31, 2019, and reinvesting these balances in debt securities available-for-sale during the nine months ended September 30, 2020. The
37


Company had larger proceeds from sales and maturities of marketable securities for the nine months ended September 30, 2019 compared to the nine months ended September 30, 2020 due to the Company carrying larger balance of debt securities available-for-sale during the nine months ended September 30, 2019.

Cash flows from financing activities

The net cash provided by financing activities was $10.3 million and $6.2 million for the nine months ended September 30, 2020 and 2019, respectively. During the nine months ended September 30, 2020 the Company received $5.6 million in proceeds in connection with long-term debt, including the PPP Loan, resulting in an increase in net cash provided by financing activities for the nine months ended September 30, 2020.

Convertible Notes

On March 27, 2018, the Company issued $150.0 million aggregate principal amount of 2.50% Convertible Senior Notes (“Notes”). In connection with the offering of the Notes, the Company granted the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes on the same terms and conditions. On April 4, 2018 the option was partially exercised, which resulted in $21.5 million of additional proceeds, for total proceeds of $171.5 million. The Notes mature on March 15, 2023, unless earlier repurchased or converted into shares of common stock subject to certain conditions. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. We pay interest on the Notes semi-annually in arrears on March 15 and September 15 of each year with interest payments beginning on September 15, 2018. Proceeds received from the issuance of the Notes were allocated between long-term debt (the “liability component”) and contributed capital (the “equity component”), within the condensed consolidated balance sheet. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. For additional information about the Notes, refer to Part I, Item 1, Note 11, (Convertible Notes) in this Form 10-Q.

In connection with the offering, we entered into a prepaid forward stock repurchase transaction (the “Prepaid Forward”) with a financial institution. Pursuant to the Prepaid Forward, we used approximately $45.1 million of the proceeds from the offering of the Notes to pay the prepayment amount. The aggregate number of our common stock underlying the Prepaid Forward is approximately 1,858,500 shares (based on the sale price of $24.25). The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to us the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward were treated as treasury stock on the condensed consolidated balance sheet (and not outstanding for purposes of the calculation of basic and diluted earnings per share), but remain outstanding for corporate law purposes, including for purposes of any future stockholders' votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to us.

Paycheck Protection Program (PPP) Loan

On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million. The PPP Note matures on April 14, 2025 and bears interest at a rate of 1% per annum. Beginning August 14, 2021, the Company is required to make 45 monthly payments of principal and interest in the amount of $0.1 million. The PPP Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from the PPP Note may only be used for payroll costs (including benefits), interest on mortgage obligations, rent, utilities and interest on certain other debt obligations. For additional information about the PPP Note, refer to Part I, Item 1, Note 10, (Long-Term Debt) in this Form 10-Q.

Pursuant to the terms of the CARES Act and the PPP, the Company may apply to the lender for forgiveness for the amount due on the Loan. The amount eligible for forgiveness is based on the amount of loan proceeds used by the Company (during the 24 week period after the lender makes the first disbursement of loan proceeds) for the payment of certain covered costs, including payroll costs (including benefits), rent and utilities, subject to certain limitations and reductions in accordance with the CARES Act and the PPP. No assurance can be given that the Company will obtain forgiveness of the PPP Note in whole or in part. As of September 30, 2020 the Company had submitted their application for forgiveness to the loan provider, which is currently under review.

38


Other notes payable

During the three months ended September 30, 2020, the Company entered into three loan agreements with two capital asset financing companies. Loan proceeds were $0.7 million, with interest rates ranging from 9.8% to 12.4 % and maturities ranging from January 1, 2022 to September 2022. For additional information about other notes payable, refer to Part I, Item 1, Note 10, (Long-Term Debt) in this Form 10-Q.

Contractual Obligations

A table reflecting certain of our specified contractual obligations as of December 31, 2019 was provided in the Management’s Discussion and Analysis of Financial Condition and Results of Operation of our 2019 Form 10-K. On April 14, 2020, the Company entered into the PPP Note in the amount of $4.8 million. The PPP Note matures on April 14, 2025 and bears interest at a rate of 1% per annum. Beginning August 14, 2021, the Company is required to make 45 monthly payments of principal and interest in the amount of $0.1 million. The PPP Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. During the three months ended September 30, 2020, the Company also entered into three loan agreements with two capital asset financing companies. Loan proceeds were $0.7 million, with interest rates ranging from 9.8% to 12.4 % and maturities ranging from January 1, 2022 to September 2022. For additional information about long-term debt, refer to Part I, Item 1, Note 10, (Long-Term Debt) in this Form 10-Q.

With the exception of this item, there were no material changes outside the ordinary course of our business in the specified contractual obligations during the three months ended September 30, 2020.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2020.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our estimates on an ongoing basis, including those related to accounts receivable, inventories, property and equipment, intangible assets, accruals, warranty liabilities, tax valuation accounts and stock-based compensation. We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and are not readily apparent from other sources. Actual results may differ from these estimates. Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Additional critical accounting policies added to Note 1, Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies include the Company's accounting policy relating to the PPP Note recorded during the nine months ended September 30, 2020.


Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

Our investment portfolio is exposed to market risk from changes in interest rates. The fair market value of fixed rate securities may be adversely impacted by fluctuations in interest rates while income earned on floating rate securities may decline as a result of decreases in interest rates. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates along the entire interest rate yield curve would change the fair value of our interest sensitive financial instruments by approximately $0.0 million as of September 30, 2020 and $0.3 million as of December 31, 2019.

Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. The goals of our investment policy are preservation of capital,
39


fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities that management believes to be of high credit quality. Further information regarding our investments is included in Part I, Item 1, Note 5, (Investments) in this Form 10-Q.

Although the Company’s Notes are based on a fixed rate, changes in interest rates could impact the fair market value of the Notes. As of September 30, 2020, the fair market value of the Notes was $110.7 million. For additional information about the Notes, refer to Part I, Item 1, Note 11, (Convertible Notes) in this Form 10-Q.

Foreign Currency Risk

We operate primarily in the U.S. and a majority of our cost, expense and capital purchasing activities for the nine months ended September 30, 2020 were transacted in U.S. dollars. As a corporation with international and domestic operations, we are exposed to changes in foreign exchange rates. Our international revenue is predominantly in Europe and the Middle East and is denominated in Euros and U.S. dollars. In our international operations, we pay payroll and other expenses in local currencies. Our exposures to foreign currency risks may change over time and could have a material adverse impact on our financial results.


Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective as of September 30, 2020, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2020 that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
40


PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are from time to time subject to various claims and legal actions in the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations or financial condition.


Item 1A. Risk Factors

In addition to the other information set forth in this Form 10-Q, you should carefully consider the risks discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 and the risks relating to the impact of the COVID-19 pandemic described below. The risks described in our Annual Report on Form 10-K for the year ended December 31, 2019 and below are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, results of operations, cash flows and financial position.

Additional Risk Related to Our Business and Strategy

The COVID-19 pandemic has had, and is expected to continue to have, a significant adverse impact on our commercial operations and also exposes our business to other risks.

In late 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China, which has since spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic. Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19, such as travel bans and restrictions, quarantines, shelter-in-place, stay-at-home, or total lock-down (or similar) orders and business limitations and shutdowns. For example, the State of Arizona has implemented several orders promoting physical distancing, limiting certain activities, and restricting the operations of certain businesses, including restaurants, bars, gyms, theaters and water parks. The COVID-19 pandemic and these measures have caused, and are continuing to cause, business slowdowns or shutdowns in affected areas, both regionally and worldwide, which have significantly impacted our business and results of operations, starting in the first quarter of 2020. For example, this included diminished access to our customers, including hospitals, which has severely limited our ability to sell or implement the Accelerate Pheno systems. In addition, in April and May 2020 our Accelerate Pheno kit orders declined as many hospitals curtailed elective surgeries to respond to COVID-19. Since May 2020, our Accelerate Pheno kit orders have returned to more normal levels, but could decline again if COVID-19 surges cause hospitals to reduce or prohibit elective surgeries. Furthermore, our expected rate of growth of our consumable test kit sales has been reduced because of the negative impact of the COVID-19 pandemic on Accelerate Pheno system new sales and implementations. For additional information, refer to “COVID-19 Update” in Part I, Item 2 of this Form 10-Q.

In addition to the negative impact on new sales and implementations of the Accelerate Pheno system and to demand for our consumable test kits, the pandemic exposes our business, operations, and workforce to a variety of other risks, including:

delays in product development or reductions in manufacturing production as a result of inventory shortages, supply chain shortages, or diversion of our efforts and resources to projects related to COVID-19;

increased expenses resulting from our COVID-19 BioCheck serology initiative in order to achieve regulatory approval, training our commercial team, and develop marketing materials;

interruptions, availability or delays in global shipping to transport our products;

regulatory approval delays due to regulators being overwhelmed reviewing COVID-19 related medical devices and drugs;

increased regulatory restrictions or continued market volatility could hinder our ability to execute strategic business activities, as well as negatively impact our stock price;
41



significant disruption of global financial markets, which could cause fluctuations in currency exchange rates or negatively impact our ability to access capital markets;

inability to access capital markets on terms that are not significantly detrimental to our business because our revenue growth rate has slowed due to our inability to sell and implement the Accelerate Pheno system as forecasted prior to the pandemic at a stage in our maturation when we are cash flow negative and have significant indebtedness in the form of convertible senior notes;

negative impact on our workforce productivity, product development, and research and development due to difficulties resulting from our personnel working remotely; and

illnesses to key employees, or a significant portion of our workforce, which may result in inefficiencies, delays, and disruptions in our business;

Any of these developments may adversely affect our business, harm our reputation, or result in legal or regulatory actions against us.

Further, the spread of COVID-19 has caused us to modify our business practices (including employee travel, employee work locations, and cancellation of physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers, partners, and suppliers. There is no certainty that such measures will be sufficient to mitigate the risks posed by the virus, and our ability to perform critical functions could be harmed.

Additionally, COVID-19 could affect our internal controls over financial reporting as a portion of our workforce is required to work from home and therefore new processes, procedures, and controls could be required to respond to changes in our business environment.

The potential effects of COVID-19 may also impact many of our other risk factors discussed in in Part I, Item 1A, Risk Factors, in our Annual report on Form 10-K for the year ended December 31, 2019. The degree to which COVID-19 ultimately impacts our business, results of operations, cash flows and financial position will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact and how quickly and to what extent normal economic and operating conditions can resume.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.


Item 3. Defaults Upon Senior Securities

Not applicable.


Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

None.

42



Item 6. Exhibits


Exhibit No.DescriptionFiling Information
3.1Incorporated by reference to Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on November 13, 2012
3.1.1Incorporated by reference to Exhibit A to the Registrant’s Definitive Information Statement on Schedule 14C filed on July 12, 2013
3.1.2Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 15, 2016
3.1.3Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 15, 2019
3.2Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on August 8, 2019
31.1Filed herewith
31.2Filed herewith
32Furnished herewith
10.1Furnished herewith
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentFiled herewith
101.SCH Inline XBRL Taxonomy Extension Schema DocumentFiled herewith
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentFiled herewith
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentFiled herewith
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentFiled herewith
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentFiled herewith
104Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)Filed herewith

43


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

ACCELERATE DIAGNOSTICS, INC.
November 6, 2020/s/ Jack Phillips
Jack Phillips
President and Chief Executive Officer
(Principal Executive Officer)
November 6, 2020/s/ Steve Reichling
Steve Reichling
Chief Financial Officer
(Principal Financial and Accounting Officer)

44
EX-10.1 2 a09302020-exh101ng.htm EX-10.1 Document

EXHIBIT 10.1

ADDENDUM A TO PROMISSORY NOTE


This Addendum A to Promissory Note (the Addendum) amends that certain Promissory Note (Note) entered into between ACCELERATE DIAGNOSTICS, INC. (hereinafter Borrower) in favor of Zions Bancorporation, N.A. dba National Bank of Arizona (hereinafter Lender).

WHEREAS, the Paycheck Protection Program Flexibility Act amended the CARES Act and automatically extended the payment deferral period of the Note and allowed the maturity of the Note to be extended to 5 years.

WHEREAS, Borrower has agreed under the general provisions paragraph of the Note that Lender may extend the term of the Note.

NOW THEREFORE, the Note is hereby modified and amended, in accordance with the terms and provisions in this Addendum to Promissory Note. Terms defined in the Note but not otherwise defined herein shall have the respective meanings given to them in the Note.

1.The Maturity paragraph in the Note and any reference to the maturity in the Related Documents is hereby deleted and hereby replaced with the following:

Maturity Date. This Note will mature five years from date of this Note.

2. The PAYMENT and INITIAL DEFERMENT PERIOD paragraphs are hereby deleted and
hereby replaced with the following:

PAYMENT. Borrower will pay this loan in accordance with the following payment schedule: Borrower will pay this loan in monthly installment payments of the outstanding balance of principal and interest after the Deferment Period amortized over the remaining term of the loan. Borrower's first payment is due 30 days after the last day of the Deferment Period, and all subsequent payments are due on the same day of each month after that (or the last day of any subsequent month that does not have the same day as the first payment date). Borrower's final payment will be due on the Maturity Date which is five years from date of this Note, and will be for all principal and all accrued interest not yet paid. Payments shall include principal and interest.

DEFERMENT PERIOD. The Deferment Period shall be the earlier of (i) the date on which the amount of forgiveness determined under section 1106 of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) is remitted to Lender (or, if earlier, the date the [SBA] determines that the loan is not eligible for forgiveness in the full amount requested), or (ii) if Borrower fails to apply for forgiveness within 10 months after the date that is the earlier of (A) 24 weeks after the date of the Note or (B) December 31, 2020 (the Covered Period), the date that is 10 months after the last day of the Covered Period. Interest will continue to accrue during the Deferment Period. Lender will provide Borrower the monthly payment amount after the Deferment Period.

EX-31.1 3 a069302020-exh311ng.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jack Phillips, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Accelerate Diagnostics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 6, 2020
/s/ Jack Phillips
 
Jack Phillips
President and Chief Executive Officer
 (Principal Executive Officer)


EX-31.2 4 a09302020-exh312ng.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steve Reichling, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Accelerate Diagnostics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 6, 2020/s/ Steve Reichling
 Steve Reichling
Chief Financial Officer
 (Principal Financial and Accounting Officer)


EX-32 5 a09302020-exh32ng.htm EX-32 Document

Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned officers of Accelerate Diagnostics, Inc. (the “Company”) hereby certifies that, to his knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2020 to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 6, 2020/s/ Jack Phillips
Jack Phillips
President and Chief Executive Officer
(Principal Executive Officer)
 
November 6, 2020/s/ Steve Reichling
Steve Reichling
Chief Financial Officer
(Principal Financial and Accounting Officer)


EX-101.SCH 6 axdx-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2106102 - Disclosure - Recently Issued Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Recently Issued Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Statement of Financial Position, Classified (Statement) link:presentationLink link:calculationLink link:definitionLink 2114105 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2119106 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2122107 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2323305 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2424411 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - License Agreements and Grants link:presentationLink link:calculationLink link:definitionLink 2427413 - Disclosure - License Agreements and Grants - National Institute of Health Grant (Details) link:presentationLink link:calculationLink link:definitionLink 2128109 - Disclosure - Deferred Revenue and Remaining Performance Obligations link:presentationLink link:calculationLink link:definitionLink 2329306 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 2430414 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2131110 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 2332307 - Disclosure - Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2433415 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2434416 - Disclosure - Long-term Debt - Schedule of Maturities of Future Principal Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2435417 - Disclosure - Long-term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2136111 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 2337308 - Disclosure - Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 2438418 - Disclosure - Convertible Notes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2439419 - Disclosure - Convertible Notes - Schedule of Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2440420 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2141112 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2342309 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2443421 - Disclosure - Earnings Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2444422 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2145113 - Disclosure - Employee Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2346310 - Disclosure - Employee Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2447423 - Disclosure - Employee Equity-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2448424 - Disclosure - Employee Equity-Based Compensation - Inputs to Calculate Estimated Fair Value of Options Awarded (Details) link:presentationLink link:calculationLink link:definitionLink 2449425 - Disclosure - Employee Equity-Based Compensation - Stock Option Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 2450426 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2451427 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 2452428 - Disclosure - Employee Equity-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2153114 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2454429 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2155115 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2356311 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2457430 - Disclosure - Leases - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2458431 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2458431 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2459432 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2459432 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2160116 - Disclosure - Industry, Geographic and Revenue Disaggregation link:presentationLink link:calculationLink link:definitionLink 2361312 - Disclosure - Industry, Geographic and Revenue Disaggregation (Tables) link:presentationLink link:calculationLink link:definitionLink 2462433 - Disclosure - Industry, Geographic and Revenue Disaggregation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2463434 - Disclosure - Industry, Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2464435 - Disclosure - Industry, Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) link:presentationLink link:calculationLink link:definitionLink 2165117 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2466436 - Disclosure - Related Party Transaction (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 axdx-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 axdx-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 axdx-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Aggregate intrinsic value (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Other expense, net Other Nonoperating Income (Expense) Schedule of Product Warranty Reserve Activity Schedule of Product Warranty Liability [Table Text Block] Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Related Party [Axis] Related Party [Axis] Amortization of the debt discount Amortization of Debt Discount (Premium) Treasury stock Treasury Stock [Member] Services Service [Member] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Fair Value Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Vested/Released (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value 2022 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Lessee Lessee, Leases [Policy Text Block] Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Thereafter Long-Term Debt, Maturity, after Year Four Long-Term Debt, Maturity, after Year Four Unamortized debt issuance Unamortized debt issuance Debt Issuance Costs, Gross Remainder of 2020 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Remainder of Fiscal Year Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Monthly payment Debt Instrument, Periodic Payment Other revenue Other Revenue [Member] Other Revenue [Member] Proceeds from debt Proceeds from Issuance of Debt Current Fiscal Year End Date Current Fiscal Year End Date Other Loans - various interest Other Loans [Member] Other Loans Domestic Geographic Distribution, Domestic [Member] Proceeds from debt Proceeds from Issuance of Long-term Debt Loss from operations Operating Income (Loss) Long-lived Assets by Geographic Territory Long-lived Assets by Geographic Areas [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Total current liabilities Liabilities, Current Accounts Receivable Accounts Receivable [Policy Text Block] Deferred Revenue and Income Summary Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Performance-based stock option expense Performance Shares [Member] Foreign Geographic Distribution, Foreign [Member] Beginning balance (dollars per share) Ending balance (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Commitments and contingencies Commitments and Contingencies ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Entity Shell Company Entity Shell Company Vested/Released (shares) Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cover page. Cover [Abstract] Operating cash flows from operating leases Operating Lease, Payments Accounts payable Accounts Payable, Current Document Type Document Type 2023 Long-Term Debt, Maturity, Year Three Granted in 2018 Granted in 2018 [Member] Granted in 2018 [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Right of use assets Operating Lease, Right-of-Use Asset Financial institution A Financial Institution A [Member] Financial Institution A [Member] Unamortized debt discount Debt Instrument, Unamortized Discount Net transfer of instruments from inventory to property and equipment Inventory Transferred to Fixed Assets Inventory Transferred to Fixed Assets 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Aggregate number of shares (shares) Treasury Stock, Shares, Acquired Lease Income Lease Income Convertible Notes Convertible Debt [Table Text Block] Outstanding, beginning balance (shares) Outstanding, ending balance (shares) Number of options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Customer [Axis] Customer [Axis] Concentration of credit risk Credit Concentration Risk [Member] Preferred shares Preferred Stock, Value, Issued Deferred Tax Assets Income Tax, Policy [Policy Text Block] U.S. Treasury securities US Treasury and Government [Member] PPP Paycheck Protection Program, CARES Act [Member] Paycheck Protection Program, CARES Act Document Quarterly Report Document Quarterly Report Number of options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common Stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Technical equipment Technology Equipment [Member] Other non-current liabilities Other Liabilities, Noncurrent Work in process Inventory, Work in Process, Net of Reserves Equity-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Effect of exchange rate on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Inventory Inventory Inventory, Net Financial institution C Financial Institution C [Member] Financial Institution C Net sales Net sales Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] Investments Investment, Policy [Policy Text Block] Risk concentration Concentration Risk, Percentage Entity File Number Entity File Number Other comprehensive loss: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Conversion ratio Debt Instrument, Convertible, Conversion Ratio Statement [Line Items] Statement [Line Items] Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Forecast Forecast [Member] Computer equipment Computer Equipment [Member] Contractual term Debt Instrument, Term Less imputed interest Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount Document Fiscal Period Focus Document Fiscal Period Focus Statement [Table] Statement [Table] Warranty Reserve Standard Product Warranty, Policy [Policy Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] U.S. Agency securities US Government Agencies Debt Securities [Member] Convertible notes Net carrying amount of the liability component Convertible Debt, Noncurrent Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Basic and diluted net loss per share (usd per share) Earnings Per Share, Basic and Diluted Principles of Consolidation Consolidation, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Convertible Notes Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Prepaid expenses Prepaid Expense, Current Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Sales, general and administrative Selling, General and Administrative Expenses [Member] Number of loan agreements Number of Debt Instruments Number of Debt Instruments Proceeds from sales of marketable securities Proceeds from sales of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Equity-Based Compensation Expenses Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Amortization of debt discount and issuance costs Accretion Expense Amendment Flag Amendment Flag Estimated Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Payment of debt Repayments of Debt Sales-type Lease Receivable Maturity Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Related Party [Domain] Related Party [Domain] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Financial Instruments [Domain] Financial Instruments [Domain] Increase (decrease) in liabilities: Increase (Decrease) in Accrued Liabilities [Abstract] Local Phone Number Local Phone Number Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Net proceeds from notes to fund Prepaid Forward Debt Proceeds Used to Fund Embedded Derivative Debt Proceeds Used to Fund Embedded Derivative Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Accrued interest Interest and Dividends Payable, Current Unrecognized equity-based compensation cost Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Leases, Lessor Lessor, Leases [Policy Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2024 Long-Term Debt, Maturity, Year Four Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Schedule of Available-for-Sale Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Sales, general and administrative Selling, General and Administrative Expense Lease Costs Lease, Cost [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Other non-current assets Other Assets, Noncurrent 2024 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four Stock price conversion threshold, percentage Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Industry, Geographic and Revenue Disaggregation Segment Reporting Disclosure [Text Block] Proceeds from issuance of common stock Stock Issued During Period, Value, New Issues Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Trade accounts receivable Receivables, Net, Current Concentration Risk [Table] Concentration Risk [Table] Total assets Assets Related Party Transactions Related Party Transactions Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Financial institution D Financial Institution D [Member] Financial Institution D Interest Expense, Debt Interest Expense, Debt Shares issued (shares) Debt Conversion, Converted Instrument, Shares Issued Antidilutive Securities [Axis] Antidilutive Securities [Axis] Note holder Convertible Note Holder [Member] Convertible Note Holder [Member] Geographic Distribution [Axis] Geographic Distribution [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Business Description and Basis of Presentation [Text Block] Entity Small Business Entity Small Business Cost of sales Cost of Sales [Member] Interest expense Interest Expense Depreciation Depreciation, Depletion and Amortization Entity Filer Category Entity Filer Category Leases Lessor, Sales-type Leases [Text Block] Unrealized losses on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Entity Address, City or Town Entity Address, City or Town Amortization of investment discount Investment Income, Net, Amortization of Discount and Premium Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2022 Long-Term Debt, Maturity, Year Two 2.50% Convertible notes due 2023 Two Point Five Zero Convertible Notes due 2023 [Member] Two Point Five Zero Convertible Notes due 2023 [Member] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Revenues recognized included in contract liabilities balances Contract with Customer, Liability, Revenue Recognized Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Inventory and instruments in property and equipment Increase (Decrease) in Inventories Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Document Fiscal Year Focus Document Fiscal Year Focus Accounts payable Increase (Decrease) in Accounts Payable Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Raw materials Inventory, Raw Materials, Net of Reserves Debt Instrument [Axis] Debt Instrument [Axis] Contributed capital Additional Paid-in Capital [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Beginning Balance (shares) Ending Balance (shares) Shares, Issued Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Common Stock, shares outstanding (shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Deferred compensation Increase (Decrease) in Deferred Compensation Present value of lease payments Sales-type and Direct Financing Leases, Lease Receivable Net loss before income taxes Pre-tax loss Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development Research and Development Expense Property and equipment Property, Plant and Equipment [Member] Outstanding, beginning balance (dollars per share) Outstanding, ending balance (dollars per share) Weighted average exercise price (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Common Stock, shares authorized (shares) Common Stock, Shares Authorized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total property and equipment Property, Plant and Equipment, Gross Beginning balance Ending balance Standard Product Warranty Accrual Cumulative amount awarded Research and Development Arrangement, Contract to Perform for Others, Invoiced Research and Development Arrangement, Contract to Perform for Others, Invoiced Document Period End Date Document Period End Date Interest expense Interest Expense, Debt, Excluding Amortization Entity Registrant Name Entity Registrant Name Income Statement [Abstract] Income Statement [Abstract] Accumulated other comprehensive (loss) income AOCI Attributable to Parent [Member] Loss on disposal of property and equipment Gain (Loss) on Disposition of Assets Non-current operating lease liability Operating Lease, Liability, Noncurrent Prepaid expense and other Increase (Decrease) in Prepaid Expense and Other Assets Provisions Standard Product Warranty Accrual, Increase for Warranties Issued Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Restricted Stock Unit (RSU) Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expected dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred Stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share 2021 Long-Term Debt, Maturity, Year One Stock Option Supplemental Information Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block] Realized loss on sale of investments Realized Investment Gains (Losses) Scenario [Domain] Scenario [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Cash paid for amounts included in lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Entity Tax Identification Number Entity Tax Identification Number Long-term Debt Long-term Debt [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Director Director [Member] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Trading Symbol Trading Symbol Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Lease term Lessee, Operating Lease, Term of Contract Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Other Loans - various interest Notes Payable, Other Payables [Member] Components of Inventories Schedule of Inventory, Current [Table Text Block] Cost capitalized to inventory Share-based Payment Arrangement, Amount Capitalized Weighted Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Equity-based compensation Share-based Payment Arrangement, Noncash Expense Over-allotment option Over-Allotment Option, Amount Over-Allotment Option, Amount Purchases of equipment Payments to Acquire Productive Assets Fair value of equity securities Equity Securities, FV-NI Remainder of 2020 Long-Term Debt, Maturity, Remainder of Fiscal Year Accrued interest Increase (Decrease) in Interest Payable, Net Assets under operating leases Assets Leased to Others [Member] Schedule of Available-For-Sale Investment Maturities Debt Securities, Available-for-sale [Table Text Block] Instrument warranty term Standard Product Warranty, Instruments, Term Standard Product Warranty, Instruments, Term Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Estimated useful life of assets Property, Plant and Equipment, Useful Life Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Total debt Long-term Debt Deferred revenue and income Increase (Decrease) in Contract with Customer, Liability Leases Lessee, Operating Leases [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Investments Investments City Area Code City Area Code Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of sales Cost of Goods and Services Sold Lease Cost Lease, Cost [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Grant period Research and Development Arrangement, Contract to Perform for Others, Proposed Period Research and Development Arrangement, Contract to Perform for Others, Proposed Period Fair Value Fair Value Debt Securities, Available-for-sale Total costs and expenses Costs and Expenses Award Date [Domain] Award Date [Domain] Performance-based RSU expense Performance-based Restricted Stock Units [Member] Performance-based Restricted Stock Units Equity Components [Axis] Equity Components [Axis] Title of 12(b) Security Title of 12(b) Security Finished goods Inventory, Finished Goods, Net of Reserves Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Current operating lease liability Operating Lease, Liability, Current Award Date [Axis] Award Date [Axis] Unrecognized equity-based compensation cost, restricted stock units Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Beginning balance (shares) Ending balance (shares) Outstanding (shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Total grant funding Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Forfeited (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Inputs to Calculate Estimated Fair Value of Options Awarded Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Exercised (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Instruments Instruments [Member] Instruments [Member] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Net accounts receivable Accounts Receivable [Member] Equity-Based Compensation Share-based Payment Arrangement [Policy Text Block] Customer [Domain] Customer [Domain] Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Long-lived Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Contributed capital Additional Paid in Capital, Common Stock Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted average discount rate (%) Operating Lease, Weighted Average Discount Rate, Percent Concentration Risk [Line Items] Concentration Risk [Line Items] Due in less than 1 year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Other income (expense): Other Nonoperating Income (Expense) [Abstract] Contributions to deferred compensation plan Deferred Compensation Arrangement with Individual, Contributions by Employer Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Research and development Research and Development Expense [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Research and Development [Abstract] Research and Development [Abstract] Nonqualified Cash Deferral Plan Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block] Equity component Adjustments to Additional Paid in Capital, Other Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Foreign Currency Translation and Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Financial institution B Financial Institution B [Member] Financial Institution B [Member] Due in less than 1 year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One 2021 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One Title of Individual [Axis] Title of Individual [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Realized gains or losses from equity securities Equity Securities, FV-NI, Realized Gain (Loss) Aggregate principal amount Debt Instrument, Face Amount Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Weighted average fair value (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value Other current assets Other Assets, Current Trading price threshold, percentage Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Total assets measured at fair value Assets, Fair Value Disclosure Issuance of common stock under employee purchase plan (shares) Stock Issued During Period, Shares, Employee Stock Ownership Plan Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Contact period Revenue, Performance Obligation, Description of Timing Entity Central Index Key Entity Central Index Key Deferred revenue Deferred revenue and income Contract with Customer, Liability, Current Entity Emerging Growth Company Entity Emerging Growth Company Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible List] Granted (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Customer concentration Customer Concentration Risk [Member] Recently Issued Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Initial conversion price (usd per share) Debt Instrument, Convertible, Conversion Price Mutual funds Mutual Fund [Member] Schedule of Fair Value Measurement Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Number of operating segments Number of Operating Segments Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Due in 1-3 years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Three Years, Fair Value Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Three Years, Fair Value Forfeited (shares) Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Geographic Distribution [Domain] Geographic Distribution [Domain] One customer One Customer [Member] One Customer Common stock Common Stock, Value, Outstanding Unsecured obligations PPP Loan - 1% interest Unsecured Debt [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Revenue expected to be recognized from remaining performance obligations Revenue, Remaining Performance Obligation, Amount Equity-based compensation expense Share-based Payment Arrangement, Expense Facilities Leaseholds and Leasehold Improvements [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Products and services not yet delivered Products and Services not Yet Delivered [Member] Products and Services not Yet Delivered [Member] Counterparty Name [Axis] Counterparty Name [Axis] Long-term debt Long-term Debt [Member] Weighted average fair value (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value Commercial paper Commercial Paper [Member] Aggregate intrinsic value (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Current portion of long-term debt Long-term Debt, Current Maturities Share price (usd per share) Sale of Stock, Price Per Share 2023 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three Interest income Investment Income, Interest and Dividend Related Party Transaction [Axis] Related Party Transaction [Axis] Purchase of marketable securities Payments to Acquire Debt Securities, Available-for-sale Weighted average fair value (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value Loss Per Share Earnings Per Share, Policy [Policy Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Proceeds from exercise of options Proceeds from Stock Options and Warrants Exercised Proceeds from Stock Options and Warrants Exercised Granted (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common Stock, shares issued (shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Assets And Liabilities Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Convertible Notes Debt, Policy [Policy Text Block] Accelerate Pheno revenue Accelerate Pheno [Member] Accelerate Pheno [Member] Lessee lease liabilities Operating Lease, Liability Long-term debt Unsecured Long-term Debt, Noncurrent Long-term debt Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Project [Domain] Project [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Total stockholders’ deficit Beginning Balance, amount Ending Balance, amount Cumulative-effect adjustment Stockholders' Equity Attributable to Parent Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total liabilities and stockholders’ deficit Liabilities and Equity Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Shares issuable upon the release of restricted stock units Restricted Stock Units (RSUs) [Member] Kits and accessories warranty term Standard Product Warranty, Kits And Accessories, Term Standard Product Warranty, Kits And Accessories, Term Operating leases Operating Lease, Cost Due in 1-3 years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Three Years, Amortized Cost Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Three Years, Amortized Cost Over-allotment option, term Over-Allotment Option, Term Over-Allotment Option, Term Financial Instrument [Axis] Financial Instrument [Axis] Antidilutive common stock instruments outstanding (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Products Product [Member] Short-term leases Short-term Lease, Cost Equity Component [Domain] Equity Component [Domain] Net unrealized gain (loss) on debt securities available-for-sale Unrealized loss on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Gross profit Gross Profit RSUs and RSAs Restricted Stock Units And Restricted Stock Awards [Member] Restricted Stock Units And Restricted Stock Awards [Member] Property and equipment, net Property and equipment, net Long-lived assets (excluding intangible assets) Property, Plant and Equipment, Net Capital projects in progress Construction in Progress [Member] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Employee Equity-Based Compensation Share-based Payment Arrangement [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Entity Address, State or Province Entity Address, State or Province Repurchase principal balance, percent Debt Instrument, Principle Repurchase Percent Debt Instrument, Principle Repurchase Percent Remainder of 2020 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year (Increase) decrease in assets: Increase (Decrease) in Operating Assets [Abstract] Inventory Inventory Disclosure [Text Block] Leases [Abstract] Leases [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Earnings Per Share [Abstract] Earnings Per Share [Abstract] Restructuring expenses Restructuring Charges Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net investment in leases Net Investment in Lease Stockholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Entity Interactive Data Current Entity Interactive Data Current Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Options Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] License Agreements and Grants License Agreements and Grants [Text Block] License agreements Certificates of deposit Certificates of Deposit [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Lessor lease term Lessor, Operating Lease, Term of Contract Conversion multiple Debt Instrument, Convertible, Conversion Principal Multiple Debt Instrument, Convertible, Conversion Principal Multiple Deferred Revenue Disclosure [Abstract] Deferred Revenue Disclosure [Abstract] Common stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Geographic concentration Geographic Concentration Risk [Member] Property and Equipment Property, Plant and Equipment [Table Text Block] Contractual life Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contractual Terms Issuance of common stock (shares) Stock Issued During Period, Shares, New Issues Total revenue Revenue Benchmark [Member] Interest rate Debt Instrument, Interest Rate, Stated Percentage Money market funds Money Market Funds [Member] Accumulated depreciation Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Non-cash investing activities: Noncash Investing and Financing Items [Abstract] Exercise of options (shares) Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Related Party Transactions [Abstract] Related Party Transactions [Abstract] (Decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other expense, net Nonoperating Income (Expense) Maturities of Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Shares issuable upon exercise of stock options Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average shares outstanding (shares) Weighted Average Number of Shares Outstanding, Basic Costs and expenses: Costs and Expenses [Abstract] Risk free interest rates Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Forfeited (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Cash and cash equivalents Cash and Cash Equivalents [Member] Deferred Revenue and Remaining Performance Obligations Revenue from Contract with Customer [Text Block] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities National Institute of Health Grant National Institute of Health Grant [Member] National Institute of Health Grant [Member] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Fair value Long-term Debt, Fair Value Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Foreign currency exchange gain (loss) Foreign Currency Transaction Gain (Loss), before Tax Inventory Inventory, Policy [Policy Text Block] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Income taxes paid, net of refunds Income Taxes Paid, Net Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Schedule of Maturities of Future Principal Obligations Schedule of Maturities of Long-term Debt [Table Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Title of Individual [Domain] Title of Individual [Domain] Accrued liabilities Accrued Liabilities, Current Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Restructure Activity Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Outstanding principal Long-term Debt, Gross Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Depreciation and amortization Depreciation Issuance of common stock under employee purchase plan Stock Issued During Period, Value, Employee Stock Ownership Plan Related Party Transaction [Domain] Related Party Transaction [Domain] Project [Axis] Project [Axis] Exercise of options Stock Issued During Period, Value, Stock Options Exercised Consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Award Type [Axis] Award Type [Axis] Weighted Average Grant Date Fair Value per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Amortization of debt issuance costs Amortization of Debt Issuance Costs Maximum Maximum [Member] Security Exchange Name Security Exchange Name Preferred Stock, shares authorized (shares) Preferred Stock, Shares Authorized Accumulated deficit Retained Earnings [Member] Preferred Stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Schedule of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Concentration of Credit Risk Concentration Risk Disclosure [Text Block] Allowance for credit losses Accounts Receivable, Allowance for Credit Loss Total undiscounted cash flows Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received Award Type [Domain] Award Type [Domain] Document Transition Report Document Transition Report Accrued liabilities, and other Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Corporate notes and bonds Corporate Debt Securities [Member] Gross assets Lessor, Operating Lease, Assumptions and Judgments, Value of Underlying Asset, Amount Weighted average exercise price (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Additional proceeds Proceeds from Over-Allotment Option Proceeds from Over-Allotment Option Number of monthly payments Debt Instrument, Number of Monthly Payments Debt Instrument, Number of Monthly Payments Property and Equipment Property, Plant and Equipment Disclosure [Text Block] ROU assets obtained in exchange for lease obligations Lessee, Operating Lease, Description [Abstract] Warranty cost incurred Standard Product Warranty Accrual, Decrease for Payments Treasury stock Treasury Stock, Value Earnings Per Share Earnings Per Share [Text Block] Thereafter Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four Current liabilities: Liabilities, Current [Abstract] Chief Operating Officer Chief Operating Officer [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair value on a recurring basis Fair Value, Recurring [Member] Expired (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Standards That Were Recently Adopted and Standards not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 10 axdx-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 axdx-20200930_htm.xml IDEA: XBRL DOCUMENT 0000727207 2020-01-01 2020-09-30 0000727207 2020-11-03 0000727207 2020-09-30 0000727207 2019-12-31 0000727207 2020-07-01 2020-09-30 0000727207 2019-07-01 2019-09-30 0000727207 2019-01-01 2019-09-30 0000727207 2018-12-31 0000727207 2019-09-30 0000727207 us-gaap:CommonStockMember 2020-06-30 0000727207 us-gaap:CommonStockMember 2019-06-30 0000727207 us-gaap:CommonStockMember 2019-12-31 0000727207 us-gaap:CommonStockMember 2018-12-31 0000727207 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000727207 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000727207 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000727207 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000727207 us-gaap:CommonStockMember 2020-09-30 0000727207 us-gaap:CommonStockMember 2019-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000727207 us-gaap:RetainedEarningsMember 2020-06-30 0000727207 us-gaap:RetainedEarningsMember 2019-06-30 0000727207 us-gaap:RetainedEarningsMember 2019-12-31 0000727207 us-gaap:RetainedEarningsMember 2018-12-31 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0000727207 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000727207 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000727207 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000727207 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0000727207 us-gaap:RetainedEarningsMember 2020-09-30 0000727207 us-gaap:RetainedEarningsMember 2019-09-30 0000727207 us-gaap:TreasuryStockMember 2020-06-30 0000727207 us-gaap:TreasuryStockMember 2019-06-30 0000727207 us-gaap:TreasuryStockMember 2019-12-31 0000727207 us-gaap:TreasuryStockMember 2018-12-31 0000727207 us-gaap:TreasuryStockMember 2020-09-30 0000727207 us-gaap:TreasuryStockMember 2019-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000727207 srt:MinimumMember 2020-01-01 2020-09-30 0000727207 srt:MaximumMember 2020-01-01 2020-09-30 0000727207 axdx:InstrumentsMember 2020-01-01 2020-09-30 0000727207 2020-06-30 0000727207 2019-06-30 0000727207 axdx:PaycheckProtectionProgramCARESActMember us-gaap:UnsecuredDebtMember 2020-04-14 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2020-09-30 0000727207 srt:MinimumMember 2020-09-30 0000727207 srt:MaximumMember 2020-09-30 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-01-01 0000727207 axdx:FinancialInstitutionAMember us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-09-30 0000727207 axdx:FinancialInstitutionBMember us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-09-30 0000727207 axdx:FinancialInstitutionCMember us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-09-30 0000727207 axdx:FinancialInstitutionDMember us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-09-30 0000727207 axdx:FinancialInstitutionAMember us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000727207 axdx:FinancialInstitutionBMember us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-12-31 0000727207 axdx:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2018-04-04 2018-04-04 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2019-12-31 0000727207 us-gaap:UnsecuredDebtMember 2020-09-30 0000727207 us-gaap:CertificatesOfDepositMember 2020-09-30 0000727207 us-gaap:USTreasuryAndGovernmentMember 2020-09-30 0000727207 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0000727207 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-09-30 0000727207 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000727207 us-gaap:CertificatesOfDepositMember 2019-12-31 0000727207 us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:ComputerEquipmentMember 2020-09-30 0000727207 us-gaap:ComputerEquipmentMember 2019-12-31 0000727207 us-gaap:TechnologyEquipmentMember 2020-09-30 0000727207 us-gaap:TechnologyEquipmentMember 2019-12-31 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2020-09-30 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2019-12-31 0000727207 axdx:InstrumentsMember 2020-09-30 0000727207 axdx:InstrumentsMember 2019-12-31 0000727207 us-gaap:ConstructionInProgressMember 2020-09-30 0000727207 us-gaap:ConstructionInProgressMember 2019-12-31 0000727207 us-gaap:AssetsLeasedToOthersMember 2020-09-30 0000727207 us-gaap:AssetsLeasedToOthersMember 2019-12-31 0000727207 axdx:NationalInstituteofHealthGrantMember 2015-02-01 2015-02-28 0000727207 2015-02-01 2020-09-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2020-01-01 2020-09-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2019-01-01 2019-09-30 0000727207 axdx:ProductsandServicesnotYetDeliveredMember 2020-09-30 0000727207 axdx:ProductsandServicesnotYetDeliveredMember 2019-12-31 0000727207 axdx:PaycheckProtectionProgramCARESActMember us-gaap:UnsecuredDebtMember 2020-09-30 0000727207 axdx:PaycheckProtectionProgramCARESActMember us-gaap:UnsecuredDebtMember 2019-12-31 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-09-30 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-07-01 2020-09-30 0000727207 srt:MinimumMember axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-09-30 0000727207 srt:MaximumMember axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-09-30 0000727207 srt:ScenarioForecastMember axdx:PaycheckProtectionProgramCARESActMember us-gaap:UnsecuredDebtMember 2020-11-14 2020-11-14 0000727207 srt:ScenarioForecastMember axdx:PaycheckProtectionProgramCARESActMember us-gaap:UnsecuredDebtMember 2021-08-14 2021-08-14 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2018-03-27 0000727207 2018-03-27 2018-03-27 0000727207 2018-04-04 2018-04-04 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2018-04-04 0000727207 us-gaap:LongTermDebtMember axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2018-04-04 0000727207 us-gaap:AdditionalPaidInCapitalMember axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2018-04-04 0000727207 2018-04-04 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-09-30 0000727207 srt:MaximumMember axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-09-30 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2019-12-31 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2020-01-01 2020-09-30 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2020-09-30 0000727207 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000727207 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000727207 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000727207 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0000727207 srt:MinimumMember us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000727207 srt:MaximumMember us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000727207 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000727207 srt:MinimumMember axdx:Grantedin2018Member us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000727207 srt:MaximumMember axdx:Grantedin2018Member us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000727207 us-gaap:PerformanceSharesMember 2018-08-01 2018-08-31 0000727207 us-gaap:PerformanceSharesMember 2020-07-01 2020-09-30 0000727207 us-gaap:PerformanceSharesMember 2019-01-01 2019-09-30 0000727207 srt:MinimumMember axdx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0000727207 srt:MaximumMember axdx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2020-07-01 2020-09-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2020-09-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2020-07-01 2020-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2019-07-01 2019-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2020-01-01 2020-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2019-01-01 2019-09-30 0000727207 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2020-09-30 0000727207 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2019-12-31 0000727207 us-gaap:GeographicDistributionDomesticMember 2020-07-01 2020-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2019-07-01 2019-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2020-01-01 2020-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2019-01-01 2019-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2020-07-01 2020-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2019-07-01 2019-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2020-01-01 2020-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2019-01-01 2019-09-30 0000727207 axdx:AcceleratePhenoMember 2020-07-01 2020-09-30 0000727207 axdx:AcceleratePhenoMember 2019-07-01 2019-09-30 0000727207 axdx:AcceleratePhenoMember 2020-01-01 2020-09-30 0000727207 axdx:AcceleratePhenoMember 2019-01-01 2019-09-30 0000727207 axdx:OtherRevenueMember 2020-07-01 2020-09-30 0000727207 axdx:OtherRevenueMember 2019-07-01 2019-09-30 0000727207 axdx:OtherRevenueMember 2020-01-01 2020-09-30 0000727207 axdx:OtherRevenueMember 2019-01-01 2019-09-30 0000727207 us-gaap:ProductMember 2020-07-01 2020-09-30 0000727207 us-gaap:ProductMember 2019-07-01 2019-09-30 0000727207 us-gaap:ProductMember 2020-01-01 2020-09-30 0000727207 us-gaap:ProductMember 2019-01-01 2019-09-30 0000727207 us-gaap:ServiceMember 2020-07-01 2020-09-30 0000727207 us-gaap:ServiceMember 2019-07-01 2019-09-30 0000727207 us-gaap:ServiceMember 2020-01-01 2020-09-30 0000727207 us-gaap:ServiceMember 2019-01-01 2019-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionDomesticMember 2020-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionDomesticMember 2019-12-31 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2020-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2019-12-31 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember 2020-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember 2019-12-31 0000727207 srt:DirectorMember axdx:ConvertibleNoteHolderMember srt:ChiefOperatingOfficerMember 2020-09-30 0000727207 srt:DirectorMember axdx:ConvertibleNoteHolderMember srt:ChiefOperatingOfficerMember 2019-12-31 0000727207 srt:ChiefOperatingOfficerMember 2019-08-20 2019-08-20 0000727207 2019-08-19 0000727207 2019-08-20 2019-08-20 shares iso4217:USD iso4217:USD shares pure axdx:loan axdx:payment axdx:day axdx:segment 0000727207 false --12-31 Q3 2020 P1Y P2Y us-gaap:AccountingStandardsUpdate201613Member 0.0323428 0.0323428 10-Q true 2020-09-30 false 001-31822 ACCELERATE DIAGNOSTICS, INC. DE 84-1072256 3950 South Country Club Road, Suite 470 Tucson, AZ 85714 520 365-3100 Common Stock, $0.001 par AXDX NASDAQ Yes Yes Large Accelerated Filer false false false 57029694 27029000 61014000 50463000 47437000 2610000 3222000 9459000 8059000 961000 955000 1517000 1165000 92039000 121852000 7104000 7905000 3402000 3917000 1674000 750000 104219000 134424000 2372000 2351000 3176000 3828000 191000 1262000 338000 271000 511000 0 482000 450000 7070000 8162000 3231000 3579000 259000 19000 5028000 0 138299000 130043000 153887000 141803000 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 85000000 57027429 57027429 85000000 54708792 54708792 57000 55000 469302000 452344000 45067000 45067000 -474054000 -414653000 94000 -58000 -49668000 -7379000 104219000 134424000 3588000 2271000 8056000 5827000 2287000 1117000 4745000 2940000 1301000 1154000 3311000 2887000 5001000 6064000 16191000 19145000 11465000 12743000 35738000 38302000 16466000 18807000 51929000 57447000 -15165000 -17653000 -48618000 -54560000 3955000 3598000 11540000 10585000 229000 -89000 191000 -142000 149000 676000 753000 2329000 -15000 -9000 -82000 -12000 -3592000 -3020000 -10678000 -8410000 -18757000 -20673000 -59296000 -62970000 0 -239000 0 0 -18757000 -20434000 -59296000 -62970000 -0.33 -0.37 -1.07 -1.16 56560000 54553000 55617000 54456000 -18757000 -20434000 -59296000 -62970000 -117000 10000 62000 229000 71000 -113000 90000 -139000 -18803000 -20537000 -59144000 -62880000 -59296000 -62970000 2270000 1862000 -43000 400000 12291000 9409000 8256000 7370000 -3000 0 -546000 -577000 248000 0 -532000 782000 1734000 3286000 1267000 319000 76000 788000 -759000 -2115000 -1071000 -1071000 67000 33000 240000 -25000 -40051000 -50929000 1364000 148000 44589000 20710000 0 13400000 41707000 78922000 -4246000 71464000 296000 1363000 4458000 4879000 5552000 0 13000 0 10293000 6242000 19000 -99000 -33985000 26678000 61014000 66260000 27029000 92938000 1284000 3225000 4288000 4288000 46000 54000 56249000 54512000 54709000 54232000 0 56000 0 56000 770000 66000 2287000 334000 8000 7000 31000 19000 57027000 54641000 57027000 54641000 56000 55000 55000 54000 1000 0 2000 1000 57000 55000 57000 55000 463178000 443857000 452344000 432885000 0 1000000 0 1000000 1427000 510000 4458000 4879000 79000 112000 294000 362000 4618000 3130000 12206000 9483000 469302000 448609000 469302000 448609000 -455297000 -372884000 -414653000 -330348000 -105000 0 -18757000 -20434000 -59296000 -62970000 -474054000 -393318000 -474054000 -393318000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 140000 44000 -58000 -149000 -117000 10000 62000 229000 71000 -113000 90000 -139000 94000 -59000 94000 -59000 -49668000 10220000 -49668000 10220000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on February 28, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2020, or any future period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, tax valuation accounts and equity–based compensation. Actual results could differ materially from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimated Fair Value of Financial Instruments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company’s convertible note represents a Level 2 measurement. See Note 11, Convertible Notes for further detail on the Company’s convertible notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company’s long-term debt represents a Level 3 measurement. The promissory notes issued under the Paycheck Protection Program (PPP) and other long-term debt is privately held with no public market. The carrying amount of these notes approximates fair value. See Note 10, Long-Term Debt for further detail on the Company’s long-term debt.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe, however, that the market risk arising from holding these financial instruments is minimal.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in various debt securities available-for-sale and equity securities which are primarily held in the custody of major financial institutions. Debt securities available-for-sale consist of certificates of deposit, U.S. government and agency securities, commercial paper, asset-backed securities, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, we perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security available-for-sale is considered impaired if its fair value is less than its amortized cost basis at the reporting date.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security available-for-sale.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the condensed consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. The allowance for credit losses as of September 30, 2020 was $0.3 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg5YTY2ODEwYWFiNTQ4OWY5MTlhYWVmZmQ4OWQxNTU1L3NlYzo4OWE2NjgxMGFhYjU0ODlmOTE5YWFlZmZkODlkMTU1NV8zMS9mcmFnOjZiOTNlYjk1YzIzNDRkOWQ5ZmFiNzAxN2Q0MGRlNTBlL3RleHRyZWdpb246NmI5M2ViOTVjMjM0NGQ5ZDlmYWI3MDE3ZDQwZGU1MGVfMTAxODU_ade1c63e-7986-4b48-a255-5caa70f41e0a">one</span> to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instruments Classified as Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and this evaluation is performed at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of September 30, 2020 and December 31, 2019.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Reserve</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty reserve activity for the three and nine months ended September 30, 2020 and 2019 is as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty cost incurred</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">337 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">337 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program (PPP) Loan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP was established by the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, through a significant expansion of the Small Business Administration (“SBA”) 7(a) loan program. On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to account for the PPP Note in accordance with ASC 470, Debt, with interest accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. The Company recognized the entire PPP Note amount as a liability on the balance sheet, with interest accrued and expensed over the term of the loan. The Company did not impute additional interest at a market rate because transactions where interest rates are prescribed by governmental agencies are excluded from the scope of ASC 835-30.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Note will remain a liability until either of the following criteria are met:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company has been legally released from being the primary obligor under the liability (i.e. the PPP Note is forgiven); or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company pays the lender and is relieved of its obligation for the liability</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, Long-Term Debt for further detail regarding the PPP Note.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for convertible debt instruments that may be settled in cash or equity upon conversion, which includes the 2.50% Senior Convertible Notes due 2023 (the “Notes”), by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determined the carrying amount of the liability component of the Notes by using estimates and assumptions that market participants would use in pricing a debt instrument. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity component is treated as a discount on the liability component of the Notes, which is amortized over the term of the Notes using the effective interest rate method. Debt issuance costs related to the Notes are allocated to the liability and equity components of the Notes based on their relative values. Debt issuance costs allocated to the liability component are amortized over the life of the Notes as additional non-cash interest expense. Transaction costs allocated to equity are netted with the equity component of the convertible debt instrument in stockholders’ deficit.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised good or service is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue as we satisfy a performance obligation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized and the term between invoicing and when payment is due is not typically significant.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine relative standalone selling prices based on the price charged to customers for each individual performance obligation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related expenses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructure Activity</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, following the completion of a strategic review of its Europe, the Middle East and Africa (“EMEA”) business, the Company's board of directors approved a plan to reduce its workforce, focus the geographies it plans to operate in, and terminate agreements with some distributors in geographies it plans on exiting (collectively, the “EMEA Restructuring Plan”). As of September 30, 2020, the Company substantially completed the workforce reduction portion of the EMEA Restructuring Plan, while the remaining restructuring activities are likely to occur through the end of the year. Restructuring charges are primarily comprised of employee severance and other post-employment benefits. The Company evaluates the nature of these costs to determine if they relate to on-going benefit arrangements which are accounted for under ASC 712 or one-time benefit arrangements which are accounted for under ASC 420. The Company incurred expense of $0.4 million in connection with the EMEA Restructuring Plan.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for commercial leases in accordance with ASC 842, Leases. We determine if an arrangement is or contains a lease and the type of lease at inception. The Company classifies commercial leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessee</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in right-of-use (“ROU”) assets and operating lease liabilities within our consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. As of September 30, 2020 and December 31, 2019, the Company was not party to finance lease arrangements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg5YTY2ODEwYWFiNTQ4OWY5MTlhYWVmZmQ4OWQxNTU1L3NlYzo4OWE2NjgxMGFhYjU0ODlmOTE5YWFlZmZkODlkMTU1NV8zMS9mcmFnOjZiOTNlYjk1YzIzNDRkOWQ5ZmFiNzAxN2Q0MGRlNTBlL3RleHRyZWdpb246NmI5M2ViOTVjMjM0NGQ5ZDlmYWI3MDE3ZDQwZGU1MGVfMjE1ODQ_f8638635-46bc-4e4b-89b5-c1ef15d4f1da">two</span> and six-year terms, and typically contain penalizing, early-termination provisions.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the “Deferral Plan”), provides certain key employees, with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may award stock options, restricted stock units (“RSUs”), performance-based awards, and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term: The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. For consultant awards, the estimated expected term is the same as the life of the award.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the fair value of RSUs or stock grants based on published closing market price on the day before the grant date. The Company accounts for forfeitures as they occur rather than on an estimated basis.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Foreign Currency Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options and unvested RSUs. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes at the balance sheet date were converted. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds investments classified as debt securities available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on February 28, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2020, or any future period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, tax valuation accounts and equity–based compensation. Actual results could differ materially from those estimates.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimated Fair Value of Financial Instruments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</span></div>The estimated fair value of the Company’s convertible note represents a Level 2 measurement. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe, however, that the market risk arising from holding these financial instruments is minimal.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in various debt securities available-for-sale and equity securities which are primarily held in the custody of major financial institutions. Debt securities available-for-sale consist of certificates of deposit, U.S. government and agency securities, commercial paper, asset-backed securities, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, we perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security available-for-sale is considered impaired if its fair value is less than its amortized cost basis at the reporting date.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security available-for-sale.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.</span></div>We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the condensed consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. 300000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg5YTY2ODEwYWFiNTQ4OWY5MTlhYWVmZmQ4OWQxNTU1L3NlYzo4OWE2NjgxMGFhYjU0ODlmOTE5YWFlZmZkODlkMTU1NV8zMS9mcmFnOjZiOTNlYjk1YzIzNDRkOWQ5ZmFiNzAxN2Q0MGRlNTBlL3RleHRyZWdpb246NmI5M2ViOTVjMjM0NGQ5ZDlmYWI3MDE3ZDQwZGU1MGVfMTAxODU_ade1c63e-7986-4b48-a255-5caa70f41e0a">one</span> to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instruments Classified as Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and this evaluation is performed at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of September 30, 2020 and December 31, 2019.</span></div> P7Y P5Y <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Reserve</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.</span></div> P1Y P60D <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty reserve activity for the three and nine months ended September 30, 2020 and 2019 is as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty cost incurred</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">337 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">337 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 305000 196000 403000 215000 72000 77000 72000 147000 40000 51000 138000 140000 337000 222000 337000 222000 4800000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for convertible debt instruments that may be settled in cash or equity upon conversion, which includes the 2.50% Senior Convertible Notes due 2023 (the “Notes”), by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determined the carrying amount of the liability component of the Notes by using estimates and assumptions that market participants would use in pricing a debt instrument. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity component is treated as a discount on the liability component of the Notes, which is amortized over the term of the Notes using the effective interest rate method. Debt issuance costs related to the Notes are allocated to the liability and equity components of the Notes based on their relative values. Debt issuance costs allocated to the liability component are amortized over the life of the Notes as additional non-cash interest expense. Transaction costs allocated to equity are netted with the equity component of the convertible debt instrument in stockholders’ deficit.</span></div> 0.0250 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised good or service is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue as we satisfy a performance obligation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized and the term between invoicing and when payment is due is not typically significant.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine relative standalone selling prices based on the price charged to customers for each individual performance obligation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related expenses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.</span></div> Restructure ActivityDuring the three months ended September 30, 2020, following the completion of a strategic review of its Europe, the Middle East and Africa (“EMEA”) business, the Company's board of directors approved a plan to reduce its workforce, focus the geographies it plans to operate in, and terminate agreements with some distributors in geographies it plans on exiting (collectively, the “EMEA Restructuring Plan”). As of September 30, 2020, the Company substantially completed the workforce reduction portion of the EMEA Restructuring Plan, while the remaining restructuring activities are likely to occur through the end of the year. Restructuring charges are primarily comprised of employee severance and other post-employment benefits. The Company evaluates the nature of these costs to determine if they relate to on-going benefit arrangements which are accounted for under ASC 712 or one-time benefit arrangements which are accounted for under ASC 420. 400000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for commercial leases in accordance with ASC 842, Leases. We determine if an arrangement is or contains a lease and the type of lease at inception. The Company classifies commercial leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessee</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in right-of-use (“ROU”) assets and operating lease liabilities within our consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. As of September 30, 2020 and December 31, 2019, the Company was not party to finance lease arrangements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg5YTY2ODEwYWFiNTQ4OWY5MTlhYWVmZmQ4OWQxNTU1L3NlYzo4OWE2NjgxMGFhYjU0ODlmOTE5YWFlZmZkODlkMTU1NV8zMS9mcmFnOjZiOTNlYjk1YzIzNDRkOWQ5ZmFiNzAxN2Q0MGRlNTBlL3RleHRyZWdpb246NmI5M2ViOTVjMjM0NGQ5ZDlmYWI3MDE3ZDQwZGU1MGVfMjE1ODQ_f8638635-46bc-4e4b-89b5-c1ef15d4f1da">two</span> and six-year terms, and typically contain penalizing, early-termination provisions.</span></div> P6Y P5Y <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the “Deferral Plan”), provides certain key employees, with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may award stock options, restricted stock units (“RSUs”), performance-based awards, and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term: The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. For consultant awards, the estimated expected term is the same as the life of the award.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the fair value of RSUs or stock grants based on published closing market price on the day before the grant date. The Company accounts for forfeitures as they occur rather than on an estimated basis.</span></div> 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Foreign Currency Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options and unvested RSUs. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes at the balance sheet date were converted. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds investments classified as debt securities available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards that were recently adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Fair Value Measurement (Topic 820); Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies, among other things, the disclosures required for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs. The guidance removes, among other things, the disclosure requirement to disclose transfers between Levels 1 and 2. Level 3 fair value measurement disclosures should be applied prospectively while all other amendments should be applied retrospectively. The Company adopted ASU 2018-13 on January 1, 2020, which had no impact to our condensed consolidated financial statements as the Company did not carry Level 3 fair value items upon implementing this ASU on January 1, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments. In November 2018, ASU 2018-19 was issued which amended the standard to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU 2019-04, 2019-05, 2019-10, ASU 2019-11, 2020-02 and 2020-03 to provide additional guidance on the credit losses standard. ASU 2016-13 amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Previously, an “incurred loss” methodology was used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. This amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities are now recorded in current period net income. The Company adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg5YTY2ODEwYWFiNTQ4OWY5MTlhYWVmZmQ4OWQxNTU1L3NlYzo4OWE2NjgxMGFhYjU0ODlmOTE5YWFlZmZkODlkMTU1NV8zNC9mcmFnOmNmYTQwNTllNGQ2MjQ5OTU4Yjc5ZTBmYzk1YWM5MjcyL3RleHRyZWdpb246Y2ZhNDA1OWU0ZDYyNDk5NThiNzllMGZjOTVhYzkyNzJfMzk0Mw_b65ab562-e1dd-4b87-8b8a-a4af7cae1a16">ASU 2016-13</span> on January 1, 2020. We adopted this standard using a modified-retrospective approach, and recorded a $0.1 million cumulative-effect adjustment to the opening balance of accumulated deficit in connection with the adoption. This adjustment was recorded to establish an allowance for trade account receivables and investment in leases. No cumulative-effect adjustment was recorded for unrealized losses on debt securities available-for-sale as the issuers of such securities held by us were of high credit quality. As a result, the condensed consolidated financial statements for the current periods are presented under the new standard, while the comparative prior year period is not adjusted and continues to be reported in accordance with our historical accounting policy.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards not yet adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2020-06 reduces the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, this ASU amends the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. This ASU will reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP standards. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU is effective for us on January 1, 2022, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the FASB Emerging Issues Task Force). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321, the accounting for the equity method investments in Topic 323 and the accounting for certain forward contracts and purchased options in Topic 815. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740); Simplifying the Accounting for Income Taxes. ASU 2019-12 reduces complexity in the accounting standard. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards that were recently adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Fair Value Measurement (Topic 820); Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies, among other things, the disclosures required for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs. The guidance removes, among other things, the disclosure requirement to disclose transfers between Levels 1 and 2. Level 3 fair value measurement disclosures should be applied prospectively while all other amendments should be applied retrospectively. The Company adopted ASU 2018-13 on January 1, 2020, which had no impact to our condensed consolidated financial statements as the Company did not carry Level 3 fair value items upon implementing this ASU on January 1, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments. In November 2018, ASU 2018-19 was issued which amended the standard to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU 2019-04, 2019-05, 2019-10, ASU 2019-11, 2020-02 and 2020-03 to provide additional guidance on the credit losses standard. ASU 2016-13 amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Previously, an “incurred loss” methodology was used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. This amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities are now recorded in current period net income. The Company adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg5YTY2ODEwYWFiNTQ4OWY5MTlhYWVmZmQ4OWQxNTU1L3NlYzo4OWE2NjgxMGFhYjU0ODlmOTE5YWFlZmZkODlkMTU1NV8zNC9mcmFnOmNmYTQwNTllNGQ2MjQ5OTU4Yjc5ZTBmYzk1YWM5MjcyL3RleHRyZWdpb246Y2ZhNDA1OWU0ZDYyNDk5NThiNzllMGZjOTVhYzkyNzJfMzk0Mw_b65ab562-e1dd-4b87-8b8a-a4af7cae1a16">ASU 2016-13</span> on January 1, 2020. We adopted this standard using a modified-retrospective approach, and recorded a $0.1 million cumulative-effect adjustment to the opening balance of accumulated deficit in connection with the adoption. This adjustment was recorded to establish an allowance for trade account receivables and investment in leases. No cumulative-effect adjustment was recorded for unrealized losses on debt securities available-for-sale as the issuers of such securities held by us were of high credit quality. As a result, the condensed consolidated financial statements for the current periods are presented under the new standard, while the comparative prior year period is not adjusted and continues to be reported in accordance with our historical accounting policy.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards not yet adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2020-06 reduces the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, this ASU amends the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. This ASU will reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP standards. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU is effective for us on January 1, 2022, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the FASB Emerging Issues Task Force). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321, the accounting for the equity method investments in Topic 323 and the accounting for certain forward contracts and purchased options in Topic 815. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740); Simplifying the Accounting for Income Taxes. ASU 2019-12 reduces complexity in the accounting standard. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.</span></div> -100000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. CONCENTRATION OF CREDIT RISK</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2020, four of the Company's financial institutions held 18%, 38%, 21% and 11% of the Company’s cash and cash equivalents, respectively. As of December 31, 2019, two of the Company's financial institutions held 73% and 18% of the Company’s cash and cash equivalents, respectively.</span></div>The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. None of the Company's customers accounted for 10% or more of the net accounts receivable balance as of September 30, 2020. The Company had one customer that accounted for 11% of the Company’s net accounts receivable balance as of December 31, 2019.The Company did not have any customers who represented 10% or more of the Company’s total revenue during the three and nine months ended September 30, 2020 and 2019 0.18 0.38 0.21 0.11 0.73 0.18 0.11 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,484 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,731 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,215 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,745 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,606 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,351 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,745 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,579 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company issued the Notes, for total proceeds of $171.5 million, as described in Note 11, Convertible Notes. At September 30, 2020 and December 31, 2019, the fair value of the Notes were $110.7 million and $133.8 million, respectively. The fair value of the Notes is highly correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. The fair value of the Notes are classified as Level 2 within the fair value hierarchy. See Note 11, Convertible Notes for further detail on the Company’s convertible notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's PPP Note along with its other long-term notes, cumulatively $5.5 million, approximate their fair value. The estimated fair value of the Company’s long-term debt represents a Level 3 measurement. See Note 10, Long-Term Debt for further detail on the Company's long-term debt.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,484 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,731 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,215 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,745 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,606 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,351 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,745 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,744 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,579 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,437 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5013000 0 0 5013000 0 1875000 0 1875000 5013000 1875000 0 6888000 248000 0 0 248000 248000 0 0 248000 0 6857000 0 6857000 13484000 0 0 13484000 0 9345000 0 9345000 0 20529000 0 20529000 13484000 36731000 0 50215000 18745000 38606000 0 57351000 43745000 0 0 43745000 0 1993000 0 1993000 0 1006000 0 1006000 43745000 2999000 0 46744000 0 5663000 0 5663000 12579000 0 0 12579000 0 3998000 0 3998000 0 2491000 0 2491000 0 22706000 0 22706000 12579000 34858000 0 47437000 56324000 37857000 0 94181000 171500000 110700000 133800000 5500000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. INVESTMENTS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,131 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,215 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,437 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1-3 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,215 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,415 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,437 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sales of debt securities available-for-sale (including principal paydowns) for each of the three months ended September 30, 2020 and 2019 was $0, and for the nine months ended September 30, 2020 and 2019 were $0 and $13.4 million, respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2020 and 2019. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%. As of September 30, 2020 there were no debt securities available-for-sale in a material unrealized loss position.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 the Company carried debt securities available-for-sale that were certificates of deposits, which were not covered by a rating agency or the credit rating was below the Company's minimum credit rating. As of September 30, 2020 all of the Company's certificate deposits were below the FDIC's insurance limit of $250,000 per depositor which mitigated the Company's investment risk. All other debt securities available-for-sale had a credit rating of A- or better as of September 30, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are comprised of investments in mutual funds. The fair value of equity securities at September 30, 2020 was $0.2 million. There were no material unrealized gains or losses on equity securities recorded in income for the three and nine months ended September 30, 2020. These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for the three and nine months ended September 30, 2020.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,131 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,215 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,437 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6838000 19000 0 6857000 13435000 49000 0 13484000 0 0 0 0 9345000 1000 1000 9345000 20513000 19000 3000 20529000 50131000 88000 4000 50215000 5646000 17000 0 5663000 12564000 16000 1000 12579000 4002000 0 4000 3998000 2492000 0 1000 2491000 22711000 6000 11000 22706000 47415000 39000 17000 47437000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1-3 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,131 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,215 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,415 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,437 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 49874000 49958000 43627000 43650000 257000 257000 3788000 3787000 50131000 50215000 47415000 47437000 0 0 0 13400000 0 0 0 0 200000 0 0 0 0 0 0 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. INVENTORY</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,459 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,059 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,459 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,059 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5128000 4854000 2257000 1561000 2074000 1644000 9459000 8059000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. PROPERTY AND EQUIPMENT</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,770 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,865)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,104 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,905 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for each of the three months ended September 30, 2020 and 2019 was $0.6 million, and for the nine months ended September 30, 2020 and 2019 was $1.8 million and $1.7 million, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross assets under operating leases where the Company is the lessor at September 30, 2020 and December 31, 2019 were $4.3 million and $4.6 million, respectively. The underlying accumulated depreciation under operating leases where the Company is the lessor at September 30, 2020 and December 31, 2019 was $1.1 million and $0.8 million, respectively.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,883 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,770 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,865)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,104 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,905 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2599000 2477000 3943000 3681000 3690000 3883000 6599000 7491000 1047000 238000 17878000 17770000 10774000 9865000 7104000 7905000 600000 600000 1800000 1700000 4300000 4600000 1100000 800000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. LICENSE AGREEMENTS AND GRANTS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">National Institute of Health Grant</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2015, the National Institute of Health awarded Denver Health and the Company a five-year, $5.0 million grant to develop a fast and reliable identification and categorical susceptibility test for carbepenem-</span></div>resistant Enterobacteriaceae directly from whole blood. The grant is paid to the Company incrementally through sub-awards. The cumulative amount awarded to date under these sub-awards is $1.5 million. The amount invoiced for the nine months ended September 30, 2020 and 2019 was $0.1 million and $0.2 million, respectively. Subsequent to the original term of the grant the National Institute of Health has provided incremental annual extensions that have allowed the Company to provide additional services. P5Y 5000000.0 1500000 100000 200000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2020 and December 31, 2019 follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products and services not yet delivered</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $0.1 million and $0.2 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2020, respectively, and $0.2 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2019. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Price Allocated to Remaining Performance Obligations</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, $8.6 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div> A summary of the balances as of September 30, 2020 and December 31, 2019 follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products and services not yet delivered</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 338000 271000 100000 200000 200000 300000 8600000 The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. LONG-TERM DEBT</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019, long-term debt consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPP Loan - 1% interest</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,803 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Loans - various interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">511 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of future principal obligations of long-term debt as of September 30, 2020 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other notes payable</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, the Company entered into three loan agreements with two capital asset financing companies. Loan proceeds were $0.7 million, with interest rates ranging from 9.8% to 12.4% and maturities ranging from January 1, 2022 to September 2022. As of September 30, 2020, the current portion of long-term debt was $0.3 million and long-term debt was $0.4 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PPP Loan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2020, the Company entered into the PPP Note evidencing an unsecured loan in the amount of $4.8 million made to the Company under the PPP. The PPP was established under the CARES Act and is administered by the SBA.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 3, 2020 the Company's loan provider amended the PPP Note per the Paycheck Protection Program Flexibility Act (“PPP Flexibility Act”), which was enacted after the PPP Note was approved and funded. The PPP Flexibility Act amended the CARES Act to require that all PPP Notes made prior to June 5, 2020 be extended to a 5-year term. In accordance with this amendment the PPP Notes' original maturity date of April 14, 2022 was amended to April 14, 2025. The original terms of the loan required 18 monthly payments of principal and interest in the amount of $0.3 million starting November 14, 2020. These amended terms now require 45 monthly payments of principal and interest in the amount of $0.1 million starting August 14, 2021. The PPP Note's interest rate was unchanged and bears interest at a rate of 1% per annum.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from the PPP Note may only be used for payroll costs (including benefits), interest on mortgage obligations, rent, utilities and interest on certain other debt obligations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Note contains customary events of default relating to, among other things, payment defaults, making materially false and misleading representations to the lender or breaching the terms of the PPP Note documents. The occurrence of an event of default will result in an increase in the interest rate to 18% per annum and provides the lender with customary remedies, including the right to require immediate payment of all amounts owed under the PPP Note.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the CARES Act and the PPP, the Company may apply to the lender for forgiveness for the amount due on the PPP Note. The amount eligible for forgiveness is based on the amount of PPP Note proceeds used by the Company (during the 24 week period after the lender makes the first disbursement of PPP Note proceeds) for the payment of certain covered costs, including payroll costs (including benefits), rent and utilities, subject to certain limitations and reductions in accordance with the CARES Act and the PPP. No assurance can be given that the Company will obtain forgiveness of the PPP Note in whole or in part. As of September 30, 2020 the Company had submitted their application for forgiveness to the loan provider, which is currently under review.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019, long-term debt consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPP Loan - 1% interest</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,803 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Loans - various interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">511 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.01 4803000 0 736000 0 5539000 0 511000 0 5028000 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of future principal obligations of long-term debt as of September 30, 2020 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 76000 825000 1604000 1291000 1304000 439000 5539000 3 700000 0.098 0.124 300000 400000 4800000 18 300000 45 100000 0.01 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. CONVERTIBLE NOTES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2018, the Company issued $150.0 million aggregate principal amount of 2.50% Senior Convertible Notes due 2023. In connection with the offering of the Notes, the Company granted the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes on the same terms and conditions. On April 4, 2018, the option was partially exercised, which resulted in $21.5 million of additional proceeds, for total proceeds of $171.5 million. The Notes are the Company's senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $171.5 million of proceeds received from the issuance of the Notes were allocated between long-term debt (the “liability component”) of $116.6 million and contributed capital (the “equity component”) of $54.9 million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Notes. The liability component will be accreted up to the face value of the Notes of $171.5 million, which will result in additional non-cash interest expense being recognized through the Maturity Date. The equity component will not be remeasured as long as it continues to meet the conditions for equity classification.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $5.0 million of issuance costs related to the issuance of the Notes, of which $3.4 million and $1.6 million were recorded to long-term debt and contributed capital, respectively. The $3.4 million of issuance costs recorded as long-term debt on the condensed consolidated balance sheet are being amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par and debt issuance cost amortization, is 11.52%.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of certain corporate events, such as a change of control, merger or liquidation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes at September 30, 2020 and December 31, 2019 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount of the liability component</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138,299 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,903 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,472 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,585 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019, no Notes were convertible pursuant to their terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.</span></div> 150000000.0 0.0250 P13D 22500000 21500000 171500000 1000 30.92 171500000 116600000 -54900000 171500000 5000000.0 3400000 1600000 3400000 P5Y 0.1152 1000 1.30 20 30 0.98 1000 1 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes at September 30, 2020 and December 31, 2019 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount of the liability component</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138,299 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 171500000 171500000 31267000 39042000 1934000 2415000 138299000 130043000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,903 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,472 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,585 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1072000 1072000 3216000 3216000 2666000 2379000 7775000 6940000 165000 147000 481000 429000 3903000 3598000 11472000 10585000 45100000 1858500 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. EARNINGS PER SHARE</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">722 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">722 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares would also include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 11, Convertible Notes, the Company issued $171.5 million of Notes due 2023. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes. As of September 30, 2020, no Notes were convertible pursuant to their terms. The number of shares issuable upon conversion of the Notes is 5.5 million shares.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">722 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">722 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 722000 20000 722000 20000 8952000 10159000 8952000 10159000 9674000 10179000 9674000 10179000 171500000 1000 0 5500000 1858500 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under all plans for the nine months ended September 30, 2020:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options Outstanding January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,132,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,693,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(486,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,219,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(167,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options Outstanding September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,952,313 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.89 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for the three months ended September 30, 2020 and 2019:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.46</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2020:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,952,313 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,767,274 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.26</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.51</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value (in thousands)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">807,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested/released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68,641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">722,135 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.80 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,676 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,131 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,291 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,409 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost capitalized to inventory or inventory transferred to property and equipment (also referred to as instruments) for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost capitalized to inventory</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $17.4 million and $3.9 million, respectively. This is expected to be recognized over the years 2020 through 2025.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based options issued under the plan. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company granted 225,000 performance-based stock options. Of these performance-based stock options performance obligations had been met for 75,000 options which became exercisable in the prior year. The remaining 150,000 options were forfeited for the performance targets not being achieved. Of the total options forfeited, 50,000 of those options were forfeited during the nine months ended September 30, 2020. No stock compensation expense for the forfeited performance-based stock options was recognized. The stock compensation expense for the vested options was recorded in prior periods.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company granted another 105,000 performance-based stock options. During the three and nine months ended September 30, 2020, 22,500 performance-based stock options vested due to the performance obligations being achieved. None of these options have been forfeited as of September 30, 2020.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based stock option expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the above-noted RSU and restricted stock award outstanding amount are performance-based RSU's which vest only upon the achievement of certain targets. Performance-based RSU's contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company granted 361,338 performance-based RSU's. During the three and nine months ended September 30, 2020, 40,500 performance-based RSU's were released due to the performance obligations being achieved. At September 30, 2020 306,785 performance-based RSU's were outstanding. None of these performance-based RSU have been forfeited due to performance obligations not being achieved.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based RSU expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under all plans for the nine months ended September 30, 2020:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options Outstanding January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,132,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,693,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(486,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,219,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(167,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options Outstanding September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,952,313 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.89 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10132562 12.28 1693083 8.55 486864 13.86 2219281 2.01 167187 19.83 8952313 13.89 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for the three months ended September 30, 2020 and 2019:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.46</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P6Y1M20D P6Y5M15D 0.62 0.59 0 0 0.0042 0.0147 8.10 9.66 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2020:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,952,313 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,767,274 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.26</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.51</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value (in thousands)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8952313 4767274 P6Y3M3D P4Y6M3D 13.89 13.28 8.73 8.60 15514000 12387000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">807,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested/released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68,641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">722,135 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.80 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14332 16.66 807751 11.47 31307 9.72 68641 9.85 722135 11.80 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,676 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,131 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,291 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,409 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost capitalized to inventory or inventory transferred to property and equipment (also referred to as instruments) for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost capitalized to inventory</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based stock option expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based RSU expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 119000 65000 249000 172000 1349000 897000 2807000 3226000 3208000 2169000 9235000 6011000 4676000 3131000 12291000 9409000 61000 92000 199000 332000 17400000 3900000 P1Y P2Y P10Y P5Y P7Y 225000 75000 150000 50000 105000 22500 22500 109000 107000 P1Y P3Y P10Y 361338 40500 40500 306785 401000 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. INCOME TAXES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2020 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $59.3 million, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions. At September 30, 2020, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the U.S. enacted the CARES Act. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Management does not expect the CARES Act to have a material impact on the Company’s income tax position for financial reporting purposes. The Company will continue its assessment of the CARES Act on its financial statements, as changes in tax legislation and further guidance for the CARES Act become available in the subsequent quarters.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2020, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.</span></div> 0 -59300000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. LEASES</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term on our operating leases is 4.7 years. The weighted average discount rate on those leases is 7%.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of operating lease liabilities in which we are the lessee as of September 30, 2020 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,713 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2020, the total net investment in these leases was $2.6 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2020 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. LEASES</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term on our operating leases is 4.7 years. The weighted average discount rate on those leases is 7%.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of operating lease liabilities in which we are the lessee as of September 30, 2020 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,713 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2020, the total net investment in these leases was $2.6 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2020 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 185000 168000 556000 333000 333000 0 3639000 17000 3639000 277000 213000 790000 378000 378000 17000 103000 45000 697000 697000 P4Y8M12D 0.07 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of operating lease liabilities in which we are the lessee as of September 30, 2020 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,713 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 174000 753000 877000 968000 1055000 619000 4446000 733000 3713000 2600000 The following presents maturities of lease receivables under sales-type leases as of September 30, 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 223000 851000 794000 431000 123000 150000 2572000 0 2572000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. INDUSTRY, GEOGRAPHIC AND REVENUE DISAGGREGATION</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment. Sales to customers outside the U.S. represented 6% and 23% for the three months ended September 30, 2020 and 2019, respectively, and 7% and 26% for the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019, balances due from foreign customers, in U.S. dollars, were $1.2 million and $2.1 million, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by geographic territory for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,308 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,056 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by line of business for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Pheno revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,582 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,980 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,056 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by products and services for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,056 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease revenue included in net sales was $1.7 million and $0.2 million for the three months ended September 30, 2020 and 2019, respectively, and $2.4 million and $0.6 million for the nine months ended September 30, 2020 and 2019, respectively, which does not represent revenues recognized from contracts with customers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents property and equipment, net by geographic territory (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,104 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,905 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 0.06 0.23 0.07 0.26 1200000 2100000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by geographic territory for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,308 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,056 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by line of business for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Pheno revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,582 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,980 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,056 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by products and services for the three and nine months ended September 30, 2020 and 2019 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,056 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3386000 1757000 7477000 4308000 202000 514000 579000 1519000 3588000 2271000 8056000 5827000 3582000 2221000 7980000 5702000 6000 50000 76000 125000 3588000 2271000 8056000 5827000 3402000 2143000 7481000 5531000 186000 128000 575000 296000 3588000 2271000 8056000 5827000 1700000 200000 2400000 600000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents property and equipment, net by geographic territory (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,104 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,905 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6563000 7244000 541000 661000 7104000 7905000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17. RELATED PARTY TRANSACTIONS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 11, Convertible Notes, the Company issued Notes in March 2018. As of September 30, 2020 and December 31, 2019 an entity controlled by one member of the Company's board of directors held an aggregate of $42.0 million of the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2019, the Company and an entity affiliated with the then Chief Operating Officer and current Chief Executive Officer of the Company entered into a securities purchase agreement (the “Purchase Agreement”) for the issuance and sale by the Company of an aggregate of 55,586 shares of the Company’s common stock (the “Shares”) in an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The Shares were sold at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the shares) of $17.99 per share, which was equal to the consolidated closing bid price reported by Nasdaq immediately preceding the time the Company entered into the Purchase Agreement. The $1.0 million of proceeds were recorded to contributed capital.</span></div> 42000000.0 42000000.0 55586 17.99 1000000.0 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
9 Months Ended
Sep. 30, 2020
Nov. 03, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 001-31822  
Entity Registrant Name ACCELERATE DIAGNOSTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 84-1072256  
Entity Address, Address Line One 3950 South Country Club Road,  
Entity Address, Address Line Two Suite 470  
Entity Address, City or Town Tucson,  
Entity Address, State or Province AZ  
Entity Address, Postal Zip Code 85714  
City Area Code 520  
Local Phone Number 365-3100  
Title of 12(b) Security Common Stock, $0.001 par  
Trading Symbol AXDX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   57,029,694
Entity Central Index Key 0000727207  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2020  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 27,029 $ 61,014
Investments 50,463 47,437
Trade accounts receivable 2,610 3,222
Inventory 9,459 8,059
Prepaid expenses 961 955
Other current assets 1,517 1,165
Total current assets 92,039 121,852
Property and equipment, net 7,104 7,905
Right of use assets 3,402 3,917
Other non-current assets 1,674 750
Total assets 104,219 134,424
Current liabilities:    
Accounts payable 2,372 2,351
Accrued liabilities 3,176 3,828
Accrued interest 191 1,262
Deferred revenue 338 271
Current portion of long-term debt 511 0
Current operating lease liability 482 450
Total current liabilities 7,070 8,162
Non-current operating lease liability 3,231 3,579
Other non-current liabilities 259 19
Long-term debt 5,028 0
Convertible notes 138,299 130,043
Total liabilities 153,887 141,803
Commitments and contingencies
Stockholders’ deficit:    
Preferred shares 0 0
Common stock 57 55
Contributed capital 469,302 452,344
Treasury stock (45,067) (45,067)
Accumulated deficit (474,054) (414,653)
Accumulated other comprehensive income (loss) 94 (58)
Total stockholders’ deficit (49,668) (7,379)
Total liabilities and stockholders’ deficit $ 104,219 $ 134,424
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Preferred Stock, par value (usd per share) $ 0.001 $ 0.001
Preferred Stock, shares authorized (shares) 5,000,000 5,000,000
Preferred Stock, shares outstanding (shares) 0 0
Common Stock, par value (usd per share) $ 0.001 $ 0.001
Common Stock, shares authorized (shares) 85,000,000 85,000,000
Common Stock, shares issued (shares) 57,027,429 54,708,792
Common Stock, shares outstanding (shares) 57,027,429 54,708,792
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Net sales $ 3,588,000 $ 2,271,000 $ 8,056,000 $ 5,827,000
Cost of sales 2,287,000 1,117,000 4,745,000 2,940,000
Gross profit 1,301,000 1,154,000 3,311,000 2,887,000
Costs and expenses:        
Research and development 5,001,000 6,064,000 16,191,000 19,145,000
Sales, general and administrative 11,465,000 12,743,000 35,738,000 38,302,000
Total costs and expenses 16,466,000 18,807,000 51,929,000 57,447,000
Loss from operations (15,165,000) (17,653,000) (48,618,000) (54,560,000)
Other income (expense):        
Interest expense (3,955,000) (3,598,000) (11,540,000) (10,585,000)
Foreign currency exchange gain (loss) 229,000 (89,000) 191,000 (142,000)
Interest income 149,000 676,000 753,000 2,329,000
Other expense, net (15,000) (9,000) (82,000) (12,000)
Total other expense, net (3,592,000) (3,020,000) (10,678,000) (8,410,000)
Net loss before income taxes (18,757,000) (20,673,000) (59,296,000) (62,970,000)
Provision for income taxes 0 239,000 0 0
Net loss $ (18,757,000) $ (20,434,000) $ (59,296,000) $ (62,970,000)
Basic and diluted net loss per share (usd per share) $ (0.33) $ (0.37) $ (1.07) $ (1.16)
Weighted average shares outstanding (shares) 56,560 54,553 55,617 54,456
Other comprehensive loss:        
Net loss $ (18,757,000) $ (20,434,000) $ (59,296,000) $ (62,970,000)
Net unrealized gain (loss) on debt securities available-for-sale (117,000) 10,000 62,000 229,000
Foreign currency translation adjustment 71,000 (113,000) 90,000 (139,000)
Comprehensive loss $ (18,803,000) $ (20,537,000) $ (59,144,000) $ (62,880,000)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities:    
Net loss $ (59,296,000) $ (62,970,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,270,000 1,862,000
Amortization of investment discount 43,000 (400,000)
Equity-based compensation 12,291,000 9,409,000
Amortization of debt discount and issuance costs 8,256,000 7,370,000
Realized loss on sale of investments 3,000 0
Loss on disposal of property and equipment 546,000 577,000
Contributions to deferred compensation plan (248,000) 0
(Increase) decrease in assets:    
Accounts receivable 532,000 (782,000)
Inventory and instruments in property and equipment (1,734,000) (3,286,000)
Prepaid expense and other (1,267,000) (319,000)
Increase (decrease) in liabilities:    
Accounts payable 76,000 788,000
Accrued liabilities, and other (759,000) (2,115,000)
Accrued interest (1,071,000) (1,071,000)
Deferred revenue and income 67,000 33,000
Deferred compensation 240,000 (25,000)
Net cash used in operating activities (40,051,000) (50,929,000)
Cash flows from investing activities:    
Purchases of equipment (1,364,000) (148,000)
Purchase of marketable securities (44,589,000) (20,710,000)
Proceeds from sales of marketable securities 0 13,400,000
Maturities of marketable securities 41,707,000 78,922,000
Net cash (used in) provided by investing activities (4,246,000) 71,464,000
Cash flows from financing activities:    
Proceeds from issuance of common stock 296,000 1,363,000
Proceeds from exercise of options 4,458,000 4,879,000
Proceeds from debt 5,552,000 0
Payment of debt (13,000) 0
Net cash provided by financing activities 10,293,000 6,242,000
Effect of exchange rate on cash 19,000 (99,000)
(Decrease) increase in cash and cash equivalents (33,985,000) 26,678,000
Cash and cash equivalents, beginning of period 61,014,000 66,260,000
Cash and cash equivalents, end of period 27,029,000 92,938,000
Non-cash investing activities:    
Net transfer of instruments from inventory to property and equipment 1,284,000 3,225,000
Supplemental cash flow information:    
Interest paid 4,288,000 4,288,000
Income taxes paid, net of refunds $ 46,000 $ 54,000
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common stock
Contributed capital
Accumulated deficit
Accumulated deficit
Adjustment
Treasury stock
Accumulated other comprehensive (loss) income
Beginning Balance (shares) at Dec. 31, 2018   54,232,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock (shares)   56,000          
Exercise of options (shares)   334,000          
Issuance of common stock under employee purchase plan (shares)   19,000          
Ending Balance (shares) at Sep. 30, 2019   54,641,000          
Beginning Balance, amount at Dec. 31, 2018   $ 54 $ 432,885 $ (330,348) $ 0 $ (45,067) $ (149)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Proceeds from issuance of common stock     1,000        
Exercise of options   1 4,879        
Issuance of common stock under employee purchase plan     362        
Equity-based compensation     9,483        
Net loss $ (62,970)     (62,970)      
Unrealized loss on available-for-sale securities 229           229
Foreign currency translation adjustment (139)           (139)
Ending Balance, amount at Sep. 30, 2019 10,220 $ 55 448,609 (393,318)   (45,067) (59)
Beginning Balance (shares) at Jun. 30, 2019   54,512,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock (shares)   56,000          
Exercise of options (shares)   66,000          
Issuance of common stock under employee purchase plan (shares)   7,000          
Ending Balance (shares) at Sep. 30, 2019   54,641,000          
Beginning Balance, amount at Jun. 30, 2019   $ 55 443,857 (372,884)   (45,067) 44
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Proceeds from issuance of common stock     1,000        
Exercise of options   0 510        
Issuance of common stock under employee purchase plan     112        
Equity-based compensation     3,130        
Net loss (20,434)     (20,434)      
Unrealized loss on available-for-sale securities 10           10
Foreign currency translation adjustment (113)           (113)
Ending Balance, amount at Sep. 30, 2019 $ 10,220 $ 55 448,609 (393,318)   (45,067) (59)
Beginning Balance (shares) at Dec. 31, 2019   54,709,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock (shares)   0          
Exercise of options (shares) 2,219,281 2,287,000          
Issuance of common stock under employee purchase plan (shares)   31,000          
Ending Balance (shares) at Sep. 30, 2020   57,027,000          
Beginning Balance, amount at Dec. 31, 2019 $ (7,379) $ 55 452,344 (414,653) $ (105) (45,067) (58)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Proceeds from issuance of common stock     0        
Exercise of options   2 4,458        
Issuance of common stock under employee purchase plan     294        
Equity-based compensation     12,206        
Net loss (59,296)     (59,296)      
Unrealized loss on available-for-sale securities 62           62
Foreign currency translation adjustment 90           90
Ending Balance, amount at Sep. 30, 2020 (49,668) $ 57 469,302 (474,054)   (45,067) 94
Beginning Balance (shares) at Jun. 30, 2020   56,249,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock (shares)   0          
Exercise of options (shares)   770,000          
Issuance of common stock under employee purchase plan (shares)   8,000          
Ending Balance (shares) at Sep. 30, 2020   57,027,000          
Beginning Balance, amount at Jun. 30, 2020   $ 56 463,178 (455,297)   (45,067) 140
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Proceeds from issuance of common stock     0        
Exercise of options   1 1,427        
Issuance of common stock under employee purchase plan     79        
Equity-based compensation     4,618        
Net loss (18,757)     (18,757)      
Unrealized loss on available-for-sale securities (117)           (117)
Foreign currency translation adjustment 71           71
Ending Balance, amount at Sep. 30, 2020 $ (49,668) $ 57 $ 469,302 $ (474,054)   $ (45,067) $ 94
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies
NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES

Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on February 28, 2020.

The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2020, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, tax valuation accounts and equity–based compensation. Actual results could differ materially from those estimates.

Estimated Fair Value of Financial Instruments

The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.

The estimated fair value of the Company’s convertible note represents a Level 2 measurement. See Note 11, Convertible Notes for further detail on the Company’s convertible notes.

The estimated fair value of the Company’s long-term debt represents a Level 3 measurement. The promissory notes issued under the Paycheck Protection Program (PPP) and other long-term debt is privately held with no public market. The carrying amount of these notes approximates fair value. See Note 10, Long-Term Debt for further detail on the Company’s long-term debt.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe, however, that the market risk arising from holding these financial instruments is minimal.

Investments

The Company invests in various debt securities available-for-sale and equity securities which are primarily held in the custody of major financial institutions. Debt securities available-for-sale consist of certificates of deposit, U.S. government and agency securities, commercial paper, asset-backed securities, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

On a quarterly basis, we perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security available-for-sale is considered impaired if its fair value is less than its amortized cost basis at the reporting date.

If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security available-for-sale.
Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.

Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.

We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the condensed consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. The allowance for credit losses as of September 30, 2020 was $0.3 million.

Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.

The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and this evaluation is performed at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of September 30, 2020 and December 31, 2019.

Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.
Warranty Reserve

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.

Warranty reserve activity for the three and nine months ended September 30, 2020 and 2019 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Beginning balance$305 $196 $403 $215 
Provisions72 77 72 147 
Warranty cost incurred
(40)(51)(138)(140)
Ending balance$337 $222 $337 $222 

Paycheck Protection Program (PPP) Loan

The PPP was established by the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, through a significant expansion of the Small Business Administration (“SBA”) 7(a) loan program. On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million.

The Company elected to account for the PPP Note in accordance with ASC 470, Debt, with interest accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. The Company recognized the entire PPP Note amount as a liability on the balance sheet, with interest accrued and expensed over the term of the loan. The Company did not impute additional interest at a market rate because transactions where interest rates are prescribed by governmental agencies are excluded from the scope of ASC 835-30.

The PPP Note will remain a liability until either of the following criteria are met:

the Company has been legally released from being the primary obligor under the liability (i.e. the PPP Note is forgiven); or

the Company pays the lender and is relieved of its obligation for the liability

See Note 10, Long-Term Debt for further detail regarding the PPP Note.

Convertible Notes

The Company accounts for convertible debt instruments that may be settled in cash or equity upon conversion, which includes the 2.50% Senior Convertible Notes due 2023 (the “Notes”), by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determined the carrying amount of the liability component of the Notes by using estimates and assumptions that market participants would use in pricing a debt instrument. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.

The equity component is treated as a discount on the liability component of the Notes, which is amortized over the term of the Notes using the effective interest rate method. Debt issuance costs related to the Notes are allocated to the liability and equity components of the Notes based on their relative values. Debt issuance costs allocated to the liability component are amortized over the life of the Notes as additional non-cash interest expense. Transaction costs allocated to equity are netted with the equity component of the convertible debt instrument in stockholders’ deficit.
Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

Identification of the contract with a customer

Identification of the performance obligations in the contract

Determination of the transaction price

Allocation of the transaction price to the performance obligations

Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized and the term between invoicing and when payment is due is not typically significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine relative standalone selling prices based on the price charged to customers for each individual performance obligation.

Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2020.

Cost of Sales

Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related expenses.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.
Restructure Activity

During the three months ended September 30, 2020, following the completion of a strategic review of its Europe, the Middle East and Africa (“EMEA”) business, the Company's board of directors approved a plan to reduce its workforce, focus the geographies it plans to operate in, and terminate agreements with some distributors in geographies it plans on exiting (collectively, the “EMEA Restructuring Plan”). As of September 30, 2020, the Company substantially completed the workforce reduction portion of the EMEA Restructuring Plan, while the remaining restructuring activities are likely to occur through the end of the year. Restructuring charges are primarily comprised of employee severance and other post-employment benefits. The Company evaluates the nature of these costs to determine if they relate to on-going benefit arrangements which are accounted for under ASC 712 or one-time benefit arrangements which are accounted for under ASC 420. The Company incurred expense of $0.4 million in connection with the EMEA Restructuring Plan.

Leases

The Company accounts for commercial leases in accordance with ASC 842, Leases. We determine if an arrangement is or contains a lease and the type of lease at inception. The Company classifies commercial leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.

Lessee

Operating leases are included in right-of-use (“ROU”) assets and operating lease liabilities within our consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. As of September 30, 2020 and December 31, 2019, the Company was not party to finance lease arrangements.

Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions.

Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.
Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.

Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”), provides certain key employees, with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.

Equity-Based Compensation

The Company may award stock options, restricted stock units (“RSUs”), performance-based awards, and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

Expected term: The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. For consultant awards, the estimated expected term is the same as the life of the award.

Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.

The Company records the fair value of RSUs or stock grants based on published closing market price on the day before the grant date. The Company accounts for forfeitures as they occur rather than on an estimated basis.
Deferred Tax Assets

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.

Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss).

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.

Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options and unvested RSUs. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes at the balance sheet date were converted. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.

Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds investments classified as debt securities available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Recently Issued Accounting Pronouncements
9 Months Ended
Sep. 30, 2020
Accounting Changes and Error Corrections [Abstract]  
Recently Issued Accounting Pronouncements
NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Standards that were recently adopted

In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Fair Value Measurement (Topic 820); Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies, among other things, the disclosures required for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs. The guidance removes, among other things, the disclosure requirement to disclose transfers between Levels 1 and 2. Level 3 fair value measurement disclosures should be applied prospectively while all other amendments should be applied retrospectively. The Company adopted ASU 2018-13 on January 1, 2020, which had no impact to our condensed consolidated financial statements as the Company did not carry Level 3 fair value items upon implementing this ASU on January 1, 2020.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments. In November 2018, ASU 2018-19 was issued which amended the standard to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU 2019-04, 2019-05, 2019-10, ASU 2019-11, 2020-02 and 2020-03 to provide additional guidance on the credit losses standard. ASU 2016-13 amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Previously, an “incurred loss” methodology was used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. This amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities are now recorded in current period net income. The Company adopted ASU 2016-13 on January 1, 2020. We adopted this standard using a modified-retrospective approach, and recorded a $0.1 million cumulative-effect adjustment to the opening balance of accumulated deficit in connection with the adoption. This adjustment was recorded to establish an allowance for trade account receivables and investment in leases. No cumulative-effect adjustment was recorded for unrealized losses on debt securities available-for-sale as the issuers of such securities held by us were of high credit quality. As a result, the condensed consolidated financial statements for the current periods are presented under the new standard, while the comparative prior year period is not adjusted and continues to be reported in accordance with our historical accounting policy.

Standards not yet adopted

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2020-06 reduces the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, this ASU amends the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. This ASU will reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP standards. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU is effective for us on January 1, 2022, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the FASB Emerging Issues Task Force). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321, the accounting for the equity method investments in Topic 323 and the accounting for certain forward contracts and purchased options in Topic 815. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740); Simplifying the Accounting for Income Taxes. ASU 2019-12 reduces complexity in the accounting standard. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Concentration of Credit Risk
9 Months Ended
Sep. 30, 2020
Risks and Uncertainties [Abstract]  
Concentration of Credit Risk
NOTE 3. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.

The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2020, four of the Company's financial institutions held 18%, 38%, 21% and 11% of the Company’s cash and cash equivalents, respectively. As of December 31, 2019, two of the Company's financial institutions held 73% and 18% of the Company’s cash and cash equivalents, respectively.
The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. None of the Company's customers accounted for 10% or more of the net accounts receivable balance as of September 30, 2020. The Company had one customer that accounted for 11% of the Company’s net accounts receivable balance as of December 31, 2019.The Company did not have any customers who represented 10% or more of the Company’s total revenue during the three and nine months ended September 30, 2020 and 2019
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Instruments
9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments
NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
Cash and cash equivalents:
Money market funds$5,013 $— $— $5,013 
Commercial paper— 1,875 — 1,875 
Total cash and cash equivalents5,013 1,875 — 6,888 
Equity investments:
Mutual funds248 — — 248 
Total equity investments248 — — 248 
Debt securities available-for-sale:
Certificates of deposit— 6,857 — 6,857 
U.S. Treasury securities13,484 — — 13,484 
Commercial paper— 9,345 — 9,345 
Corporate notes and bonds— 20,529 — 20,529 
Debt securities available-for-sale13,484 36,731 — 50,215 
Total assets measured at fair value$18,745 $38,606 $— $57,351 
December 31, 2019
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
Cash and cash equivalents:
Money market funds$43,745 $— $— $43,745 
Commercial paper— 1,993 — 1,993 
Corporate notes and bonds— 1,006 — 1,006 
Total cash and cash equivalents43,745 2,999 — 46,744 
Debt securities available-for-sale:
Certificates of deposit— 5,663 — 5,663 
U.S. Treasury securities12,579 — — 12,579 
U.S. Agency securities— 3,998 — 3,998 
Commercial paper— 2,491 — 2,491 
Corporate notes and bonds— 22,706 — 22,706 
Debt securities available-for-sale12,579 34,858 — 47,437 
Total assets measured at fair value$56,324 $37,857 $— $94,181 

Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.

Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.

Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

In 2018, the Company issued the Notes, for total proceeds of $171.5 million, as described in Note 11, Convertible Notes. At September 30, 2020 and December 31, 2019, the fair value of the Notes were $110.7 million and $133.8 million, respectively. The fair value of the Notes is highly correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. The fair value of the Notes are classified as Level 2 within the fair value hierarchy. See Note 11, Convertible Notes for further detail on the Company’s convertible notes.

The Company's PPP Note along with its other long-term notes, cumulatively $5.5 million, approximate their fair value. The estimated fair value of the Company’s long-term debt represents a Level 3 measurement. See Note 10, Long-Term Debt for further detail on the Company's long-term debt.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Investments
9 Months Ended
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
Investments
NOTE 5. INVESTMENTS

The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit$6,838 $19 $— $6,857 
U.S. Treasury securities13,435 49 — 13,484 
U.S. Agency securities— — — — 
Commercial paper9,345 (1)9,345 
Corporate notes and bonds20,513 19 (3)20,529 
Total$50,131 $88 $(4)$50,215 

December 31, 2019
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit$5,646 $17 $— $5,663 
U.S. Treasury securities12,564 16 (1)12,579 
U.S. Agency securities4,002 — (4)3,998 
Commercial paper2,492 — (1)2,491 
Corporate notes and bonds22,711 (11)22,706 
Total$47,415 $39 $(17)$47,437 

The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020December 31, 2019
Amortized
Cost
Fair ValueAmortized
Cost
Fair Value
Due in less than 1 year$49,874 $49,958 $43,627 $43,650 
Due in 1-3 years257 257 3,788 3,787 
$50,131 $50,215 $47,415 $47,437 

Proceeds from sales of debt securities available-for-sale (including principal paydowns) for each of the three months ended September 30, 2020 and 2019 was $0, and for the nine months ended September 30, 2020 and 2019 were $0 and $13.4 million, respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2020 and 2019. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2020 and 2019.

As of September 30, 2020, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%. As of September 30, 2020 there were no debt securities available-for-sale in a material unrealized loss position.
As of September 30, 2020 the Company carried debt securities available-for-sale that were certificates of deposits, which were not covered by a rating agency or the credit rating was below the Company's minimum credit rating. As of September 30, 2020 all of the Company's certificate deposits were below the FDIC's insurance limit of $250,000 per depositor which mitigated the Company's investment risk. All other debt securities available-for-sale had a credit rating of A- or better as of September 30, 2020.

Equity securities are comprised of investments in mutual funds. The fair value of equity securities at September 30, 2020 was $0.2 million. There were no material unrealized gains or losses on equity securities recorded in income for the three and nine months ended September 30, 2020. These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for the three and nine months ended September 30, 2020.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory
9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Inventory
NOTE 6. INVENTORY

Inventories consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):

September 30,December 31,
20202019
Raw materials$5,128 $4,854 
Work in process2,257 1,561 
Finished goods2,074 1,644 
$9,459 $8,059 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment
9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Property and Equipment
NOTE 7. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):

September 30,December 31,
20202019
Computer equipment$2,599 $2,477 
Technical equipment3,943 3,681 
Facilities3,690 3,883 
Instruments6,599 7,491 
Capital projects in progress1,047 238 
Total property and equipment$17,878 $17,770 
Accumulated depreciation(10,774)(9,865)
Property and equipment, net$7,104 $7,905 

Depreciation expense for each of the three months ended September 30, 2020 and 2019 was $0.6 million, and for the nine months ended September 30, 2020 and 2019 was $1.8 million and $1.7 million, respectively.

Gross assets under operating leases where the Company is the lessor at September 30, 2020 and December 31, 2019 were $4.3 million and $4.6 million, respectively. The underlying accumulated depreciation under operating leases where the Company is the lessor at September 30, 2020 and December 31, 2019 was $1.1 million and $0.8 million, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
License Agreements and Grants
9 Months Ended
Sep. 30, 2020
Research and Development [Abstract]  
License Agreements and Grants
NOTE 8. LICENSE AGREEMENTS AND GRANTS

National Institute of Health Grant

In February 2015, the National Institute of Health awarded Denver Health and the Company a five-year, $5.0 million grant to develop a fast and reliable identification and categorical susceptibility test for carbepenem-
resistant Enterobacteriaceae directly from whole blood. The grant is paid to the Company incrementally through sub-awards. The cumulative amount awarded to date under these sub-awards is $1.5 million. The amount invoiced for the nine months ended September 30, 2020 and 2019 was $0.1 million and $0.2 million, respectively. Subsequent to the original term of the grant the National Institute of Health has provided incremental annual extensions that have allowed the Company to provide additional services.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Deferred Revenue and Remaining Performance Obligations
9 Months Ended
Sep. 30, 2020
Deferred Revenue Disclosure [Abstract]  
Deferred Revenue and Remaining Performance Obligations
NOTE 9. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS

Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2020 and December 31, 2019 follows (in thousands):

September 30,December 31,
20202019
Products and services not yet delivered$338 $271 

We recognized $0.1 million and $0.2 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2020, respectively, and $0.2 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2019. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.

Transaction Price Allocated to Remaining Performance Obligations

As of September 30, 2020, $8.6 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.

The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Long-term Debt
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Long-term Debt
NOTE 10. LONG-TERM DEBT

As of September 30, 2020 and December 31, 2019, long-term debt consisted of the following (in thousands):

September 30,December 31,
20202019
PPP Loan - 1% interest
$4,803 $— 
Other Loans - various interest736 — 
Total debt5,539 — 
Current portion of long-term debt511 — 
Long-term debt$5,028 $— 
The following presents maturities of future principal obligations of long-term debt as of September 30, 2020 (in thousands):

Remainder of 2020$76 
2021825 
20221,604 
20231,291 
20241,304 
Thereafter439 
Total$5,539 

Other notes payable

During the three months ended September 30, 2020, the Company entered into three loan agreements with two capital asset financing companies. Loan proceeds were $0.7 million, with interest rates ranging from 9.8% to 12.4% and maturities ranging from January 1, 2022 to September 2022. As of September 30, 2020, the current portion of long-term debt was $0.3 million and long-term debt was $0.4 million.

PPP Loan

On April 14, 2020, the Company entered into the PPP Note evidencing an unsecured loan in the amount of $4.8 million made to the Company under the PPP. The PPP was established under the CARES Act and is administered by the SBA.

On September 3, 2020 the Company's loan provider amended the PPP Note per the Paycheck Protection Program Flexibility Act (“PPP Flexibility Act”), which was enacted after the PPP Note was approved and funded. The PPP Flexibility Act amended the CARES Act to require that all PPP Notes made prior to June 5, 2020 be extended to a 5-year term. In accordance with this amendment the PPP Notes' original maturity date of April 14, 2022 was amended to April 14, 2025. The original terms of the loan required 18 monthly payments of principal and interest in the amount of $0.3 million starting November 14, 2020. These amended terms now require 45 monthly payments of principal and interest in the amount of $0.1 million starting August 14, 2021. The PPP Note's interest rate was unchanged and bears interest at a rate of 1% per annum.

The PPP Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from the PPP Note may only be used for payroll costs (including benefits), interest on mortgage obligations, rent, utilities and interest on certain other debt obligations.

The PPP Note contains customary events of default relating to, among other things, payment defaults, making materially false and misleading representations to the lender or breaching the terms of the PPP Note documents. The occurrence of an event of default will result in an increase in the interest rate to 18% per annum and provides the lender with customary remedies, including the right to require immediate payment of all amounts owed under the PPP Note.

Pursuant to the terms of the CARES Act and the PPP, the Company may apply to the lender for forgiveness for the amount due on the PPP Note. The amount eligible for forgiveness is based on the amount of PPP Note proceeds used by the Company (during the 24 week period after the lender makes the first disbursement of PPP Note proceeds) for the payment of certain covered costs, including payroll costs (including benefits), rent and utilities, subject to certain limitations and reductions in accordance with the CARES Act and the PPP. No assurance can be given that the Company will obtain forgiveness of the PPP Note in whole or in part. As of September 30, 2020 the Company had submitted their application for forgiveness to the loan provider, which is currently under review.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Convertible Notes
NOTE 11. CONVERTIBLE NOTES

On March 27, 2018, the Company issued $150.0 million aggregate principal amount of 2.50% Senior Convertible Notes due 2023. In connection with the offering of the Notes, the Company granted the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes on the same terms and conditions. On April 4, 2018, the option was partially exercised, which resulted in $21.5 million of additional proceeds, for total proceeds of $171.5 million. The Notes are the Company's senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year.

The $171.5 million of proceeds received from the issuance of the Notes were allocated between long-term debt (the “liability component”) of $116.6 million and contributed capital (the “equity component”) of $54.9 million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Notes. The liability component will be accreted up to the face value of the Notes of $171.5 million, which will result in additional non-cash interest expense being recognized through the Maturity Date. The equity component will not be remeasured as long as it continues to meet the conditions for equity classification.

The Company incurred approximately $5.0 million of issuance costs related to the issuance of the Notes, of which $3.4 million and $1.6 million were recorded to long-term debt and contributed capital, respectively. The $3.4 million of issuance costs recorded as long-term debt on the condensed consolidated balance sheet are being amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par and debt issuance cost amortization, is 11.52%.

The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:

if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;

during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or

the occurrence of certain corporate events, such as a change of control, merger or liquidation.

At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date.
The Notes at September 30, 2020 and December 31, 2019 consisted of the following (in thousands):

September 30,December 31,
20202019
Outstanding principal$171,500 $171,500 
Unamortized debt discount(31,267)(39,042)
Unamortized debt issuance(1,934)(2,415)
Net carrying amount of the liability component$138,299 $130,043 

Interest expense for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Contractual coupon interest
$1,072 $1,072 $3,216 $3,216 
Amortization of the debt discount
2,666 2,379 7,775 6,940 
Amortization of debt issuance costs
165 147 481 429 
Total interest expense on convertible notes$3,903 $3,598 $11,472 $10,585 

As of September 30, 2020 and December 31, 2019, no Notes were convertible pursuant to their terms.

In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Earnings Per Share
NOTE 12. EARNINGS PER SHARE

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Shares issuable upon the release of restricted stock units722 20 722 20 
Shares issuable upon exercise of stock options8,952 10,159 8,952 10,159 
9,674 10,179 9,674 10,179 

Potentially dilutive common shares would also include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 11, Convertible Notes, the Company issued $171.5 million of Notes due 2023. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes. As of September 30, 2020, no Notes were convertible pursuant to their terms. The number of shares issuable upon conversion of the Notes is 5.5 million shares.

In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Employee Equity-Based Compensation
9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Employee Equity-Based Compensation
NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION

The following table summarizes option activity under all plans for the nine months ended September 30, 2020:

Number of SharesWeighted Average Exercise Price per Share
Options Outstanding January 1, 202010,132,562 $12.28 
Granted1,693,083 8.55 
Forfeited(486,864)13.86 
Exercised(2,219,281)2.01 
Expired(167,187)19.83 
Options Outstanding September 30, 20208,952,313 $13.89 
The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for the three months ended September 30, 2020 and 2019:

Three Months Ended September 30,
20202019
Expected term (in years)6.146.46
Volatility62 %59 %
Expected dividends— — 
Risk free interest rates0.42 %1.47 %
Weighted average fair value$8.10 $9.66 

The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2020:

Options
Outstanding
Options
Exercisable
Number of options8,952,313 4,767,274 
Weighted average remaining contractual term (in years)6.264.51
Weighted average exercise price$13.89 $13.28 
Weighted average fair value$8.73 $8.60 
Aggregate intrinsic value (in thousands)$15,514 $12,387 

The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2020:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 202014,332 $16.66 
Granted807,751 11.47 
Forfeited(31,307)9.72 
Vested/released(68,641)9.85 
Outstanding September 30, 2020722,135 $11.80 

The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cost of sales$119 $65 $249 $172 
Research and development1,349 897 2,807 3,226 
Sales, general and administrative3,208 2,169 9,235 6,011 
$4,676 $3,131 $12,291 $9,409 
The table below summarizes share-based compensation cost capitalized to inventory or inventory transferred to property and equipment (also referred to as instruments) for the three and nine months ended September 30, 2020 and 2019 (in thousands):


Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cost capitalized to inventory
$61 $92 $199 $332 

As of September 30, 2020, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $17.4 million and $3.9 million, respectively. This is expected to be recognized over the years 2020 through 2025.

Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based options issued under the plan. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

In August 2018, the Company granted 225,000 performance-based stock options. Of these performance-based stock options performance obligations had been met for 75,000 options which became exercisable in the prior year. The remaining 150,000 options were forfeited for the performance targets not being achieved. Of the total options forfeited, 50,000 of those options were forfeited during the nine months ended September 30, 2020. No stock compensation expense for the forfeited performance-based stock options was recognized. The stock compensation expense for the vested options was recorded in prior periods.

During the nine months ended September 30, 2020, the Company granted another 105,000 performance-based stock options. During the three and nine months ended September 30, 2020, 22,500 performance-based stock options vested due to the performance obligations being achieved. None of these options have been forfeited as of September 30, 2020.

The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):


Nine Months Ended September 30,
20202019
Performance-based stock option expense
$109 $107 

Included in the above-noted RSU and restricted stock award outstanding amount are performance-based RSU's which vest only upon the achievement of certain targets. Performance-based RSU's contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During the nine months ended September 30, 2020, the Company granted 361,338 performance-based RSU's. During the three and nine months ended September 30, 2020, 40,500 performance-based RSU's were released due to the performance obligations being achieved. At September 30, 2020 306,785 performance-based RSU's were outstanding. None of these performance-based RSU have been forfeited due to performance obligations not being achieved.
The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):

Nine Months Ended September 30,
20202019
Performance-based RSU expense
$401 $— 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes
9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Income Taxes
NOTE 14. INCOME TAXES

For the nine months ended September 30, 2020, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2020 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $59.3 million, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions. At September 30, 2020, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.

On March 27, 2020, the U.S. enacted the CARES Act. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Management does not expect the CARES Act to have a material impact on the Company’s income tax position for financial reporting purposes. The Company will continue its assessment of the CARES Act on its financial statements, as changes in tax legislation and further guidance for the CARES Act become available in the subsequent quarters.

The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2020, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Leases
9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Leases
NOTE 15. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cash paid for amounts included in lease liabilities
Operating cash flows from operating leases$185 $168 $556 $333 
ROU assets obtained in exchange for lease obligations
Operating leases$— $3,639 $17 $3,639 
Lease Cost
Operating leases$277 $213 $790 $378 
Short-term leases$17 $103 $45 $697 

The weighted average remaining lease term on our operating leases is 4.7 years. The weighted average discount rate on those leases is 7%.
The following presents maturities of operating lease liabilities in which we are the lessee as of September 30, 2020 (in thousands):

Remainder of 2020$174 
2021753 
2022877 
2023968 
20241,055 
Thereafter619 
Total lease payments4,446 
Less imputed interest(733)
$3,713 

The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2020, the total net investment in these leases was $2.6 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2020 (in thousands):

Remainder of 2020$223 
2021851 
2022794 
2023431 
2024123 
Thereafter150 
Total undiscounted cash flows2,572 
Less imputed interest— 
Present value of lease payments$2,572 
Leases
NOTE 15. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cash paid for amounts included in lease liabilities
Operating cash flows from operating leases$185 $168 $556 $333 
ROU assets obtained in exchange for lease obligations
Operating leases$— $3,639 $17 $3,639 
Lease Cost
Operating leases$277 $213 $790 $378 
Short-term leases$17 $103 $45 $697 

The weighted average remaining lease term on our operating leases is 4.7 years. The weighted average discount rate on those leases is 7%.
The following presents maturities of operating lease liabilities in which we are the lessee as of September 30, 2020 (in thousands):

Remainder of 2020$174 
2021753 
2022877 
2023968 
20241,055 
Thereafter619 
Total lease payments4,446 
Less imputed interest(733)
$3,713 

The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2020, the total net investment in these leases was $2.6 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2020 (in thousands):

Remainder of 2020$223 
2021851 
2022794 
2023431 
2024123 
Thereafter150 
Total undiscounted cash flows2,572 
Less imputed interest— 
Present value of lease payments$2,572 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Industry, Geographic and Revenue Disaggregation
9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Industry, Geographic and Revenue Disaggregation
NOTE 16. INDUSTRY, GEOGRAPHIC AND REVENUE DISAGGREGATION

The Company operates as one operating segment. Sales to customers outside the U.S. represented 6% and 23% for the three months ended September 30, 2020 and 2019, respectively, and 7% and 26% for the nine months ended September 30, 2020 and 2019, respectively.

As of September 30, 2020 and December 31, 2019, balances due from foreign customers, in U.S. dollars, were $1.2 million and $2.1 million, respectively.

The following presents total net sales by geographic territory for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Domestic$3,386 $1,757 $7,477 $4,308 
Foreign202 514 579 1,519 
$3,588 $2,271 $8,056 $5,827 
The following presents total net sales by line of business for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Accelerate Pheno revenue
$3,582 $2,221 $7,980 $5,702 
Other revenue50 76 125 
$3,588 $2,271 $8,056 $5,827 

The following presents total net sales by products and services for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Products$3,402 $2,143 $7,481 $5,531 
Services186 128 575 296 
$3,588 $2,271 $8,056 $5,827 

Lease revenue included in net sales was $1.7 million and $0.2 million for the three months ended September 30, 2020 and 2019, respectively, and $2.4 million and $0.6 million for the nine months ended September 30, 2020 and 2019, respectively, which does not represent revenues recognized from contracts with customers.

The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20202019
Domestic$6,563 $7,244 
Foreign541 661 
$7,104 $7,905 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions
9 Months Ended
Sep. 30, 2020
Related Party Transactions [Abstract]  
Related Party Transactions
NOTE 17. RELATED PARTY TRANSACTIONS

As discussed in Note 11, Convertible Notes, the Company issued Notes in March 2018. As of September 30, 2020 and December 31, 2019 an entity controlled by one member of the Company's board of directors held an aggregate of $42.0 million of the Notes.

On August 20, 2019, the Company and an entity affiliated with the then Chief Operating Officer and current Chief Executive Officer of the Company entered into a securities purchase agreement (the “Purchase Agreement”) for the issuance and sale by the Company of an aggregate of 55,586 shares of the Company’s common stock (the “Shares”) in an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The Shares were sold at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the shares) of $17.99 per share, which was equal to the consolidated closing bid price reported by Nasdaq immediately preceding the time the Company entered into the Purchase Agreement. The $1.0 million of proceeds were recorded to contributed capital.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on February 28, 2020.

The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2020, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.
Principles of Consolidation
Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.
Use of Estimates
Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, tax valuation accounts and equity–based compensation. Actual results could differ materially from those estimates.
Estimated Fair Value of Financial Instruments
Estimated Fair Value of Financial Instruments

The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.
The estimated fair value of the Company’s convertible note represents a Level 2 measurement.
Cash and Cash Equivalents
Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe, however, that the market risk arising from holding these financial instruments is minimal.
Investments
Investments

The Company invests in various debt securities available-for-sale and equity securities which are primarily held in the custody of major financial institutions. Debt securities available-for-sale consist of certificates of deposit, U.S. government and agency securities, commercial paper, asset-backed securities, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

On a quarterly basis, we perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security available-for-sale is considered impaired if its fair value is less than its amortized cost basis at the reporting date.

If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security available-for-sale.
Inventory
Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.
Accounts Receivable
Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.
We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the condensed consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.
Property and Equipment
Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.

The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and this evaluation is performed at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of September 30, 2020 and December 31, 2019.
Long-lived Assets
Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.
Warranty Reserve
Warranty Reserve

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.
Convertible Notes
Convertible Notes

The Company accounts for convertible debt instruments that may be settled in cash or equity upon conversion, which includes the 2.50% Senior Convertible Notes due 2023 (the “Notes”), by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determined the carrying amount of the liability component of the Notes by using estimates and assumptions that market participants would use in pricing a debt instrument. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.

The equity component is treated as a discount on the liability component of the Notes, which is amortized over the term of the Notes using the effective interest rate method. Debt issuance costs related to the Notes are allocated to the liability and equity components of the Notes based on their relative values. Debt issuance costs allocated to the liability component are amortized over the life of the Notes as additional non-cash interest expense. Transaction costs allocated to equity are netted with the equity component of the convertible debt instrument in stockholders’ deficit.
Revenue Recognition
Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

Identification of the contract with a customer

Identification of the performance obligations in the contract

Determination of the transaction price

Allocation of the transaction price to the performance obligations

Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized and the term between invoicing and when payment is due is not typically significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine relative standalone selling prices based on the price charged to customers for each individual performance obligation.

Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2020.

Cost of Sales

Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related expenses.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.
Restructure Activity Restructure ActivityDuring the three months ended September 30, 2020, following the completion of a strategic review of its Europe, the Middle East and Africa (“EMEA”) business, the Company's board of directors approved a plan to reduce its workforce, focus the geographies it plans to operate in, and terminate agreements with some distributors in geographies it plans on exiting (collectively, the “EMEA Restructuring Plan”). As of September 30, 2020, the Company substantially completed the workforce reduction portion of the EMEA Restructuring Plan, while the remaining restructuring activities are likely to occur through the end of the year. Restructuring charges are primarily comprised of employee severance and other post-employment benefits. The Company evaluates the nature of these costs to determine if they relate to on-going benefit arrangements which are accounted for under ASC 712 or one-time benefit arrangements which are accounted for under ASC 420.
Leases, Lessor
Leases

The Company accounts for commercial leases in accordance with ASC 842, Leases. We determine if an arrangement is or contains a lease and the type of lease at inception. The Company classifies commercial leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.
Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.
Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.
Lessee
Lessee

Operating leases are included in right-of-use (“ROU”) assets and operating lease liabilities within our consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. As of September 30, 2020 and December 31, 2019, the Company was not party to finance lease arrangements.

Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions.
Nonqualified Cash Deferral Plan
Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”), provides certain key employees, with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.
Equity-Based Compensation
Equity-Based Compensation

The Company may award stock options, restricted stock units (“RSUs”), performance-based awards, and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

Expected term: The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. For consultant awards, the estimated expected term is the same as the life of the award.

Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.

The Company records the fair value of RSUs or stock grants based on published closing market price on the day before the grant date. The Company accounts for forfeitures as they occur rather than on an estimated basis.
Deferred Tax Assets
Deferred Tax Assets

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.
Foreign Currency Translation and Foreign Currency Transactions
Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss).

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.
Loss Per Share
Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options and unvested RSUs. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes at the balance sheet date were converted. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.
Comprehensive Loss
Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds investments classified as debt securities available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.
Standards That Were Recently Adopted and Standards not Yet Adopted
Standards that were recently adopted

In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Fair Value Measurement (Topic 820); Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies, among other things, the disclosures required for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs. The guidance removes, among other things, the disclosure requirement to disclose transfers between Levels 1 and 2. Level 3 fair value measurement disclosures should be applied prospectively while all other amendments should be applied retrospectively. The Company adopted ASU 2018-13 on January 1, 2020, which had no impact to our condensed consolidated financial statements as the Company did not carry Level 3 fair value items upon implementing this ASU on January 1, 2020.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments. In November 2018, ASU 2018-19 was issued which amended the standard to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU 2019-04, 2019-05, 2019-10, ASU 2019-11, 2020-02 and 2020-03 to provide additional guidance on the credit losses standard. ASU 2016-13 amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Previously, an “incurred loss” methodology was used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. This amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities are now recorded in current period net income. The Company adopted ASU 2016-13 on January 1, 2020. We adopted this standard using a modified-retrospective approach, and recorded a $0.1 million cumulative-effect adjustment to the opening balance of accumulated deficit in connection with the adoption. This adjustment was recorded to establish an allowance for trade account receivables and investment in leases. No cumulative-effect adjustment was recorded for unrealized losses on debt securities available-for-sale as the issuers of such securities held by us were of high credit quality. As a result, the condensed consolidated financial statements for the current periods are presented under the new standard, while the comparative prior year period is not adjusted and continues to be reported in accordance with our historical accounting policy.

Standards not yet adopted

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2020-06 reduces the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, this ASU amends the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. This ASU will reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP standards. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU is effective for us on January 1, 2022, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the FASB Emerging Issues Task Force). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321, the accounting for the equity method investments in Topic 323 and the accounting for certain forward contracts and purchased options in Topic 815. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740); Simplifying the Accounting for Income Taxes. ASU 2019-12 reduces complexity in the accounting standard. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Schedule of Product Warranty Reserve Activity
Warranty reserve activity for the three and nine months ended September 30, 2020 and 2019 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Beginning balance$305 $196 $403 $215 
Provisions72 77 72 147 
Warranty cost incurred
(40)(51)(138)(140)
Ending balance$337 $222 $337 $222 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurement
The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
Cash and cash equivalents:
Money market funds$5,013 $— $— $5,013 
Commercial paper— 1,875 — 1,875 
Total cash and cash equivalents5,013 1,875 — 6,888 
Equity investments:
Mutual funds248 — — 248 
Total equity investments248 — — 248 
Debt securities available-for-sale:
Certificates of deposit— 6,857 — 6,857 
U.S. Treasury securities13,484 — — 13,484 
Commercial paper— 9,345 — 9,345 
Corporate notes and bonds— 20,529 — 20,529 
Debt securities available-for-sale13,484 36,731 — 50,215 
Total assets measured at fair value$18,745 $38,606 $— $57,351 
December 31, 2019
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
Cash and cash equivalents:
Money market funds$43,745 $— $— $43,745 
Commercial paper— 1,993 — 1,993 
Corporate notes and bonds— 1,006 — 1,006 
Total cash and cash equivalents43,745 2,999 — 46,744 
Debt securities available-for-sale:
Certificates of deposit— 5,663 — 5,663 
U.S. Treasury securities12,579 — — 12,579 
U.S. Agency securities— 3,998 — 3,998 
Commercial paper— 2,491 — 2,491 
Corporate notes and bonds— 22,706 — 22,706 
Debt securities available-for-sale12,579 34,858 — 47,437 
Total assets measured at fair value$56,324 $37,857 $— $94,181 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Investments (Tables)
9 Months Ended
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
Schedule of Available-for-Sale Investments
The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit$6,838 $19 $— $6,857 
U.S. Treasury securities13,435 49 — 13,484 
U.S. Agency securities— — — — 
Commercial paper9,345 (1)9,345 
Corporate notes and bonds20,513 19 (3)20,529 
Total$50,131 $88 $(4)$50,215 

December 31, 2019
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit$5,646 $17 $— $5,663 
U.S. Treasury securities12,564 16 (1)12,579 
U.S. Agency securities4,002 — (4)3,998 
Commercial paper2,492 — (1)2,491 
Corporate notes and bonds22,711 (11)22,706 
Total$47,415 $39 $(17)$47,437 
Schedule of Available-For-Sale Investment Maturities
The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2020 and December 31, 2019 (in thousands):

September 30, 2020December 31, 2019
Amortized
Cost
Fair ValueAmortized
Cost
Fair Value
Due in less than 1 year$49,874 $49,958 $43,627 $43,650 
Due in 1-3 years257 257 3,788 3,787 
$50,131 $50,215 $47,415 $47,437 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory (Tables)
9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Components of Inventories
Inventories consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):

September 30,December 31,
20202019
Raw materials$5,128 $4,854 
Work in process2,257 1,561 
Finished goods2,074 1,644 
$9,459 $8,059 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Tables)
9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment consisted of the following at September 30, 2020 and December 31, 2019 (in thousands):

September 30,December 31,
20202019
Computer equipment$2,599 $2,477 
Technical equipment3,943 3,681 
Facilities3,690 3,883 
Instruments6,599 7,491 
Capital projects in progress1,047 238 
Total property and equipment$17,878 $17,770 
Accumulated depreciation(10,774)(9,865)
Property and equipment, net$7,104 $7,905 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Deferred Revenue and Remaining Performance Obligations (Tables)
9 Months Ended
Sep. 30, 2020
Deferred Revenue Disclosure [Abstract]  
Deferred Revenue and Income Summary A summary of the balances as of September 30, 2020 and December 31, 2019 follows (in thousands):
September 30,December 31,
20202019
Products and services not yet delivered$338 $271 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Long-term Debt (Tables)
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
As of September 30, 2020 and December 31, 2019, long-term debt consisted of the following (in thousands):

September 30,December 31,
20202019
PPP Loan - 1% interest
$4,803 $— 
Other Loans - various interest736 — 
Total debt5,539 — 
Current portion of long-term debt511 — 
Long-term debt$5,028 $— 
Schedule of Maturities of Future Principal Obligations
The following presents maturities of future principal obligations of long-term debt as of September 30, 2020 (in thousands):

Remainder of 2020$76 
2021825 
20221,604 
20231,291 
20241,304 
Thereafter439 
Total$5,539 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes (Tables)
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Convertible Notes
The Notes at September 30, 2020 and December 31, 2019 consisted of the following (in thousands):

September 30,December 31,
20202019
Outstanding principal$171,500 $171,500 
Unamortized debt discount(31,267)(39,042)
Unamortized debt issuance(1,934)(2,415)
Net carrying amount of the liability component$138,299 $130,043 
Schedule of Interest Expense
Interest expense for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Contractual coupon interest
$1,072 $1,072 $3,216 $3,216 
Amortization of the debt discount
2,666 2,379 7,775 6,940 
Amortization of debt issuance costs
165 147 481 429 
Total interest expense on convertible notes$3,903 $3,598 $11,472 $10,585 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share (Tables)
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Shares issuable upon the release of restricted stock units722 20 722 20 
Shares issuable upon exercise of stock options8,952 10,159 8,952 10,159 
9,674 10,179 9,674 10,179 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Employee Equity-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Stock Option Activity
The following table summarizes option activity under all plans for the nine months ended September 30, 2020:

Number of SharesWeighted Average Exercise Price per Share
Options Outstanding January 1, 202010,132,562 $12.28 
Granted1,693,083 8.55 
Forfeited(486,864)13.86 
Exercised(2,219,281)2.01 
Expired(167,187)19.83 
Options Outstanding September 30, 20208,952,313 $13.89 
Inputs to Calculate Estimated Fair Value of Options Awarded
The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for the three months ended September 30, 2020 and 2019:

Three Months Ended September 30,
20202019
Expected term (in years)6.146.46
Volatility62 %59 %
Expected dividends— — 
Risk free interest rates0.42 %1.47 %
Weighted average fair value$8.10 $9.66 
Stock Option Supplemental Information
The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2020:

Options
Outstanding
Options
Exercisable
Number of options8,952,313 4,767,274 
Weighted average remaining contractual term (in years)6.264.51
Weighted average exercise price$13.89 $13.28 
Weighted average fair value$8.73 $8.60 
Aggregate intrinsic value (in thousands)$15,514 $12,387 
Restricted Stock Unit (RSU) Activity
The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2020:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 202014,332 $16.66 
Granted807,751 11.47 
Forfeited(31,307)9.72 
Vested/released(68,641)9.85 
Outstanding September 30, 2020722,135 $11.80 
Equity-Based Compensation Expenses
The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cost of sales$119 $65 $249 $172 
Research and development1,349 897 2,807 3,226 
Sales, general and administrative3,208 2,169 9,235 6,011 
$4,676 $3,131 $12,291 $9,409 
The table below summarizes share-based compensation cost capitalized to inventory or inventory transferred to property and equipment (also referred to as instruments) for the three and nine months ended September 30, 2020 and 2019 (in thousands):


Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cost capitalized to inventory
$61 $92 $199 $332 
The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):


Nine Months Ended September 30,
20202019
Performance-based stock option expense
$109 $107 
The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2020 and 2019 (in thousands):

Nine Months Ended September 30,
20202019
Performance-based RSU expense
$401 $— 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Tables)
9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Assets And Liabilities
The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cash paid for amounts included in lease liabilities
Operating cash flows from operating leases$185 $168 $556 $333 
ROU assets obtained in exchange for lease obligations
Operating leases$— $3,639 $17 $3,639 
Lease Cost
Operating leases$277 $213 $790 $378 
Short-term leases$17 $103 $45 $697 
Lease Costs
The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Cash paid for amounts included in lease liabilities
Operating cash flows from operating leases$185 $168 $556 $333 
ROU assets obtained in exchange for lease obligations
Operating leases$— $3,639 $17 $3,639 
Lease Cost
Operating leases$277 $213 $790 $378 
Short-term leases$17 $103 $45 $697 
Maturities of Lease Liabilities
The following presents maturities of operating lease liabilities in which we are the lessee as of September 30, 2020 (in thousands):

Remainder of 2020$174 
2021753 
2022877 
2023968 
20241,055 
Thereafter619 
Total lease payments4,446 
Less imputed interest(733)
$3,713 
Sales-type Lease Receivable Maturity The following presents maturities of lease receivables under sales-type leases as of September 30, 2020 (in thousands):
Remainder of 2020$223 
2021851 
2022794 
2023431 
2024123 
Thereafter150 
Total undiscounted cash flows2,572 
Less imputed interest— 
Present value of lease payments$2,572 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Industry, Geographic and Revenue Disaggregation (Tables)
9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Disaggregation of Revenue
The following presents total net sales by geographic territory for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Domestic$3,386 $1,757 $7,477 $4,308 
Foreign202 514 579 1,519 
$3,588 $2,271 $8,056 $5,827 
The following presents total net sales by line of business for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Accelerate Pheno revenue
$3,582 $2,221 $7,980 $5,702 
Other revenue50 76 125 
$3,588 $2,271 $8,056 $5,827 

The following presents total net sales by products and services for the three and nine months ended September 30, 2020 and 2019 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Products$3,402 $2,143 $7,481 $5,531 
Services186 128 575 296 
$3,588 $2,271 $8,056 $5,827 
Long-lived Assets by Geographic Territory
The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20202019
Domestic$6,563 $7,244 
Foreign541 661 
$7,104 $7,905 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Apr. 14, 2020
Apr. 04, 2018
Mar. 27, 2018
Property, Plant and Equipment [Line Items]            
Allowance for credit losses $ 300,000   $ 300,000      
Instrument warranty term     1 year      
Kits and accessories warranty term     60 days      
Lessor lease term 5 years   5 years      
Expected dividends 0.00% 0.00% 0.00%      
Restructuring expenses $ 400,000          
Unsecured obligations            
Property, Plant and Equipment [Line Items]            
Aggregate principal amount $ 5,500,000   $ 5,500,000      
2.50% Convertible notes due 2023 | Unsecured obligations            
Property, Plant and Equipment [Line Items]            
Aggregate principal amount         $ 171,500,000 $ 150,000,000.0
Interest rate 2.50%   2.50%     2.50%
PPP | Unsecured obligations            
Property, Plant and Equipment [Line Items]            
Aggregate principal amount       $ 4,800,000    
Interest rate 1.00%   1.00% 1.00%    
Instruments            
Property, Plant and Equipment [Line Items]            
Estimated useful life of assets     5 years      
Minimum            
Property, Plant and Equipment [Line Items]            
Estimated useful life of assets     1 year      
Lease term 2 years   2 years      
Maximum            
Property, Plant and Equipment [Line Items]            
Estimated useful life of assets     7 years      
Lease term 6 years   6 years      
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Movement in Standard Product Warranty Accrual [Roll Forward]        
Beginning balance $ 305 $ 196 $ 403 $ 215
Provisions 72 77 72 147
Warranty cost incurred (40) (51) (138) (140)
Ending balance $ 337 $ 222 $ 337 $ 222
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Recently Issued Accounting Pronouncements (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Jan. 01, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Cumulative-effect adjustment $ 49,668     $ 7,379 $ (10,220)    
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201613Member            
Accumulated deficit              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Cumulative-effect adjustment $ 474,054 $ 455,297   414,653 $ 393,318 $ 372,884 $ 330,348
Adjustment | Accumulated deficit              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]              
Cumulative-effect adjustment     $ 100 $ 105     $ 0
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Concentration of Credit Risk (Details)
9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Net accounts receivable | Customer concentration | One customer    
Concentration Risk [Line Items]    
Risk concentration   11.00%
Financial institution A | Cash and cash equivalents | Concentration of credit risk    
Concentration Risk [Line Items]    
Risk concentration 18.00% 73.00%
Financial institution B | Cash and cash equivalents | Concentration of credit risk    
Concentration Risk [Line Items]    
Risk concentration 38.00% 18.00%
Financial institution C | Cash and cash equivalents | Concentration of credit risk    
Concentration Risk [Line Items]    
Risk concentration 21.00%  
Financial institution D | Cash and cash equivalents | Concentration of credit risk    
Concentration Risk [Line Items]    
Risk concentration 11.00%  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of equity securities $ 200  
Fair Value 50,215 $ 47,437
Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 6,857 5,663
U.S. Treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 13,484 12,579
U.S. Agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 3,998
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 9,345 2,491
Corporate notes and bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 20,529 22,706
Fair value on a recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 6,888 46,744
Fair value of equity securities 248  
Fair Value 50,215 47,437
Total assets measured at fair value 57,351 94,181
Fair value on a recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 5,013 43,745
Fair value of equity securities 248  
Fair Value 13,484 12,579
Total assets measured at fair value 18,745 56,324
Fair value on a recurring basis | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 1,875 2,999
Fair value of equity securities 0  
Fair Value 36,731 34,858
Total assets measured at fair value 38,606 37,857
Fair value on a recurring basis | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Fair value of equity securities 0  
Fair Value 0 0
Total assets measured at fair value 0 0
Fair value on a recurring basis | Mutual funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of equity securities 248  
Fair value on a recurring basis | Mutual funds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of equity securities 248  
Fair value on a recurring basis | Mutual funds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of equity securities 0  
Fair value on a recurring basis | Mutual funds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of equity securities 0  
Fair value on a recurring basis | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 6,857 5,663
Fair value on a recurring basis | Certificates of deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 0
Fair value on a recurring basis | Certificates of deposit | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 6,857 5,663
Fair value on a recurring basis | Certificates of deposit | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 0
Fair value on a recurring basis | U.S. Treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 13,484 12,579
Fair value on a recurring basis | U.S. Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 13,484 12,579
Fair value on a recurring basis | U.S. Treasury securities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 0
Fair value on a recurring basis | U.S. Treasury securities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 0
Fair value on a recurring basis | U.S. Agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value   3,998
Fair value on a recurring basis | U.S. Agency securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value   0
Fair value on a recurring basis | U.S. Agency securities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value   3,998
Fair value on a recurring basis | U.S. Agency securities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value   0
Fair value on a recurring basis | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 9,345 2,491
Fair value on a recurring basis | Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 0
Fair value on a recurring basis | Commercial paper | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 9,345 2,491
Fair value on a recurring basis | Commercial paper | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 0
Fair value on a recurring basis | Corporate notes and bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents   1,006
Fair Value 20,529 22,706
Fair value on a recurring basis | Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0 0
Fair value on a recurring basis | Corporate notes and bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents   1,006
Fair Value 20,529 22,706
Fair value on a recurring basis | Corporate notes and bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents   0
Fair Value 0 0
Fair value on a recurring basis | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 5,013 43,745
Fair value on a recurring basis | Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 5,013 43,745
Fair value on a recurring basis | Money market funds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Fair value on a recurring basis | Money market funds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Fair value on a recurring basis | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 1,875 1,993
Fair value on a recurring basis | Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Fair value on a recurring basis | Commercial paper | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 1,875 1,993
Fair value on a recurring basis | Commercial paper | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 0 0
Fair value on a recurring basis | Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents   $ 0
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
9 Months Ended
Apr. 04, 2018
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Mar. 27, 2018
Debt Instrument [Line Items]          
Proceeds from debt   $ 5,552,000 $ 0    
Unsecured obligations          
Debt Instrument [Line Items]          
Aggregate principal amount   5,500,000      
Unsecured obligations | 2.50% Convertible notes due 2023          
Debt Instrument [Line Items]          
Proceeds from debt $ 171,500,000        
Fair value   $ 110,700,000   $ 133,800,000  
Aggregate principal amount $ 171,500,000       $ 150,000,000.0
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Investments - Schedule of Available-for-sale Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost $ 50,131 $ 47,415
Gross Unrealized Gains 88 39
Gross Unrealized Losses (4) (17)
Fair Value 50,215 47,437
Certificates of deposit    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 6,838 5,646
Gross Unrealized Gains 19 17
Gross Unrealized Losses 0 0
Fair Value 6,857 5,663
U.S. Treasury securities    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 13,435 12,564
Gross Unrealized Gains 49 16
Gross Unrealized Losses 0 (1)
Fair Value 13,484 12,579
U.S. Agency securities    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 0 4,002
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 (4)
Fair Value 0 3,998
Commercial paper    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 9,345 2,492
Gross Unrealized Gains 1 0
Gross Unrealized Losses (1) (1)
Fair Value 9,345 2,491
Corporate notes and bonds    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 20,513 22,711
Gross Unrealized Gains 19 6
Gross Unrealized Losses (3) (11)
Fair Value $ 20,529 $ 22,706
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Investments - Schedule of Available-for-Sale Investment Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Amortized Cost    
Due in less than 1 year $ 49,874 $ 43,627
Due in 1-3 years 257 3,788
Amortized Cost 50,131 47,415
Fair Value    
Due in less than 1 year 49,958 43,650
Due in 1-3 years 257 3,787
Fair Value $ 50,215 $ 47,437
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Investments - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]        
Proceeds from sales of marketable securities $ 0 $ 0 $ 0 $ 13,400,000
Realized gains or losses from equity securities 0 $ 0 0 $ 0
Fair value of equity securities 200,000   200,000  
Unrealized losses on equity securities $ 0   $ 0  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 5,128 $ 4,854
Work in process 2,257 1,561
Finished goods 2,074 1,644
Inventory $ 9,459 $ 8,059
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 17,878 $ 17,770
Accumulated depreciation (10,774) (9,865)
Property and equipment, net 7,104 7,905
Computer equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 2,599 2,477
Technical equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 3,943 3,681
Facilities    
Property, Plant and Equipment [Line Items]    
Total property and equipment 3,690 3,883
Instruments    
Property, Plant and Equipment [Line Items]    
Total property and equipment 6,599 7,491
Capital projects in progress    
Property, Plant and Equipment [Line Items]    
Total property and equipment 1,047 238
Assets under operating leases    
Property, Plant and Equipment [Line Items]    
Accumulated depreciation $ (1,100) $ (800)
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Property, Plant and Equipment [Line Items]          
Depreciation $ 600 $ 600 $ 1,800 $ 1,700  
Accumulated depreciation 10,774   10,774   $ 9,865
Assets under operating leases          
Property, Plant and Equipment [Line Items]          
Gross assets 4,300   4,300   4,600
Accumulated depreciation $ 1,100   $ 1,100   $ 800
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.20.2
License Agreements and Grants - National Institute of Health Grant (Details) - USD ($)
$ in Millions
1 Months Ended 9 Months Ended 68 Months Ended
Feb. 28, 2015
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Cumulative amount awarded       $ 1.5
National Institute of Health Grant        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Grant period 5 years      
Total grant funding $ 5.0 $ 0.1 $ 0.2  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Deferred Revenue and Remaining Performance Obligations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Disaggregation of Revenue [Line Items]          
Deferred revenue and income $ 338   $ 338   $ 271
Revenues recognized included in contract liabilities balances 100 $ 200 200 $ 300  
Revenue expected to be recognized from remaining performance obligations 8,600   $ 8,600    
Contact period     The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.    
Products and services not yet delivered          
Disaggregation of Revenue [Line Items]          
Deferred revenue and income $ 338   $ 338   $ 271
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Long-term Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Apr. 14, 2020
Dec. 31, 2019
Debt Instrument [Line Items]      
Total debt $ 5,539   $ 0
Current portion of long-term debt 511   0
Long-term debt 5,028   0
PPP | PPP Loan - 1% interest      
Debt Instrument [Line Items]      
Total debt $ 4,803   0
Interest rate 1.00% 1.00%  
Other Loans - various interest | Other Loans - various interest      
Debt Instrument [Line Items]      
Total debt $ 736   $ 0
Current portion of long-term debt 300    
Long-term debt $ 400    
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Long-term Debt - Schedule of Maturities of Future Principal Obligations (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
Remainder of 2020 $ 76  
2021 825  
2022 1,604  
2023 1,291  
2024 1,304  
Thereafter 439  
Total debt $ 5,539 $ 0
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Long-term Debt - Narrative (Details)
3 Months Ended
Aug. 14, 2021
USD ($)
payment
Nov. 14, 2020
USD ($)
payment
Sep. 30, 2020
USD ($)
loan
Apr. 14, 2020
USD ($)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]          
Current portion of long-term debt     $ 511,000   $ 0
Long-term debt     5,028,000   $ 0
Unsecured obligations          
Debt Instrument [Line Items]          
Aggregate principal amount     $ 5,500,000    
Other Loans - various interest | Other Loans - various interest          
Debt Instrument [Line Items]          
Number of loan agreements | loan     3    
Proceeds from debt     $ 700,000    
Current portion of long-term debt     300,000    
Long-term debt     $ 400,000    
Other Loans - various interest | Minimum | Other Loans - various interest          
Debt Instrument [Line Items]          
Interest rate     9.80%    
Other Loans - various interest | Maximum | Other Loans - various interest          
Debt Instrument [Line Items]          
Interest rate     12.40%    
PPP | Unsecured obligations          
Debt Instrument [Line Items]          
Interest rate     1.00% 1.00%  
Aggregate principal amount       $ 4,800,000  
PPP | Unsecured obligations | Forecast          
Debt Instrument [Line Items]          
Number of monthly payments | payment 45 18      
Monthly payment $ 100,000 $ 300,000      
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes - Narrative (Details)
3 Months Ended 9 Months Ended
Apr. 04, 2018
USD ($)
day
shares
Mar. 27, 2018
USD ($)
$ / shares
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]              
Over-allotment option, term   13 days          
Over-allotment option   $ 22,500,000          
Additional proceeds $ 21,500,000            
Proceeds from debt         $ 5,552,000 $ 0  
Conversion ratio   0.0323428          
Outstanding principal     $ 171,500,000   171,500,000   $ 171,500,000
Unamortized debt issuance     1,934,000   1,934,000   $ 2,415,000
Stock price conversion threshold, percentage 130.00%            
Consecutive trading days | day 20            
Threshold trading days | day 30            
Trading price threshold, percentage 98.00%            
Repurchase principal balance, percent 100.00%            
Interest expense     1,072,000 $ 1,072,000 3,216,000 3,216,000  
Amortization of debt issuance costs     165,000 147,000 481,000 429,000  
Amortization of the debt discount     2,666,000 $ 2,379,000 7,775,000 $ 6,940,000  
Net proceeds from notes to fund Prepaid Forward $ 45,100,000            
Aggregate number of shares (shares) | shares 1,858,500            
Unsecured obligations              
Debt Instrument [Line Items]              
Aggregate principal amount     $ 5,500,000   $ 5,500,000    
Unsecured obligations | 2.50% Convertible notes due 2023              
Debt Instrument [Line Items]              
Aggregate principal amount $ 171,500,000 $ 150,000,000.0          
Interest rate   2.50% 2.50%   2.50%    
Proceeds from debt 171,500,000            
Conversion multiple 1,000            
Initial conversion price (usd per share) | $ / shares   $ 30.92          
Outstanding principal 116,600,000            
Equity component (54,900,000)            
Unamortized debt issuance $ 5,000,000.0            
Contractual term 5 years            
Effective interest rate 11.52%            
Unsecured obligations | 2.50% Convertible notes due 2023 | Long-term debt              
Debt Instrument [Line Items]              
Unamortized debt issuance $ 3,400,000            
Unsecured obligations | 2.50% Convertible notes due 2023 | Contributed capital              
Debt Instrument [Line Items]              
Unamortized debt issuance $ 1,600,000            
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes - Schedule of Convertible Notes (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
Outstanding principal $ 171,500 $ 171,500
Unamortized debt discount (31,267) (39,042)
Unamortized debt issuance (1,934) (2,415)
Net carrying amount of the liability component $ 138,299 $ 130,043
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes - Schedule of Interest Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Debt Disclosure [Abstract]        
Interest expense $ 1,072 $ 1,072 $ 3,216 $ 3,216
Amortization of the debt discount 2,666 2,379 7,775 6,940
Amortization of debt issuance costs 165 147 481 429
Interest Expense, Debt $ 3,903 $ 3,598 $ 11,472 $ 10,585
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (shares) 9,674 10,179 9,674 10,179
Shares issuable upon the release of restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (shares) 722 20 722 20
Shares issuable upon exercise of stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (shares) 8,952 10,159 8,952 10,159
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share - Narrative (Details)
9 Months Ended
Apr. 04, 2018
USD ($)
shares
Mar. 27, 2018
USD ($)
Sep. 30, 2020
USD ($)
shares
Debt Instrument [Line Items]      
Conversion ratio   0.0323428  
Aggregate number of shares (shares) | shares 1,858,500    
Unsecured obligations      
Debt Instrument [Line Items]      
Aggregate principal amount | $     $ 5,500,000
Unsecured obligations | 2.50% Convertible notes due 2023      
Debt Instrument [Line Items]      
Aggregate principal amount | $ $ 171,500,000 $ 150,000,000.0  
Conversion multiple | $ $ 1,000    
Shares issued (shares) | shares     0
Unsecured obligations | 2.50% Convertible notes due 2023 | Maximum      
Debt Instrument [Line Items]      
Shares issued (shares) | shares     5,500,000
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Employee Equity-Based Compensation - Stock Option Activity (Details)
9 Months Ended
Sep. 30, 2020
$ / shares
shares
Number of Shares  
Outstanding, beginning balance (shares) | shares 10,132,562
Granted (shares) | shares 1,693,083
Forfeited (shares) | shares (486,864)
Exercised (shares) | shares (2,219,281)
Expired (shares) | shares (167,187)
Outstanding, ending balance (shares) | shares 8,952,313
Weighted Average Exercise Price per Share  
Outstanding, beginning balance (dollars per share) | $ / shares $ 12.28
Granted (dollars per share) | $ / shares 8.55
Forfeited (dollars per share) | $ / shares 13.86
Exercised (dollars per share) | $ / shares 2.01
Expired (dollars per share) | $ / shares 19.83
Outstanding, ending balance (dollars per share) | $ / shares $ 13.89
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Employee Equity-Based Compensation - Inputs to Calculate Estimated Fair Value of Options Awarded (Details) - $ / shares
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]      
Expected term (in years) 6 years 1 month 20 days 6 years 5 months 15 days  
Volatility 62.00% 59.00%  
Expected dividends 0.00% 0.00% 0.00%
Risk free interest rates 0.42% 1.47%  
Weighted average fair value (dollars per share) $ 8.10 $ 9.66 $ 8.10
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Employee Equity-Based Compensation - Stock Option Supplemental Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Options Outstanding    
Number of options (shares) 8,952,313 10,132,562
Weighted average remaining contractual term (in years) 6 years 3 months 3 days  
Weighted average exercise price (dollars per share) $ 13.89 $ 12.28
Weighted average fair value (dollars per share) $ 8.73  
Aggregate intrinsic value (in thousands) $ 15,514  
Options Exercisable    
Number of options (shares) 4,767,274  
Weighted average remaining contractual term (in years) 4 years 6 months 3 days  
Weighted average exercise price (dollars per share) $ 13.28  
Weighted average fair value (dollars per share) $ 8.60  
Aggregate intrinsic value (in thousands) $ 12,387  
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Employee Equity-Based Compensation - Restricted Stock Activity (Details) - RSUs and RSAs
9 Months Ended
Sep. 30, 2020
$ / shares
shares
Number of Shares  
Beginning balance (shares) | shares 14,332
Granted (shares) | shares 807,751
Forfeited (shares) | shares (31,307)
Vested/Released (shares) | shares (68,641)
Ending balance (shares) | shares 722,135
Weighted Average Grant Date Fair Value per Share  
Beginning balance (dollars per share) | $ / shares $ 16.66
Granted (dollars per share) | $ / shares 11.47
Forfeited (dollars per share) | $ / shares 9.72
Vested/Released (dollars per share) | $ / shares 9.85
Ending balance (dollars per share) | $ / shares $ 11.80
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Employee Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense $ 4,676 $ 3,131 $ 12,291 $ 9,409
Cost capitalized to inventory 61 92 199 332
Performance-based stock option expense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense     109 107
Performance-based RSU expense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense     401 0
Cost of sales        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense 119 65 249 172
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense 1,349 897 2,807 3,226
Sales, general and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense $ 3,208 $ 2,169 $ 9,235 $ 6,011
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Employee Equity-Based Compensation - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2018
Sep. 30, 2020
Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Unrecognized equity-based compensation cost   $ 17.4 $ 17.4
Shares issuable upon the release of restricted stock units      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Unrecognized equity-based compensation cost, restricted stock units   $ 3.9 $ 3.9
Performance-based stock option expense      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Contractual life     10 years
Granted (shares) 225,000   105,000
Vested (shares) 75,000 22,500 22,500
Forfeited (shares) 150,000   50,000
Performance-based stock option expense | Minimum      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Vesting period     1 year
Performance-based stock option expense | Minimum | Granted in 2018      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Vesting period     5 years
Performance-based stock option expense | Maximum      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Vesting period     2 years
Performance-based stock option expense | Maximum | Granted in 2018      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Vesting period     7 years
Performance-based RSU expense      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Contractual life     10 years
Granted (shares)     361,338
Vested (shares)   40,500 40,500
Outstanding (shares)   306,785 306,785
Performance-based RSU expense | Minimum      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Vesting period     1 year
Performance-based RSU expense | Maximum      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Vesting period     3 years
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 0 $ (239,000) $ 0 $ 0
Pre-tax loss $ (18,757,000) $ (20,673,000) $ (59,296,000) $ (62,970,000)
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Assets and Liabilities (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Cash paid for amounts included in lease liabilities        
Operating cash flows from operating leases $ 185 $ 168 $ 556 $ 333
ROU assets obtained in exchange for lease obligations        
Operating leases 0 3,639 17 3,639
Lease Cost        
Operating leases 277 213 790 378
Short-term leases $ 17 $ 103 $ 45 $ 697
Weighted average remaining lease term (years) 4 years 8 months 12 days   4 years 8 months 12 days  
Weighted average discount rate (%) 7.00%   7.00%  
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Maturities of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Leases [Abstract]  
Remainder of 2020 $ 174
2021 753
2022 877
2023 968
2024 1,055
Thereafter 619
Total lease payments 4,446
Less imputed interest (733)
Lessee lease liabilities $ 3,713
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Sales-type Lease Receivable Maturity (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Leases [Abstract]  
Net investment in leases $ 2,600
Remainder of 2020 223
2021 851
2022 794
2023 431
2024 123
Thereafter 150
Total undiscounted cash flows 2,572
Less imputed interest 0
Present value of lease payments $ 2,572
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Industry, Geographic and Revenue Disaggregation - Narrative (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
segment
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Segment Reporting [Abstract]          
Number of operating segments | segment     1    
Segment Reporting Information [Line Items]          
Trade accounts receivable $ 2,610   $ 2,610   $ 3,222
Lease Income $ 1,700 $ 200 $ 2,400 $ 600  
Geographic concentration | Foreign | Total revenue          
Segment Reporting Information [Line Items]          
Risk concentration 6.00% 23.00% 7.00% 26.00%  
Geographic concentration | Foreign | Net accounts receivable          
Segment Reporting Information [Line Items]          
Trade accounts receivable $ 1,200   $ 1,200   $ 2,100
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Industry, Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]        
Net sales $ 3,588 $ 2,271 $ 8,056 $ 5,827
Accelerate Pheno revenue        
Disaggregation of Revenue [Line Items]        
Net sales 3,582 2,221 7,980 5,702
Other revenue        
Disaggregation of Revenue [Line Items]        
Net sales 6 50 76 125
Products        
Disaggregation of Revenue [Line Items]        
Net sales 3,402 2,143 7,481 5,531
Services        
Disaggregation of Revenue [Line Items]        
Net sales 186 128 575 296
Domestic        
Disaggregation of Revenue [Line Items]        
Net sales 3,386 1,757 7,477 4,308
Foreign        
Disaggregation of Revenue [Line Items]        
Net sales $ 202 $ 514 $ 579 $ 1,519
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.20.2
Industry, Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) $ 7,104 $ 7,905
Property and equipment | Geographic concentration    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) 7,104 7,905
Property and equipment | Geographic concentration | Domestic    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) 6,563 7,244
Property and equipment | Geographic concentration | Foreign    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) $ 541 $ 661
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transaction (Details) - USD ($)
9 Months Ended
Aug. 20, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Aug. 19, 2019
Related Party Transaction [Line Items]          
Share price (usd per share)         $ 17.99
Proceeds from issuance of common stock $ 1,000,000.0 $ 296,000 $ 1,363,000    
Chief Operating Officer          
Related Party Transaction [Line Items]          
Issuance of common stock (shares) 55,586        
Director | Note holder | Chief Operating Officer          
Related Party Transaction [Line Items]          
Aggregate principal amount   $ 42,000,000.0   $ 42,000,000.0  
EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 267 400 1 false 68 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://acceleratediagnostics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET CONDENSED CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 6 false false R7.htm 2101101 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Notes 7 false false R8.htm 2106102 - Disclosure - Recently Issued Accounting Pronouncements Sheet http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements Recently Issued Accounting Pronouncements Notes 8 false false R9.htm 2108103 - Disclosure - Concentration of Credit Risk Sheet http://acceleratediagnostics.com/role/ConcentrationofCreditRisk Concentration of Credit Risk Notes 9 false false R10.htm 2110104 - Disclosure - Fair Value of Financial Instruments Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 2114105 - Disclosure - Investments Sheet http://acceleratediagnostics.com/role/Investments Investments Notes 11 false false R12.htm 2119106 - Disclosure - Inventory Sheet http://acceleratediagnostics.com/role/Inventory Inventory Notes 12 false false R13.htm 2122107 - Disclosure - Property and Equipment Sheet http://acceleratediagnostics.com/role/PropertyandEquipment Property and Equipment Notes 13 false false R14.htm 2126108 - Disclosure - License Agreements and Grants Sheet http://acceleratediagnostics.com/role/LicenseAgreementsandGrants License Agreements and Grants Notes 14 false false R15.htm 2128109 - Disclosure - Deferred Revenue and Remaining Performance Obligations Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations Deferred Revenue and Remaining Performance Obligations Notes 15 false false R16.htm 2131110 - Disclosure - Long-term Debt Sheet http://acceleratediagnostics.com/role/LongtermDebt Long-term Debt Notes 16 false false R17.htm 2136111 - Disclosure - Convertible Notes Notes http://acceleratediagnostics.com/role/ConvertibleNotes Convertible Notes Notes 17 false false R18.htm 2141112 - Disclosure - Earnings Per Share Sheet http://acceleratediagnostics.com/role/EarningsPerShare Earnings Per Share Notes 18 false false R19.htm 2145113 - Disclosure - Employee Equity-Based Compensation Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation Employee Equity-Based Compensation Notes 19 false false R20.htm 2153114 - Disclosure - Income Taxes Sheet http://acceleratediagnostics.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2155115 - Disclosure - Leases Sheet http://acceleratediagnostics.com/role/Leases Leases Notes 21 false false R22.htm 2160116 - Disclosure - Industry, Geographic and Revenue Disaggregation Sheet http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregation Industry, Geographic and Revenue Disaggregation Notes 22 false false R23.htm 2165117 - Disclosure - Related Party Transactions Sheet http://acceleratediagnostics.com/role/RelatedPartyTransactions Related Party Transactions Notes 23 false false R24.htm 2202201 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) Policies http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies 24 false false R25.htm 2303301 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) Tables http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies 25 false false R26.htm 2311302 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://acceleratediagnostics.com/role/FairValueofFinancialInstruments 26 false false R27.htm 2315303 - Disclosure - Investments (Tables) Sheet http://acceleratediagnostics.com/role/InvestmentsTables Investments (Tables) Tables http://acceleratediagnostics.com/role/Investments 27 false false R28.htm 2320304 - Disclosure - Inventory (Tables) Sheet http://acceleratediagnostics.com/role/InventoryTables Inventory (Tables) Tables http://acceleratediagnostics.com/role/Inventory 28 false false R29.htm 2323305 - Disclosure - Property and Equipment (Tables) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://acceleratediagnostics.com/role/PropertyandEquipment 29 false false R30.htm 2329306 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables) Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables Deferred Revenue and Remaining Performance Obligations (Tables) Tables http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations 30 false false R31.htm 2332307 - Disclosure - Long-term Debt (Tables) Sheet http://acceleratediagnostics.com/role/LongtermDebtTables Long-term Debt (Tables) Tables http://acceleratediagnostics.com/role/LongtermDebt 31 false false R32.htm 2337308 - Disclosure - Convertible Notes (Tables) Notes http://acceleratediagnostics.com/role/ConvertibleNotesTables Convertible Notes (Tables) Tables http://acceleratediagnostics.com/role/ConvertibleNotes 32 false false R33.htm 2342309 - Disclosure - Earnings Per Share (Tables) Sheet http://acceleratediagnostics.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://acceleratediagnostics.com/role/EarningsPerShare 33 false false R34.htm 2346310 - Disclosure - Employee Equity-Based Compensation (Tables) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables Employee Equity-Based Compensation (Tables) Tables http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation 34 false false R35.htm 2356311 - Disclosure - Leases (Tables) Sheet http://acceleratediagnostics.com/role/LeasesTables Leases (Tables) Tables http://acceleratediagnostics.com/role/Leases 35 false false R36.htm 2361312 - Disclosure - Industry, Geographic and Revenue Disaggregation (Tables) Sheet http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationTables Industry, Geographic and Revenue Disaggregation (Tables) Tables http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregation 36 false false R37.htm 2404401 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) Details http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables 37 false false R38.htm 2405402 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) Details 38 false false R39.htm 2407403 - Disclosure - Recently Issued Accounting Pronouncements (Details) Sheet http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails Recently Issued Accounting Pronouncements (Details) Details http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements 39 false false R40.htm 2409404 - Disclosure - Concentration of Credit Risk (Details) Sheet http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails Concentration of Credit Risk (Details) Details http://acceleratediagnostics.com/role/ConcentrationofCreditRisk 40 false false R41.htm 2412405 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) Details 41 false false R42.htm 2413406 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 42 false false R43.htm 2416407 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails Investments - Schedule of Available-for-sale Securities (Details) Details 43 false false R44.htm 2417408 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails Investments - Schedule of Available-for-Sale Investment Maturities (Details) Details 44 false false R45.htm 2418409 - Disclosure - Investments - Narrative (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 45 false false R46.htm 2421410 - Disclosure - Inventory (Details) Sheet http://acceleratediagnostics.com/role/InventoryDetails Inventory (Details) Details http://acceleratediagnostics.com/role/InventoryTables 46 false false R47.htm 2424411 - Disclosure - Property and Equipment (Details) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://acceleratediagnostics.com/role/PropertyandEquipmentTables 47 false false R48.htm 2425412 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 48 false false R49.htm 2427413 - Disclosure - License Agreements and Grants - National Institute of Health Grant (Details) Sheet http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails License Agreements and Grants - National Institute of Health Grant (Details) Details 49 false false R50.htm 2430414 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details) Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails Deferred Revenue and Remaining Performance Obligations (Details) Details http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables 50 false false R51.htm 2433415 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details) Sheet http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails Long-term Debt - Schedule of Long-term Debt (Details) Details 51 false false R52.htm 2434416 - Disclosure - Long-term Debt - Schedule of Maturities of Future Principal Obligations (Details) Sheet http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails Long-term Debt - Schedule of Maturities of Future Principal Obligations (Details) Details 52 false false R53.htm 2435417 - Disclosure - Long-term Debt - Narrative (Details) Sheet http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails Long-term Debt - Narrative (Details) Details 53 false false R54.htm 2438418 - Disclosure - Convertible Notes - Narrative (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails Convertible Notes - Narrative (Details) Details 54 false false R55.htm 2439419 - Disclosure - Convertible Notes - Schedule of Convertible Notes (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails Convertible Notes - Schedule of Convertible Notes (Details) Details 55 false false R56.htm 2440420 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails Convertible Notes - Schedule of Interest Expense (Details) Details 56 false false R57.htm 2443421 - Disclosure - Earnings Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) Sheet http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails Earnings Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) Details 57 false false R58.htm 2444422 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 58 false false R59.htm 2447423 - Disclosure - Employee Equity-Based Compensation - Stock Option Activity (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails Employee Equity-Based Compensation - Stock Option Activity (Details) Details 59 false false R60.htm 2448424 - Disclosure - Employee Equity-Based Compensation - Inputs to Calculate Estimated Fair Value of Options Awarded (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationInputstoCalculateEstimatedFairValueofOptionsAwardedDetails Employee Equity-Based Compensation - Inputs to Calculate Estimated Fair Value of Options Awarded (Details) Details 60 false false R61.htm 2449425 - Disclosure - Employee Equity-Based Compensation - Stock Option Supplemental Information (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails Employee Equity-Based Compensation - Stock Option Supplemental Information (Details) Details 61 false false R62.htm 2450426 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails Employee Equity-Based Compensation - Restricted Stock Activity (Details) Details 62 false false R63.htm 2451427 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails Employee Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) Details 63 false false R64.htm 2452428 - Disclosure - Employee Equity-Based Compensation - Narrative (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails Employee Equity-Based Compensation - Narrative (Details) Details 64 false false R65.htm 2454429 - Disclosure - Income Taxes (Details) Sheet http://acceleratediagnostics.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://acceleratediagnostics.com/role/IncomeTaxes 65 false false R66.htm 2457430 - Disclosure - Leases - Assets and Liabilities (Details) Sheet http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails Leases - Assets and Liabilities (Details) Details 66 false false R67.htm 2458431 - Disclosure - Leases - Maturities of Lease Liabilities (Details) Sheet http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails Leases - Maturities of Lease Liabilities (Details) Details 67 false false R68.htm 2459432 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) Sheet http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails Leases - Sales-type Lease Receivable Maturity (Details) Details 68 false false R69.htm 2462433 - Disclosure - Industry, Geographic and Revenue Disaggregation - Narrative (Details) Sheet http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails Industry, Geographic and Revenue Disaggregation - Narrative (Details) Details 69 false false R70.htm 2463434 - Disclosure - Industry, Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) Sheet http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails Industry, Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) Details 70 false false R71.htm 2464435 - Disclosure - Industry, Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) Sheet http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails Industry, Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) Details 71 false false R72.htm 2466436 - Disclosure - Related Party Transaction (Details) Sheet http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails Related Party Transaction (Details) Details http://acceleratediagnostics.com/role/RelatedPartyTransactions 72 false false All Reports Book All Reports axdx-20200930.htm a069302020-exh311ng.htm a09302020-exh101ng.htm a09302020-exh312ng.htm a09302020-exh32ng.htm axdx-20200930.xsd axdx-20200930_cal.xml axdx-20200930_def.xml axdx-20200930_lab.xml axdx-20200930_pre.xml http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "axdx-20200930.htm": { "axisCustom": 0, "axisStandard": 26, "contextCount": 267, "dts": { "calculationLink": { "local": [ "axdx-20200930_cal.xml" ] }, "definitionLink": { "local": [ "axdx-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "axdx-20200930.htm" ] }, "labelLink": { "local": [ "axdx-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "axdx-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "axdx-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 530, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 5, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 10 }, "keyCustom": 26, "keyStandard": 374, "memberCustom": 17, "memberStandard": 48, "nsprefix": "axdx", "nsuri": "http://acceleratediagnostics.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://acceleratediagnostics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - Fair Value of Financial Instruments", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - Investments", "role": "http://acceleratediagnostics.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119106 - Disclosure - Inventory", "role": "http://acceleratediagnostics.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122107 - Disclosure - Property and Equipment", "role": "http://acceleratediagnostics.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:LicenseAgreementsAndGrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - License Agreements and Grants", "role": "http://acceleratediagnostics.com/role/LicenseAgreementsandGrants", "shortName": "License Agreements and Grants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:LicenseAgreementsAndGrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128109 - Disclosure - Deferred Revenue and Remaining Performance Obligations", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations", "shortName": "Deferred Revenue and Remaining Performance Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131110 - Disclosure - Long-term Debt", "role": "http://acceleratediagnostics.com/role/LongtermDebt", "shortName": "Long-term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136111 - Disclosure - Convertible Notes", "role": "http://acceleratediagnostics.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141112 - Disclosure - Earnings Per Share", "role": "http://acceleratediagnostics.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145113 - Disclosure - Employee Equity-Based Compensation", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation", "shortName": "Employee Equity-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153114 - Disclosure - Income Taxes", "role": "http://acceleratediagnostics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155115 - Disclosure - Leases", "role": "http://acceleratediagnostics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2160116 - Disclosure - Industry, Geographic and Revenue Disaggregation", "role": "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregation", "shortName": "Industry, Geographic and Revenue Disaggregation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2165117 - Disclosure - Related Party Transactions", "role": "http://acceleratediagnostics.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Investments (Tables)", "role": "http://acceleratediagnostics.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Inventory (Tables)", "role": "http://acceleratediagnostics.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323305 - Disclosure - Property and Equipment (Tables)", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329306 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables)", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables", "shortName": "Deferred Revenue and Remaining Performance Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332307 - Disclosure - Long-term Debt (Tables)", "role": "http://acceleratediagnostics.com/role/LongtermDebtTables", "shortName": "Long-term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337308 - Disclosure - Convertible Notes (Tables)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesTables", "shortName": "Convertible Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342309 - Disclosure - Earnings Per Share (Tables)", "role": "http://acceleratediagnostics.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2346310 - Disclosure - Employee Equity-Based Compensation (Tables)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables", "shortName": "Employee Equity-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2356311 - Disclosure - Leases (Tables)", "role": "http://acceleratediagnostics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2361312 - Disclosure - Industry, Geographic and Revenue Disaggregation (Tables)", "role": "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationTables", "shortName": "Industry, Geographic and Revenue Disaggregation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "lang": "en-US", "name": "axdx:StandardProductWarrantyInstrumentsTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "idf2ba5a99e9d47c7a619d1bf0fa2956f_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "idf2ba5a99e9d47c7a619d1bf0fa2956f_I20200630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Recently Issued Accounting Pronouncements (Details)", "role": "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails", "shortName": "Recently Issued Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i2d74041a2dcf4362a9a70bcf92201c77_I20200101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7cbe9395544a45698af9153a8c7d1dc6_D20190101-20191231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Concentration of Credit Risk (Details)", "role": "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "shortName": "Concentration of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7cbe9395544a45698af9153a8c7d1dc6_D20190101-20191231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details)", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "shortName": "Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "id79a6f24c1124c8694a43120f4c3ef0d_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i090951fcdf7c44319e0cb9924f11905f_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details)", "role": "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails", "shortName": "Investments - Schedule of Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details)", "role": "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "shortName": "Investments - Schedule of Available-for-Sale Investment Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "span", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Investments - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - Inventory (Details)", "role": "http://acceleratediagnostics.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424411 - Disclosure - Property and Equipment (Details)", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i64d0f19d341d49e7b41c16a935a34e87_D20150201-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "axdx:ResearchandDevelopmentArrangementContracttoPerformforOthersInvoiced", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427413 - Disclosure - License Agreements and Grants - National Institute of Health Grant (Details)", "role": "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails", "shortName": "License Agreements and Grants - National Institute of Health Grant (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i64d0f19d341d49e7b41c16a935a34e87_D20150201-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "axdx:ResearchandDevelopmentArrangementContracttoPerformforOthersInvoiced", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430414 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details)", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "shortName": "Deferred Revenue and Remaining Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433415 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details)", "role": "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "shortName": "Long-term Debt - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i8bfe214f117c4e6699787fa1e111bd86_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434416 - Disclosure - Long-term Debt - Schedule of Maturities of Future Principal Obligations (Details)", "role": "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails", "shortName": "Long-term Debt - Schedule of Maturities of Future Principal Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435417 - Disclosure - Long-term Debt - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "shortName": "Long-term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i17cf5c1bbb514ef1ab5a223d196e5f5f_D20200701-20200930", "decimals": "INF", "lang": "en-US", "name": "axdx:NumberOfDebtInstruments", "reportCount": 1, "unique": true, "unitRef": "loan", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i3ac9d430bf444392803ed0f87466734d_D20180327-20180327", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:OverAllotmentOptionTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438418 - Disclosure - Convertible Notes - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "shortName": "Convertible Notes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i3ac9d430bf444392803ed0f87466734d_D20180327-20180327", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:OverAllotmentOptionTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439419 - Disclosure - Convertible Notes - Schedule of Convertible Notes (Details)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails", "shortName": "Convertible Notes - Schedule of Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440420 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "shortName": "Convertible Notes - Schedule of Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443421 - Disclosure - Earnings Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details)", "role": "http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails", "shortName": "Earnings Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "icc11acfb6d204fbbbfaab2383863bdb1_D20180404-20180404", "decimals": "-2", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444422 - Disclosure - Earnings Per Share - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "shortName": "Earnings Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i40f5569f261d426093ce09bcab864cde_D20200101-20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i85cc4e5aa8554824a0ef54240954c512_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447423 - Disclosure - Employee Equity-Based Compensation - Stock Option Activity (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails", "shortName": "Employee Equity-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "if1beb50f683f44deb520b6f6f9ef3551_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "if1beb50f683f44deb520b6f6f9ef3551_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448424 - Disclosure - Employee Equity-Based Compensation - Inputs to Calculate Estimated Fair Value of Options Awarded (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationInputstoCalculateEstimatedFairValueofOptionsAwardedDetails", "shortName": "Employee Equity-Based Compensation - Inputs to Calculate Estimated Fair Value of Options Awarded (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449425 - Disclosure - Employee Equity-Based Compensation - Stock Option Supplemental Information (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails", "shortName": "Employee Equity-Based Compensation - Stock Option Supplemental Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i66c8719a7fe54c54b691cace716ca25c_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450426 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails", "shortName": "Employee Equity-Based Compensation - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i66c8719a7fe54c54b691cace716ca25c_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451427 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "shortName": "Employee Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452428 - Disclosure - Employee Equity-Based Compensation - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "shortName": "Employee Equity-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i49e052a9083546d094f1459897aaedc2_D20200101-20200930", "decimals": null, "lang": "en-US", "name": "axdx:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsContractualTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454429 - Disclosure - Income Taxes (Details)", "role": "http://acceleratediagnostics.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457430 - Disclosure - Leases - Assets and Liabilities (Details)", "role": "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails", "shortName": "Leases - Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458431 - Disclosure - Leases - Maturities of Lease Liabilities (Details)", "role": "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetInvestmentInLease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459432 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details)", "role": "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails", "shortName": "Leases - Sales-type Lease Receivable Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetInvestmentInLease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462433 - Disclosure - Industry, Geographic and Revenue Disaggregation - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails", "shortName": "Industry, Geographic and Revenue Disaggregation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ib864d70914f14f49bc4c4539cb4f249d_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463434 - Disclosure - Industry, Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details)", "role": "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "shortName": "Industry, Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ic52b1ab6d33b4da0b55f0b0c1305f360_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i7c67f4de869948ac8b2cc69f5528431a_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464435 - Disclosure - Industry, Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details)", "role": "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "shortName": "Industry, Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i141a9d2ab6fb45468210d9d7fb77a908_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ibb395058d2554c53b23f177cdf9a0ba2_I20190819", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466436 - Disclosure - Related Party Transaction (Details)", "role": "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails", "shortName": "Related Party Transaction (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "ibb395058d2554c53b23f177cdf9a0ba2_I20190819", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106102 - Disclosure - Recently Issued Accounting Pronouncements", "role": "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements", "shortName": "Recently Issued Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Concentration of Credit Risk", "role": "http://acceleratediagnostics.com/role/ConcentrationofCreditRisk", "shortName": "Concentration of Credit Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20200930.htm", "contextRef": "i775bd2fbfb4f43fbaaf5defd550d5082_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "axdx_AcceleratePhenoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accelerate Pheno [Member]", "label": "Accelerate Pheno [Member]", "terseLabel": "Accelerate Pheno revenue" } } }, "localname": "AcceleratePhenoMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "axdx_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Assets And Liabilities" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "axdx_ConvertibleNoteHolderMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Note Holder [Member]", "label": "Convertible Note Holder [Member]", "terseLabel": "Note holder" } } }, "localname": "ConvertibleNoteHolderMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "domainItemType" }, "axdx_DebtInstrumentConvertibleConversionPrincipalMultiple": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Convertible, Conversion Principal Multiple", "label": "Debt Instrument, Convertible, Conversion Principal Multiple", "terseLabel": "Conversion multiple" } } }, "localname": "DebtInstrumentConvertibleConversionPrincipalMultiple", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtInstrumentConvertibleThresholdPercentageofNotesTradingPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger", "label": "Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger", "terseLabel": "Trading price threshold, percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageofNotesTradingPriceTrigger", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "axdx_DebtInstrumentNumberOfMonthlyPayments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Number of Monthly Payments", "label": "Debt Instrument, Number of Monthly Payments", "terseLabel": "Number of monthly payments" } } }, "localname": "DebtInstrumentNumberOfMonthlyPayments", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_DebtInstrumentPrincipleRepurchasePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Principle Repurchase Percent", "label": "Debt Instrument, Principle Repurchase Percent", "terseLabel": "Repurchase principal balance, percent" } } }, "localname": "DebtInstrumentPrincipleRepurchasePercent", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "axdx_DebtProceedsUsedtoFundEmbeddedDerivative": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Proceeds Used to Fund Embedded Derivative", "label": "Debt Proceeds Used to Fund Embedded Derivative", "terseLabel": "Net proceeds from notes to fund Prepaid Forward" } } }, "localname": "DebtProceedsUsedtoFundEmbeddedDerivative", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtSecuritiesAvailableforsaleMaturityAllocatedandSingleMaturityDateafterOneThroughThreeYearsAmortizedCost": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Three Years, Amortized Cost", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Three Years, Amortized Cost", "terseLabel": "Due in 1-3 years" } } }, "localname": "DebtSecuritiesAvailableforsaleMaturityAllocatedandSingleMaturityDateafterOneThroughThreeYearsAmortizedCost", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtSecuritiesAvailableforsaleMaturityAllocatedandSingleMaturityDateafterOneThroughThreeYearsFairValue": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Three Years, Fair Value", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Three Years, Fair Value", "terseLabel": "Due in 1-3 years" } } }, "localname": "DebtSecuritiesAvailableforsaleMaturityAllocatedandSingleMaturityDateafterOneThroughThreeYearsFairValue", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_FinancialInstitutionAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial Institution A [Member]", "label": "Financial Institution A [Member]", "terseLabel": "Financial institution A" } } }, "localname": "FinancialInstitutionAMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FinancialInstitutionBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial Institution B [Member]", "label": "Financial Institution B [Member]", "terseLabel": "Financial institution B" } } }, "localname": "FinancialInstitutionBMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FinancialInstitutionCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial Institution C", "label": "Financial Institution C [Member]", "terseLabel": "Financial institution C" } } }, "localname": "FinancialInstitutionCMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FinancialInstitutionDMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial Institution D", "label": "Financial Institution D [Member]", "terseLabel": "Financial institution D" } } }, "localname": "FinancialInstitutionDMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_Grantedin2018Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Granted in 2018 [Member]", "label": "Granted in 2018 [Member]", "terseLabel": "Granted in 2018" } } }, "localname": "Grantedin2018Member", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_InstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Instruments [Member]", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "localname": "InstrumentsMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "axdx_InventoryTransferredtoFixedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventory Transferred to Fixed Assets", "label": "Inventory Transferred to Fixed Assets", "terseLabel": "Net transfer of instruments from inventory to property and equipment" } } }, "localname": "InventoryTransferredtoFixedAssets", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "axdx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_LicenseAgreementsAndGrantsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License agreements", "label": "License Agreements and Grants [Text Block]", "terseLabel": "License Agreements and Grants" } } }, "localname": "LicenseAgreementsAndGrantsTextBlock", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrants" ], "xbrltype": "textBlockItemType" }, "axdx_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long-Term Debt, Maturity, after Year Four", "label": "Long-Term Debt, Maturity, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "axdx_NationalInstituteofHealthGrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "National Institute of Health Grant [Member]", "label": "National Institute of Health Grant [Member]", "terseLabel": "National Institute of Health Grant" } } }, "localname": "NationalInstituteofHealthGrantMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails" ], "xbrltype": "domainItemType" }, "axdx_NumberOfDebtInstruments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Debt Instruments", "label": "Number of Debt Instruments", "terseLabel": "Number of loan agreements" } } }, "localname": "NumberOfDebtInstruments", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_OneCustomerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One Customer", "label": "One Customer [Member]", "terseLabel": "One customer" } } }, "localname": "OneCustomerMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_OtherLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Loans", "label": "Other Loans [Member]", "terseLabel": "Other Loans - various interest" } } }, "localname": "OtherLoansMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "axdx_OtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Revenue [Member]", "label": "Other Revenue [Member]", "terseLabel": "Other revenue" } } }, "localname": "OtherRevenueMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "axdx_OverAllotmentOptionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Over-Allotment Option, Amount", "label": "Over-Allotment Option, Amount", "terseLabel": "Over-allotment option" } } }, "localname": "OverAllotmentOptionAmount", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_OverAllotmentOptionTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Over-Allotment Option, Term", "label": "Over-Allotment Option, Term", "terseLabel": "Over-allotment option, term" } } }, "localname": "OverAllotmentOptionTerm", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_PaycheckProtectionProgramCARESActMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Paycheck Protection Program, CARES Act", "label": "Paycheck Protection Program, CARES Act [Member]", "terseLabel": "PPP" } } }, "localname": "PaycheckProtectionProgramCARESActMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance-based Restricted Stock Units", "label": "Performance-based Restricted Stock Units [Member]", "terseLabel": "Performance-based RSU expense" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_ProceedsfromOverAllotmentOption": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from Over-Allotment Option", "label": "Proceeds from Over-Allotment Option", "terseLabel": "Additional proceeds" } } }, "localname": "ProceedsfromOverAllotmentOption", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_ProceedsfromStockOptionsandWarrantsExercised": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from Stock Options and Warrants Exercised", "label": "Proceeds from Stock Options and Warrants Exercised", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsfromStockOptionsandWarrantsExercised", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "axdx_ProductsandServicesnotYetDeliveredMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Products and Services not Yet Delivered [Member]", "label": "Products and Services not Yet Delivered [Member]", "terseLabel": "Products and services not yet delivered" } } }, "localname": "ProductsandServicesnotYetDeliveredMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "domainItemType" }, "axdx_ResearchandDevelopmentArrangementContracttoPerformforOthersInvoiced": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Contract to Perform for Others, Invoiced", "label": "Research and Development Arrangement, Contract to Perform for Others, Invoiced", "terseLabel": "Cumulative amount awarded" } } }, "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthersInvoiced", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails" ], "xbrltype": "monetaryItemType" }, "axdx_ResearchandDevelopmentArrangementContracttoPerformforOthersProposedPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Contract to Perform for Others, Proposed Period", "label": "Research and Development Arrangement, Contract to Perform for Others, Proposed Period", "terseLabel": "Grant period" } } }, "localname": "ResearchandDevelopmentArrangementContracttoPerformforOthersProposedPeriod", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails" ], "xbrltype": "durationItemType" }, "axdx_RestrictedStockUnitsAndRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Stock Units And Restricted Stock Awards [Member]", "label": "Restricted Stock Units And Restricted Stock Awards [Member]", "terseLabel": "RSUs and RSAs" } } }, "localname": "RestrictedStockUnitsAndRestrictedStockAwardsMember", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "axdx_SalesTypeAndDirectFinancingLeasesLeaseReceivableToBeReceivedAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 6.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableToBeReceivedAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsContractualTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contractual Terms", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contractual Terms", "terseLabel": "Contractual life" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsContractualTerms", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value", "terseLabel": "Weighted average fair value (dollars per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationInputstoCalculateEstimatedFairValueofOptionsAwardedDetails" ], "xbrltype": "perShareItemType" }, "axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value (dollars per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "perShareItemType" }, "axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value", "terseLabel": "Weighted average fair value (dollars per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "perShareItemType" }, "axdx_StandardProductWarrantyInstrumentsTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Standard Product Warranty, Instruments, Term", "label": "Standard Product Warranty, Instruments, Term", "terseLabel": "Instrument warranty term" } } }, "localname": "StandardProductWarrantyInstrumentsTerm", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_StandardProductWarrantyKitsAndAccessoriesTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Standard Product Warranty, Kits And Accessories, Term", "label": "Standard Product Warranty, Kits And Accessories, Term", "terseLabel": "Kits and accessories warranty term" } } }, "localname": "StandardProductWarrantyKitsAndAccessoriesTerm", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_TwoPointFiveZeroConvertibleNotesdue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point Five Zero Convertible Notes due 2023 [Member]", "label": "Two Point Five Zero Convertible Notes due 2023 [Member]", "terseLabel": "2.50% Convertible notes due 2023" } } }, "localname": "TwoPointFiveZeroConvertibleNotesdue2023Member", "nsuri": "http://acceleratediagnostics.com/20200930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r603" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r604" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r605" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r605" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r605" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r606" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r605" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r605" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r605" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r605" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r601" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r602" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ChiefOperatingOfficerMember": { "auth_ref": [ "r188", "r479" ], "lang": { "en-US": { "role": { "label": "Chief Operating Officer [Member]", "terseLabel": "Chief Operating Officer" } } }, "localname": "ChiefOperatingOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r52", "r106" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r113", "r124", "r214", "r370", "r371", "r372", "r396", "r397" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r113", "r124", "r214", "r370", "r371", "r372", "r396", "r397" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r113", "r124", "r214", "r370", "r371", "r372", "r396", "r397" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r186", "r301", "r307", "r578" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r329", "r331", "r490", "r491", "r492", "r493", "r494", "r495", "r514", "r576", "r579" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r329", "r331", "r490", "r491", "r492", "r493", "r494", "r495", "r514", "r576", "r579" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r186", "r301", "r307", "r578" ], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r182", "r301", "r305", "r515", "r575", "r577" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r182", "r301", "r305", "r515", "r575", "r577" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r317", "r329", "r331", "r490", "r491", "r492", "r493", "r494", "r495", "r514", "r576", "r579" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r317", "r329", "r331", "r490", "r491", "r492", "r493", "r494", "r495", "r514", "r576", "r579" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r257", "r330", "r483" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r188", "r479" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r116", "r117", "r118", "r120", "r211", "r212", "r213", "r214", "r217", "r218", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r374", "r396", "r397", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ], "lang": { "en-US": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Net accounts receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r249", "r250" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r245" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r57", "r58", "r59", "r561", "r587", "r591" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r60", "r110", "r111", "r112", "r411", "r582", "r583" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r18" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Contributed capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r110", "r111", "r112", "r370", "r371", "r372" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Contributed capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Equity component" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r333", "r335", "r377", "r378" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Equity-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r335", "r362", "r376" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Equity-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r193", "r219", "r221", "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r78", "r93", "r443" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of the debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r71", "r93", "r445" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive common stock instruments outstanding (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r166", "r171", "r178", "r210", "r408", "r412", "r429", "r540", "r559" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r51", "r103", "r210", "r408", "r412", "r429" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r416" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsLeasedToOthersMember": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable property, plant or equipment held for lease to others under contractual agreements meeting the criteria for operating lease classification.", "label": "Assets Leased to Others [Member]", "terseLabel": "Assets under operating leases" } } }, "localname": "AssetsLeasedToOthersMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r201" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r202" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r199", "r230" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r204" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in less than 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r203", "r204", "r553" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in less than 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r197", "r200", "r230", "r544" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value", "totalLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r336", "r365" ], "lang": { "en-US": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r336", "r365" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r414", "r415" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r109", "r156" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "auth_ref": [ "r522", "r523", "r524" ], "lang": { "en-US": { "role": { "documentation": "Information by project.", "label": "Project [Axis]", "terseLabel": "Project [Axis]" } } }, "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r31", "r95" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r96", "r101" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r89", "r95", "r100" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r89", "r434" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "(Decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in lease liabilities" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r555" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r318", "r421" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r256", "r545", "r566" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r110", "r111" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r272" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r16" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r62", "r64", "r65", "r70", "r548", "r569" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r150", "r151", "r186", "r426", "r427" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r150", "r151", "r186", "r426", "r427", "r593" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r150", "r151", "r186", "r426", "r427", "r593" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r150", "r151", "r186", "r426", "r427" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Risk concentration" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r147", "r150", "r151", "r152", "r426", "r428" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r150", "r151", "r186", "r426", "r427" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r101", "r410" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Capital projects in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Deferred Revenue and Income Summary" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r281", "r282", "r302" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "verboseLabel": "Deferred revenue and income" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r303" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenues recognized included in contract liabilities balances" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible notes", "totalLabel": "Net carrying amount of the liability component" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r318", "r326", "r592" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r74", "r515" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r72" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r101", "r252", "r253", "r255" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "terseLabel": "Restructure Activity" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Concentration of credit risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r148", "r186" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r98", "r99" ], "lang": { "en-US": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued (shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r541", "r542", "r558" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r14", "r266", "r542", "r558" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails": { "order": 3.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Outstanding principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price (usd per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r42", "r273", "r274", "r276" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Stock price conversion threshold, percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r444", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r41", "r269", "r444" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r43", "r556" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Monthly payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r43", "r107", "r273", "r275", "r276", "r277", "r443", "r444", "r446", "r557" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Contractual term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r443", "r446" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r101", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Schedule of Available-For-Sale Investment Maturities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer", "negatedTerseLabel": "Contributions to deferred compensation plan" } } }, "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r445" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "negatedTerseLabel": "Unamortized debt issuance", "verboseLabel": "Unamortized debt issuance" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Revenue Disclosure [Abstract]", "terseLabel": "Deferred Revenue Disclosure [Abstract]" } } }, "localname": "DeferredRevenueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r93", "r243" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r93", "r164" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r301", "r305", "r306", "r307", "r308", "r309", "r310", "r311" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Employee Equity-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r336", "r365" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Equity-Based Compensation Expenses" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per share (usd per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r101", "r136", "r137" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r434" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "terseLabel": "Cost capitalized to inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized equity-based compensation cost, restricted stock units" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized equity-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r360" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Shares issuable upon exercise of stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r110", "r111", "r112", "r117", "r126", "r128", "r142", "r214", "r272", "r278", "r370", "r371", "r372", "r396", "r397", "r435", "r436", "r437", "r438", "r439", "r440", "r582", "r583", "r584" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r425" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Fair value of equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r208", "r571" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Realized gains or losses from equity securities" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r208", "r571" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Unrealized losses on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r416", "r417", "r418", "r423" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r416", "r417", "r418", "r422", "r423" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurement" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r417", "r487", "r488", "r489" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r416", "r417", "r419", "r420", "r424" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r318", "r319", "r324", "r326", "r417", "r487" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r318", "r319", "r324", "r326", "r417", "r488" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r417", "r489" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Estimated Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r487", "r488", "r489" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r421", "r424" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair value on a recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r205", "r206", "r220", "r223", "r224", "r225", "r226", "r231", "r232", "r233", "r234", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r430", "r431", "r432", "r433" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign currency exchange gain (loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r101", "r441" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r93" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic concentration" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r227", "r550", "r551" ], "lang": { "en-US": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]", "terseLabel": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r550", "r551" ], "lang": { "en-US": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]", "terseLabel": "Geographic Distribution [Domain]" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionDomesticMember": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Allocation of business activity identified as domestic.", "label": "Geographic Distribution, Domestic [Member]", "terseLabel": "Domestic" } } }, "localname": "GeographicDistributionDomesticMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionForeignMember": { "auth_ref": [ "r229", "r550", "r551" ], "lang": { "en-US": { "role": { "documentation": "Allocation of business activity identified as foreign.", "label": "Geographic Distribution, Foreign [Member]", "terseLabel": "Foreign" } } }, "localname": "GeographicDistributionForeignMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r101", "r242" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Long-lived Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r73", "r103", "r166", "r170", "r174", "r177", "r180", "r210", "r429" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r68", "r166", "r170", "r174", "r177", "r180", "r538", "r546", "r551", "r572" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Pre-tax loss", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://acceleratediagnostics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r388", "r389", "r392", "r401", "r403", "r405", "r406", "r407" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r127", "r128", "r165", "r387", "r402", "r404", "r573" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://acceleratediagnostics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r66", "r101", "r385", "r386", "r389", "r390", "r391", "r393", "r596" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Deferred Tax Assets" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Accrued Liabilities [Abstract]", "terseLabel": "Increase (decrease) in liabilities:" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue and income" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory and instruments in property and equipment" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "(Increase) decrease in assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accrued liabilities, and other" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expense and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_InterestAndDividendsPayableCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest and Dividends Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestAndDividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r67", "r163", "r442", "r445", "r549" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r78", "r270" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r80" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of Interest Expense" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r88", "r90", "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r25", "r237" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r48" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://acceleratediagnostics.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r8", "r49", "r101", "r141", "r235", "r236", "r238" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r27", "r237" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r26", "r237" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r76" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r78" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedTerseLabel": "Amortization of investment discount" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r209", "r570" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r567" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r207", "r539", "r554", "r595" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseIncome": { "auth_ref": [ "r470" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.", "label": "Lease Income", "terseLabel": "Lease Income" } } }, "localname": "LeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Facilities" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Lessee" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "ROU assets obtained in exchange for lease obligations" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r459" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r459" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r459" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r459" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r459" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r459" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r459" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r459" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r461" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r463", "r468", "r469", "r472" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lessor, Leases [Policy Text Block]", "terseLabel": "Leases, Lessor" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseAssumptionsAndJudgmentsValueOfUnderlyingAssetAmount": { "auth_ref": [ "r467" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount lessor expects from underlying asset following end of operating lease term.", "label": "Lessor, Operating Lease, Assumptions and Judgments, Value of Underlying Asset, Amount", "terseLabel": "Gross assets" } } }, "localname": "LessorOperatingLeaseAssumptionsAndJudgmentsValueOfUnderlyingAssetAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r466" ], "lang": { "en-US": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Lessor lease term" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorSalesTypeLeasesTextBlock": { "auth_ref": [ "r473" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of lessor's sales-type leases.", "label": "Lessor, Sales-type Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LessorSalesTypeLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r103", "r172", "r210", "r409", "r412", "r413", "r429" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r103", "r210", "r429", "r543", "r563" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r103", "r210", "r409", "r412", "r413", "r429" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Long-lived Assets by Geographic Territory" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r267", "r542", "r560" ], "calculation": { "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r108", "r264" ], "calculation": { "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r108", "r264" ], "calculation": { "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r108", "r264" ], "calculation": { "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r108", "r264" ], "calculation": { "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r108" ], "calculation": { "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r43", "r265" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MutualFundMember": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.", "label": "Mutual Fund [Member]", "terseLabel": "Mutual funds" } } }, "localname": "MutualFundMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r89", "r91", "r94" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r61", "r63", "r69", "r94", "r103", "r116", "r122", "r123", "r124", "r125", "r127", "r128", "r133", "r166", "r170", "r174", "r177", "r180", "r210", "r429", "r547", "r568" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentInLease": { "auth_ref": [ "r462" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net investment in sales-type and direct financing lease.", "label": "Net Investment in Lease", "terseLabel": "Net investment in leases" } } }, "localname": "NetInvestmentInLease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r114", "r115", "r118", "r119", "r129", "r130", "r131", "r215", "r216", "r312", "r313", "r314", "r315", "r373", "r398", "r399", "r400", "r519", "r520", "r521", "r586", "r587", "r588", "r589", "r591" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r113", "r116", "r117", "r118", "r120", "r121", "r124", "r139", "r211", "r212", "r213", "r214", "r217", "r218", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r374", "r394", "r395", "r396", "r397", "r516", "r517", "r518", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Standards That Were Recently Adopted and Standards not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Restricted Stock Unit (RSU) Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Other Loans - various interest" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r166", "r170", "r174", "r177", "r180" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r452", "r460" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r448" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lessee lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r448" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r448" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r449", "r454" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r447" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r457", "r460" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (%)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r456", "r460" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r54", "r55", "r57" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Net unrealized gain (loss) on debt securities available-for-sale", "verboseLabel": "Unrealized loss on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r53" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r81", "r83", "r198" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r84" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedTerseLabel": "Purchases of equipment" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy": { "auth_ref": [ "r101", "r327", "r328", "r332" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]", "terseLabel": "Nonqualified Cash Deferral Plan" } } }, "localname": "PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-based stock option expense" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, shares outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred shares" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r239", "r240" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r85" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r86" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r81", "r82", "r198" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from sales of marketable securities", "verboseLabel": "Proceeds from sales of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProjectMember": { "auth_ref": [ "r527" ], "lang": { "en-US": { "role": { "documentation": "Planned program of work.", "label": "Project [Domain]", "terseLabel": "Project [Domain]" } } }, "localname": "ProjectMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r246" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r248", "r597", "r598", "r599" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r244" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r246", "r565" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "verboseLabel": "Long-lived assets (excluding intangible assets)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r32", "r101", "r246", "r597", "r598" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r244" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r574" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Realized loss on sale of investments" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r17", "r24", "r564", "r594" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade accounts receivable" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r325", "r476", "r477" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r325", "r476", "r477", "r480" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r325", "r476", "r480", "r525", "r526", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r474", "r475", "r477", "r481", "r482" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r87" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Payment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Research and Development [Abstract]", "terseLabel": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "auth_ref": [ "r382", "r384" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Total grant funding" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r381", "r600" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Shares issuable upon the release of restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r93", "r251", "r252", "r254" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring expenses" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r278", "r374", "r562", "r586", "r591" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r110", "r111", "r112", "r117", "r126", "r128", "r214", "r370", "r371", "r372", "r396", "r397", "r582", "r584" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r161", "r162", "r169", "r175", "r176", "r182", "r183", "r186", "r300", "r301", "r515" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r102", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r316" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r304", "r316" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Deferred Revenue and Remaining Performance Obligations" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.", "label": "Revenue, Performance Obligation, Description of Timing", "terseLabel": "Contact period" } } }, "localname": "RevenuePerformanceObligationDescriptionOfTiming", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue expected to be recognized from remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r455", "r460" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Share price (usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r150", "r186" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Total revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": { "auth_ref": [ "r464", "r471" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": 1.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable", "terseLabel": "Present value of lease payments" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]", "terseLabel": "Sales-type Lease Receivable Maturity" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": { "auth_ref": [ "r464" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received", "totalLabel": "Total undiscounted cash flows" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": { "auth_ref": [ "r464" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four", "terseLabel": "2024" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r464" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One", "terseLabel": "2021" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r464" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r464" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three", "terseLabel": "2023" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r464" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two", "terseLabel": "2022" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount": { "auth_ref": [ "r464" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": 2.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Available-for-Sale Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r43", "r107", "r273", "r275", "r276", "r277", "r443", "r444", "r446", "r557" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r335", "r361", "r376" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r8", "r28", "r29", "r30" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Future Principal Obligations" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LongtermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Reserve Activity" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r246" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r105", "r478", "r480" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r383", "r384" ], "lang": { "en-US": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LicenseAgreementsandGrantsNationalInstituteofHealthGrantDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r166", "r167", "r173", "r241" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r336", "r365" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r341", "r353", "r354" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "terseLabel": "Stock Option Supplemental Information" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Inputs to Calculate Estimated Fair Value of Options Awarded" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r157", "r159", "r160", "r166", "r168", "r174", "r178", "r179", "r180", "r181", "r182", "r185", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Industry, Geographic and Revenue Disaggregation" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Services" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/IndustryGeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Equity-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]", "terseLabel": "Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (shares)", "terseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of\u00a0Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (dollars per share)", "periodStartLabel": "Beginning balance (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested/Released (shares)", "terseLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested/Released (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationInputstoCalculateEstimatedFairValueofOptionsAwardedDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationInputstoCalculateEstimatedFairValueofOptionsAwardedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r359" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rates" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationInputstoCalculateEstimatedFairValueofOptionsAwardedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r342", "r344" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Ending balance (shares)", "periodStartLabel": "Beginning balance (shares)", "terseLabel": "Outstanding (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of options (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r343", "r365" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (shares)", "periodStartLabel": "Outstanding, beginning balance (shares)", "terseLabel": "Number of options (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of\u00a0Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending balance (dollars per share)", "periodStartLabel": "Outstanding, beginning balance (dollars per share)", "terseLabel": "Weighted average exercise price (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r334", "r338" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseandTaxBenefitDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r101", "r336", "r339" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r357", "r375" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationInputstoCalculateEstimatedFairValueofOptionsAwardedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value (in thousands)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionSupplementalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending Balance (shares)", "periodStartLabel": "Beginning Balance (shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r453", "r460" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term leases" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r261" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Warranty cost incurred" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r259" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provisions" } } }, "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r101", "r260" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty Reserve" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r47", "r110", "r111", "r112", "r117", "r126", "r128", "r142", "r214", "r272", "r278", "r370", "r371", "r372", "r396", "r397", "r435", "r436", "r437", "r438", "r439", "r440", "r582", "r583", "r584" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r110", "r111", "r112", "r142", "r515" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "auth_ref": [ "r15", "r16", "r272", "r278", "r379" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "terseLabel": "Issuance of common stock under employee purchase plan (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r272", "r278" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/RelatedPartyTransactionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r272", "r278", "r346" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)", "verboseLabel": "Exercise of options (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "auth_ref": [ "r15", "r16", "r272", "r278", "r379" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan", "terseLabel": "Issuance of common stock under employee purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r15", "r16", "r272", "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r47", "r272", "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r21", "r22", "r103", "r195", "r210", "r429" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "negatedTerseLabel": "Cumulative-effect adjustment", "periodEndLabel": "Ending Balance, amount", "periodStartLabel": "Beginning Balance, amount", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals.", "label": "Technology Equipment [Member]", "terseLabel": "Technical equipment" } } }, "localname": "TechnologyEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r189", "r190", "r191", "r192", "r194", "r196" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r205", "r206", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r46", "r279" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r16", "r272", "r278" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Aggregate number of shares (shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r46", "r279", "r280" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r318", "r552" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r318", "r552", "r592" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured obligations", "verboseLabel": "PPP Loan - 1% interest" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/EarningsPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongtermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnsecuredLongTermDebt": { "auth_ref": [ "r43" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Unsecured Long-term Debt, Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "UnsecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r143", "r144", "r145", "r146", "r153", "r154", "r155" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r132", "r135" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding (shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/subtopic&trid=2235172" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/subtopic&trid=2235116" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/subtopic&trid=2235144" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r441": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r461": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919306-209978" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919352-209981" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919391-209981" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919398-209981" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL117410129-209981" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL117410129-209981" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919379-209981" }, "r472": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "14", "Topic": "842", "URI": "http://asc.fasb.org/section&trid=77888298" }, "r473": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888252" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r482": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(a)(32))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r539": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r554": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r595": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r601": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r602": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r603": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r604": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r605": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r606": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" } }, "version": "2.1" } ZIP 91 0001628280-20-015938-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-20-015938-xbrl.zip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